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The concept of  lipids as signaling molecules facilitating communication within and 
between cells has emerged and developed over the past fifty years, significantly contrib-
uting to state-of-the art research in a multitude of  scientific disciplines. Much attention 
has been paid to N‑acyl conjugates of  amino acids and neurotransmitters (NAANs) 
as their potential roles in  the nervous system, vasculature, and immune system have 
emerged. NAANs are compounds such as glycine, gamma-aminobutyric acid, or dopa-
mine conjugated with long-chain fatty acids. N-acyl dopamines (NADs), initially thought 
to be a means of  dopamine inactivation [1, 2], have evolved as a family of  compounds with 
important biological activities and will be the main topic of  this thesis.
Fueled by the discovery of  the cannabinoid receptor in 1988 [3] and its endogenous 
ligand-anandamide [4], further interest in fatty acid conjugates arose, and several NADs 
were synthesized. Many of  these synthetic NADs interacted with proteins of  the endoge-
nous cannabinoid system [5–7] and were potent inhibitors of  5-lipoxygenase [8]. In 2002, 
the first endogenous fatty acid amide of  dopamine N‑arachidonoyl dopamine (NADA) 
was discovered in rat and bovine brain tissue and reported as an endogenous ligand of  
the transient receptor potential channel of  the vanilloid receptor subfamily, subtype 1 
(TRPV1) [9]. A year later Chu et al. identified other endogenous NADs—N‑oleoyl dopamine 
(OLDA), N-palmitoyl dopamine, and N-stearoyl dopamine—in lipid extracts of  the bovine 
brain [10]. The presence of  endogenous NADs has so far only been assessed in the central 
nervous system, and their concentration or body distribution remains unknown [9, 10].
NADs consist of  an aromatic head group and a hydrocarbon tail. The hydrocarbon 
tail with polar groups provides some of  these compounds’ ability, to a limited extent, to 
dissolve in water. In an analogy with capsaicin (the classical TRPV1 agonist), these mol-
ecules can be structurally divided into three regions: the aromatic moiety (A region), the 
linker (B region), and the hydrocarbon side chain (C region) [11–13] (Figure 1). Because 
all NADs are conjugates of  dopamine, they carry the same A and B regions, while the C 




Figure	 1.	Generalized	structure	of	 the	NADs. The structures can be divided into three regions: the 
aromatic moiety (A region), the amide bond (B region), and the hydrophobic side chain (C region). X is 
the hydrocarbon chain, which can be of  varying length and degree of  saturation.
Although the biosynthesis of  the NADs is yet to be fully elucidated, two major 
biosynthetic routes have been proposed: The first is the conjugation of  the amino acid/
neurotransmitter with arachidonic acid or arachidonoyl coenzyme A, and the second 
involves sequential modification of  a  precursor fatty acid conjugate to form the final 
NAD [9, 14].
In vitro, NADs appear to be subject to degradation involving hydrolysis of  the ester 
bond and modification of  the dopamine moiety and fatty acid residue. In mammals, the 
NADs are mainly metabolized through low-efficiency hydrolysis with a possible involve-
ment of  hydrolase of  fatty acid amides [9, 10] and methylation of  the catechol group 
by  the cytoplasmic Catechol-O-Methyltransferase [9, 15], as well as through oxidation 
of  the dopamine moiety by NADH oxidoreductases in the plasma membrane and mito-
chondria [15]. In rat tissues, sulfation of  the dopamine entity of  NADs has been reported 
by aryl sulfotransferase [16].
Biological Properties of N‑acyl Dopamines
NADs display diverse biological activities from information transformation within the 
nervous system, modulation of  signal transduction, and antioxidative properties to 
immune modulatory effects. Some of  the important biological properties of  NADs are 
described in the following paragraphs:
Agonist at the Cannabinoid Receptors
Although all NADs exhibit modest affinity toward the cannabinoid receptor type 1 (CB1) 
and cannabinoid receptor type 2 (CB2) receptor in vitro, not all NADs activate the can-
nabinoid receptors. For instance, NADA is shown to activate CB1 [7, 17], while OLDA is 





NADs are the endogenous agonist at TRPV1—a multimodal (pH-, temperature-, and 
mechano-sensitive) nonselective ion channel. TRPV1 activation leads to influx of  Na  +  and 
Ca  +  2 ions. NADA and OLDA are agonists at the TRPV1 channel. NADA and OLDA have 
both induced calcium transients in TRPV1-transfected Human Embryonic Kidney cells, 
with EC50 potencies of  ≈ 50 nm and ≈ 36 nm, respectively [9, 10].
It is noteworthy to mention that the activation pattern of  TRPV1 by NADs is rather 
complex; for instance, the receptor sensitivity and maximal response for NADA is 
reported to increase dramatically after phosphorylation of  the receptor by protein kinase 
C by  approximately fifteen fold [18]. Similarly, capsaicin responses in  sensory neurons 
have exhibited robust potentiation by cAMP-dependent protein kinase A [19].
In vivo NADs exhibit a complex pattern of  effects based on the duality of  their tar-
gets—anti-nociceptive CB1 receptors and pro-nociceptive TRPV1 [20, 21].
Anti-Inflammatory Properties
Almost all NADs exhibit anti-inflammatory properties. The endogenous NADs—NADA 
and OLDA—inhibit human T cell activation by blocking Nuclear Factor of  Activated T-cells 
(NFAT), nuclear factor κB (NF-κB), and activator protein 1 (AP-1) pathways [22]. Another 
NAD, N‑acetyl dopamine, was shown to decrease lipopolysaccharide stimulated Tumor 
Necrosis Factor (TNF) production in monocytes and phorbol ester-stimulated superoxide 
production in neutrophils [23].
NADs may elicit anti-inflammatory properties independent of  CB1 and TRPV1. 
For example, NADA is reported to activate redox-sensitive mitogen-activated protein 
kinase p38, resulting in stabilization of  cyclooxygenase-2 (COX-2) mRNA, which in turn 
increases COX-2 protein expression. At the same time NADA inhibits the expression of  
Prostaglandin E synthase-1 while upregulating Lipocalin-type prostaglandin D synthase 
expression. The net effect of  this action is a  shift from eicosanoid prostaglandin E2 to 
prostaglandin D2, resulting in  the onset of  the resolution phase of  the inflammatory 
response. This ability of  NADA is solely dependent on its dopamine moiety [24].
NADA stimulates transcriptional activity of  peroxisome proliferator-activated 
receptors (PPAR), a  family of  nuclear receptors/transcription factors that regulate cell 
differentiation, metabolism, and immune function [25]. The interaction of  NADA with 
PPAR-γ has been shown to cause endothelium-, nitrogen oxide (NO)-, and superoxide 
dismutase-dependent vasorelaxation in rat-isolated aorta [25].
Antioxidative Properties
The presence of  the catechol moiety in NADs makes these compounds eligible to partic-
ipate in redox cycling. Hence, depending on their environment, they can either donate 
or accept 2H  +  and 2e-, thereby changing from an enol to an enone configuration or vice 
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versa; for example, NADA protects cultured granular neurons of  rat cerebellum against 
H2O2 with the reduction of  intracellular peroxide concentration [26]. Oxenkrug et  al. 
showed that N‑acetyl dopamine inhibits rat brain lipid peroxidation induced by lipopoly-
saccharide [23], and Perianayagam et al. reported lipopolysaccharide-induced oxidative 
stress suppression by the same substance [23]. Saturated NADs (derivatives of  octanoic, 
decanoic, dodecanoic, and tetradecanoic acids) efficiently protected human umbilical 
vein endothelial cells [27] and cardiomyocytes [28] against cold-inflicted oxidative stress.
As a result of  their ability to easily undergo oxidation, these NADs under normal 
conditions produce mild oxidative stress. Several studies suggest that mild triggers keep 
the system alert; for example, it has been shown that mild oxidative stress strongly acti-
vates antioxidant response element (ARE)-dependent gene expression and contributes to 
neuroprotective ischemic preconditioning [29].
Biological Stability
Although a number of  NADs have been found in brain tissue [9, 10, 30] and in human 
plasma [31], the half-life and biological stability of  NADs in vivo are not yet known. Their 
physiological role and production site are unknown. Synthesized NADs show tempera-
ture sensitivity and degrade faster at room temperature, indicating that NADs in general 
might have a rapid response system similar to neurotransmitters.
NOD	–	A synthetic	N‑Acyl dopamine
In vitro experimental studies [32–34], in vivo animal studies [35, 36], and clinical prospective 
and retrospective studies [37–40] all unequivocally point to the protective effects of  low-
dose donor dopamine treatment on allograft quality. The downside of  donor dopamine 
treatment, however, is that in approximately fifteen percent of  the brain-dead donors, 
tachycardia or hypertension may occur, requiring cessation of  dopamine infusion [41]. 
Because dopamine is rapidly degraded in the circulation by monoamine oxidase, suffi-
cient tissue dopamine levels can only be obtained if  dopamine treatment is continued 
until cross-clamping. Renal allografts obtained from donors in whom treatment was ter-
minated earlier no longer profit from dopamine. It should also be emphasized that even 
though renal allografts retrieved from non-heart-beating donors may have an increased 
risk of  delayed graft function, dopamine treatment of  such donors is not an option. With 
the aim of  overcoming the hemodynamic adverse effects of  dopamine and of  finding 
compounds more efficacious than dopamine, Loesel et al. synthesized NADs with short 
saturated fatty acids. N-octanoyl dopamine (NOD) was forty times more effective than 
dopamine in terms of  protection against cold-inflicted injury. NOD does not affect mean 
arterial blood pressure in vivo; its effect is neither adrenergic nor dopaminergic receptor 




NOD protects cultured cardiomyocytes, as well as endothelial and renal epithelial 
cells, against cold-inflicted injury much more effectively than dopamine can [27, 28]. In 
addition, NOD strongly inhibits TNFα-mediated Vascular cell adhesion protein 1 (VCAM-
1) expression along with a variety of  inflammatory chemo-and cytokines [42]. Moreover, 
like other catechol-containing structures, NOD induces the expression of  heme oxy-
genase-1 (HO-1) as a consequence of  Nuclear factor erythroid 2-related factor 2 (Nrf-2) 
activation [42, 43]. In the setting of  warm ischemia-induced acute kidney injury (AKI) 
in rats, bolus application of  NOD shortly before and after the induction of  AKI displayed 
renoprotective properties [44].
In vitro NOD transiently inhibits T cell proliferation in  a  dose-dependent fashion 
and, displays a  synergistic effect with calcineurin inhibitor to suppress T cell prolifer-
ation [45]. Furthermore, NOD inhibited platelet function [46], improved renal function 
in allograft recipients when applied to brain-dead donors [47], improved donor cardiac 
and graft function after transplantation [48], attenuated transplant vasculopathy in rat 
aortic allografts [49], induced the unfolded protein response (UPR) in endothelial cells, 
and appeared to shift cells toward hypometabolism [50].
All these properties of  NOD tempt one to think of  NOD as an attractive drug candi-
date to ameliorate tissue damage caused either by inflammation or other inciting events 
[51]. Yet those who conduct pharmacokinetic, toxicological, or structure-activity studies 
are required to think of  NOD as a potential drug.
Beneficial	Effects	of	NADs	in Ischemia-Induced	AKI
Before discussing the beneficial effect of  NADs in ischemia-induced AKI, the pathophys-
iology of  the latter is briefly summarized in the following paragraphs.
Pathophysiology of AKI
Although AKI has a multifactorial aetiology, ischemia is a common denominator in many 
of  these aetiologies—vascular injury, tubular injury, loss of  tubuloglomerular feedback, 
and finally the involvement of  the immune system—which are important events in isch-
emia-induced AKI.
Ischemia-mediated AKI results from a  generalized or localized impairment of  
oxygen and nutrient delivery to, and waste product removal from, the cells of  the kidney 
[52]. There is a mismatch of  local tissue oxygen supply and demand and accumulation 
of  waste products of  metabolism. Ischemia damages the renal vasculature, causing 
increased tissue levels of  vasoconstrictor (e.g., endothelin-1, angiotensin II) [53, 54], while 
the production of  vasodilators by the endothelium, such as NO, is reduced [55]. The blood 
vessels constrict in response to out-of-balance vasoconstrictors. The scenario is further 
worsened by  the sympathetic nerve stimulation, resulting in  loss of  autoregulation of  
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renal blood flow. Because ischemia is accompanied by inflammation, the inflammatory 
cytokines exert direct or indirect vasoactive properties, further perpetuating the dys-
function in local vascular tone [56].
Renal microvascular permeability increases as a result of  disruption of  the endothe-
lial monolayer and actin cytoskeleton and a severely compromised integrity of  adherence 
junctions. Consequently, tissue edema is formed, resulting in  an increased interstitial 
pressure, which in turn may occlude small vessels, further impairing perfusion and oxy-
genation of  the affected tissue [57]. Endothelial cell dysfunction is aggravated by activa-
tion of  the coagulation system, leading to thrombus formation and facilitation of  tissue 
inflammation [58]. As such, continued activation of  inflammation, vascular leakage, and 
activation of  the coagulation pathway may lead to secondary ischemia, causing a vicious 
circle of  ischemia and endothelial dysfunction.
Oxygen deprivation, together with a high energy demand in tubular epithelial cells, 
leads to rapid degradation of  Adenosine triphosphate (ATP) to Adenosine diphosphate 
(ADP) and Adenosine monophosphate (AMP). Prolongation of  ischemia results in break-
down of  AMP to adenine nucleotides, which are subsequently converted to hypoxan-
thine. Accumulation of  hypoxanthine, in turn, contributes to the generation of  reactive 
oxygen species, which then perpetuate renal tubule cell injury by peroxidation of  lipids, 
oxidation of  proteins, damage to DNA, and induction of  apoptosis [59].
Because ATP is required for calcium homeostasis within cells, ATP depletion leads 
to increase in  free intracellular calcium, causing activation of  the proteases and the 
phospholipases and cytoskeletal degradation [60]. This rapid disruption of  the apical 
actin cytoskeleton and rearrangement of  the actin from the apical domain and microvilli 
into the cytoplasm gives rise to the formation of  blebs—membrane-bound, free-floating 
extracellular vesicles that are either lost or internalized in the tubular lumen. These blebs 
contribute to cast formation and obstruction in the lumen and have been detected in the 
urine of  animals and humans suffering from AKI [61].
Disruption of  the actin cytoskeleton is followed by  redistribution of  basolateral 
Na  +  /K  +  - ATPase pumps to the apical membrane [62], resulting in the back transport of  
sodium into the tubular lumen. When filtrates with a high sodium concentration reach 
the distal tubules, this is sensed by the macula densa and translated into vasoconstriction 
of  the afferent arteriole, a  physiological process to regulate glomerular filtration, also 
known as tubuloglomerular feedback [63]. Disruption of  the apical cytoskeleton further 
potentiates loss of  tight junctions and adherent junctions, resulting in  loss of  tubular 
barrier function and, consequently, a back leak of  the glomerular filtrate [64, 65]. Thus, 
proximal tubular cell injury and dysfunction during ischemia lead to afferent arteriolar 
vasoconstriction mediated by  the tubuloglomerular feed back, luminal obstruction as 
a consequence of  cast formation, and back leak of  the filtrate across the injured proximal 




NOD, a TRPV1 Agonist and an Attractive Drug Candidate in 
Ameliorating AKI
In the past decade, several studies have demonstrated the protective effect of  the 
TRPV1 agonists in ischemia-reperfusion-induced renal dysfunction [68–70]. This can be 
attributed to the fact that the renal pelvis, pelviureteric junction, and ureter are inner-
vated with TRPV1-positive sensory nerves [71, 72]. These sensory nerve endings contain 
vasoactive neuropeptides, such as calcitonin gene-related peptide (CGRP) and substance 
P (SP), which are released upon TRPV1 activation [73–75]. Release of  these vasoactive 
neuropeptides from TRPV1-positive sensory nerve fibers may regulate local blood flow.
Although in vitro experiments have indicated that NOD is an agonist of  TRPV1 [44], 
and NOD treatment yields renoprotective effects in ischemia-induced AKI, it is currently 
not clear if the reno-protective properties of  NOD are mediated via TRPV1. Nonetheless, 
other TRPV1 agonists have shown a beneficial effect on ischemia reperfusion injury (IRI) 
in different organs [69, 76, 77]. Activation of  TRPV1 may result in the release of  CGRP and 
SP [78–80] from sensory nerves, possibly causing local vasodilation in  end organs [76, 
81–84]. Its TRPV1-activating property and anti-inflammatory property, along with other 
tissue-protective properties, make NOD an attractive drug candidate to ameliorate tissue 
damage caused either by inflammation or other inciting events [51].
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Aim of This Thesis
The main aim of  this thesis was to determine the signaling pathway by  which NOD 
conveys protection in  the setting of  ischaemia-induced AKI. Furthermore, secondary 
aims were to delineate the molecular entities within NOD that are required for biological 
properties—TRPV1 activation and anti-inflammatory property; to study in  vivo tissue 
distribution and elimination kinetics of  NOD; and finally, to demonstrate that the redox 
activity of  NOD significantly affects cell behaviour. The following paragraphs describe 
the scope of  this thesis.
NADs have been reported to be tissue protective in a variety of  models, albeit the 
underlying mode of  action has not clearly been demonstrated. The potential use of  NADs 
in transplantation medicine has been reviewed in Chapter	2.
TRPV1 agonists are capable of  rendering a renoprotective effect in settings of  isch-
aemia-induced AKI. Because NOD is a TRPV1 agonist and exhibits a renoprotective effect 
in ischaemia-induced AKI, Chapter	3 addresses the question of  whether the renoprotec-
tive properties of  NOD are mediated via TRPV1 and whether renal transplant recipients 
can also benefit from the NOD treatment.
In Chapter	4, we subsequently tried to delineate the structural entities of  the NADs 
required for TRPV1 agonistic and anti-inflammatory properties. This was achieved via 
systematic modification of  the aromatic, linker, and side chain regions of  NOD. In this 
chapter, the interaction between NOD and the TRPV1-binding pocket that leads to TRPV1 
activation is also studied.
Pharmacokinetics and tissue distribution are important prerequisites for further 
development of  NADs toward clinical application. In Chapter	5, we sought to address 
this by developing a NOD-based radiotracer F-NOD. After assessing that the in vitro bio-
logical properties of  a nonradioactive reference compound F-NOD are similar to those 
of  NOD, tissue distribution and elimination kinetics of  [18F] F-NOD were determined 
by means of  Positron-emission tomography (PET) imaging.
Based on  the facts that the NADs are able to donate reduction equivalents, the 
catechol structure of  NADs can chelate iron [24], and the amphiphilic nature of  NADs 
provides them with access to various cellular compartments, in Chapter	6 we investi-
gated if  NADs would influence the redox homeostasis in  the Endoplasmic Reticulum 
(ER) and, in turn, oxidative protein folding [25, 26]. In addition, we made use of  synthetic 
NADs that were either changed at the aromatic ring or in the aliphatic chain to identify 
the structural entities within NOD that might be important for UPR activation. Further-
more, we addressed whether activation of  the UPR by NOD compromises cell viability or 
whether it represents a protective response, allowing cells to adapt to more aggravating 
conditions such as hypothermic preservation.
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Conjugates of  fatty acids with ethanolamine, amino acids or monoamine neurotransmit-
ters occur widely in nature giving rise to so-called endocannabinoids. Anandamide and 
2-arachidonoyl glycerol are the best characterized endocannabinoids activating both 
cannabinoid receptors (CB1 and CB2) and transient receptor potential vanilloid type 1 
(TRPV1) channels (anandamide) or activating cannabinoid receptors only (2-arachido-
noyl glycerol). TRPV1 is also activated by vanilloids, such as capsaicin, and endogenous 
neurolipins, e.g. N‑arachidonoyl dopamine (NADA) and N‑oleoyl dopamine (OLDA). 
Because donor dopamine treatment has shown to improve transplantation outcome 
in renal and heart recipients, this review will mainly focus on the biological activities of  
N‑acyl dopamines (NADs) as potential non-hemodynamic alternative for implementa-
tion in transplantation medicine. Hence the influence of  NADs on transplantation rel-
evant entities, i.e. cold inflicted injury, cytoprotection, I/R-injury, immune-modulation 
and inflammation will be summarized. The cytoprotective properties of  endogenous 




Donor organ shortage is the major bottle neck in  contemporary organ transplantation 
and warrants new strategies to increase the donor pool, to diminish the number of  organ 
allografts that are not suitable for transplantation, to improve post-transplant survival 
and thus to reduce the need for re-transplantation. While it is generally considered that 
the quality of  organ allografts obtained from living donors is superior to that of  allografts 
procured from post-mortem donors [1], the latter constitutes the largest part of  the donor 
organ pool. The inferior quality of  post-mortem donor allografts is a consequence of  vari-
ous deleterious events which occur after the onset of  brain death. Brain death is character-
ized by a massive catecholamine release, initially leading to an increased blood pressure 
and subsequently to a sharp decline, frequently followed by a hemodynamic collapse [2]. 
In addition, brain death is accompanied by  reduced levels of  cortisol, insulin, thyroid 
and pituitary hormones [3], which may have both a hemodynamic and metabolic impact 
on donor organs. Moreover, brain death is considered to be an inflammatory condition [4], 
albeit that the precise mechanism that leads to inflammation in end-organs is still being 
discussed. Early and adequate donor management is of  utmost importance not only for 
maintaining donor organ quality but also for increasing the number of  retrievable organs 
from potential donors [5]. Thus many transplantation centers and critical care societies 
have developed standardized donor management protocols, focusing on  hemodynamic 
and hormonal resuscitation [6] and [7].
For many decades low-dose dopamine has been applied for prevention and 
treatment of  acute kidney injury (AKI) in  critically ill patients [8, 9]. However, several 
meta-analyses and prospective studies have concluded that dopamine treatment nei-
ther prevents nor ameliorates AKI in these patients [10–14]. This is in sharp contrast to 
the retro-and prospective studies performed by  Schnuelle et  al. which clearly indicate 
that donor dopamine treatment improves transplantation outcome in kidney and heart 
allograft recipients [15, 16]. The mechanism by  which this occurs remains to be deter-
mined. Nonetheless, the protective effect cannot be fully explained by improved hemo-
dynamics, as the mean blood pressure in the dopamine-treated arm was not significantly 
different from the untreated arm [15]. Experimental brain dead models demonstrate 
that hemodynamic stabilization alone is not sufficient to reduce brain death-mediated 
inflammation in  renal allografts [17]. In line with this, Spindler et  al. recently demon-
strated that treatment with the hemodynamic inactive dopamine derivate N‑octanoyl 
dopamine (NOD) of  brain dead donor rats improves renal allograft function in recipient 
rats, despite the fact that it does not affect blood pressure in the brain dead donor rat [18].




Experimental in vitro and in vivo studies have delineated numerous potential mechanisms 
that collectively explain why dopamine may afford its salutary effect on transplantation 
outcome [19–21]. However, it remains to be elucidated which of  these effects are responsible 
for the clinical findings on donor dopamine treatment as described by Schnuelle et al. [15]. 
Among the beneficial mechanisms, the finding that catecholamines in  general can pro-
tect endothelial cells against cold inflicted injury [22] is highly intriguing and opens the 
possibility for novel therapeutic modalities to prevent or limit organ damage during static 
cold storage [15, 16] and [23–25]. The mechanism by which catecholamines protect against 
organ damage during hypothermic preservation is not completely understood, albeit that 
involvement of  the H2S pathway [26], the HO-1 pathway [27]and redox activity [22] has been 
postulated. With respect to the latter, Lösel et al. have demonstrated that the cryoprotective 
properties of  catecholamines are mediated via the redox active catechol structure in con-
junction with a minimal degree of  hydrophobicity [28]. Importantly synthetic NADs (Fig. 1), 
which also carries a catechol structure, is by far more protective as compared to dopamine 
as a consequence of  their increased hydrophobicity. Furthermore octylamide derivates of  
all possible dihydroxy benzoic acids revealed that only the reducing structures were pro-
tective while the non-reducing were ineffective despite comparable hydrophobicity. It thus 
seems that catecholamines afford cryoprotection due to their reducing properties; their 
efficacy is strongly influenced by their relative hydrophobicity.
Inasmuch as the catechol structure plays a pivotal role in cryoprotection indepen-
dent of  receptor engagement, this offers the possibility of  designing compounds that are 
devoid of  hemodynamic action and yet retain their cryoprotective properties. This might 
be of  particular importance since approximately 12 percent of  brain dead donors that are 
treated with low-dose dopamine may develop tachycardia or hypertension [15]. Also other 
dopamine-related side effects, e.g. depression of  the respiratory drive or cardiac arrhyth-
mias seem to be receptor-mediated [29, 30]. As demonstrated by Kohli et al. N-substituted 
dopamine derivates lack affinity to dopamine receptors and only possess a  weak beta 
agonistic activity [31]. Hence, NADs may display protective effects in the setting of  donor 
treatment at much lower concentrations compared to dopamine, while dopamine-like 
side effects would occur at much higher concentrations as required for their protective 
effect. However, no clinical data on NADs are yet available, which impedes drawing firm 
conclusions on dopamine-related side effects or safety of  NADs in humans.
Nakao et al. have postulated that cytochrome P450 heme proteins are degraded during 
hypothermic organ preservation. This causes a detrimental increased level of  intracellular 
free heme which subsequently leads to oxidative injury [32]. In addition to their reducing 
properties, catechol structures also have the propensity to coordinate with iron. Hence, it 
is at present unclear if the relevance of  the catechol structure in preventing cold inflicted 
injury resides in its capacity to scavenge reactive oxygen intermediates or in preventing the 


































The cytoprotective properties of  endogenous NADs have been studied mainly in relation 
to brain function and neuroprotection, including positive effects on  hypoxic–ischemic 
injury or brain inflammatory processes. Their protective effect is mainly attributed 
to the long-chain polyunsaturated fatty acids. Apart from the fact that dopamine fatty 
acid conjugates can act as cannabinoid receptor ligand [33] and as TRPV1 agonist [34, 35] 
, Shashoua et  al. reported that some of  these conjugates also act as carrier to increase 
brain dopamine content [35]. In line with the tendency of  docosahexaenoic acid (DHA) to 
accumulate in brain tissue [36], the DHA–dopamine conjugate is most active in increas-
ing dopamine uptake by the brain. Bobrov et al. showed that DHA–dopamine exhibited 
antioxidant activity and produced a dose-dependent protective effect on cultured gran-
ular cells from rat cerebellum under conditions of  oxidative stress. It also decelerated 
the development of  Parkinson’s disease-like symptoms in  a  MPTP (1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine) mouse model [37].
The antioxidant properties of  DHA-dopamine is most likely attributed to the cate-
chol structure as it is also present in synthetic NADs with short saturated fatty acids, e.g. 
NOD and N‑pivaloyl dopamine. Recently, Stamellou et al. reported that these synthetic 
NADs transiently activate the unfolded protein response (UPR) in endothelial cells [38]. 
This property is again dependent on  the redox activity of  these compounds. Although 
persistent activation of  the UPR may result in  apoptosis, the synthetic NADs did not 
affect cell viability in a μM range, yet they strongly impaired proliferation of  endothelial 
cells [38] and smooth muscle cells [unpublished data]. Interestingly, Stamellou et al. also 
demonstrated that long-term treatment of  endothelial cells with synthetic NADs results 
in hypo metabolism and thermotolerance. This is associated with decreased intracellular 
ATP concentrations, activation of  AMP-activated protein kinase and increased resistance 
to cold inflicted cell injury. It thus seems that induction of  the UPR by short synthetic 
NADs causes an adaptive response in endothelial cells. Since it has been suggested that 
induction of  the UPR is an integral part of  the protective strategies used by hibernating 
mammals for long term survival in a state of  cold torpor [39–41], adaptation of  donor 
organs to withstand cold ischemia via induction of  the UPR would be an intriguing 
strategy to improve organ quality under ischemic conditions. It should be emphasized 
however that organ adaptation in  hibernating mammals goes far beyond induction of  
the UPR [42].
Protection	against	I/R-injury
Even though our understanding in the pathophysiology of  I/R-injury has improved to 
a large extent in the past decades, there is still a need for novel compounds that minimize 
the extent of  tissue damage. Ischemic preconditioning (IPC) is a  protective procedure 
accomplished by  exposing the organ to a  minor stress, which by  itself  does not cause 
noticeable harm. The benefit of  IPC was first demonstrated by Murry et al. in dogs [43]; 
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its protective potential on reperfusion injury is now widely accepted. When the heart was 
subjected to short ischemic episodes separated by short perfusion periods the myocar-
dium was more tolerant to subsequent prolonged ischemia. Although IPC is difficult to 
implement as a clinical strategy, identifying effective molecules in IPC can lead to new 
therapeutic treatment modalities. Yet, the underlying mechanisms of  IPC have been 
equivocally discussed [44–46].
Proteasomal iron–protein degradation has been suggested by  Bulvik et  al. as 
important mechanism of  IPC. In this scenario it is postulated that expeditious cytoso-
lic iron release alters iron homeostasis which subsequently protects the myocardium 
during I/R [44]. In contrast Wu et al. proposed that the benefit of  IPC was mediated via 
suppressing excessive endoplasmic reticulum stress thereby diminishing C/EBP homol-
ogous protein (CHOP)-dependent apoptosis [45]. Also suppression of  cardiac progenitor 
cell apoptosis has been suggested [46]. More recently Lu et al. suggested a role of  TRPV1 
in  IPC [47]. Their data suggest that IPC upregulates arachidonate 12-lipoxygenase and 
consequently increases the production of  the endovanilloid 12(S)-hydroxyeicosatetrae-
noic acid, which in turn activates TRPV1. It is believed that TRPV1 functions as polymodal 
sensor to detect micro-environmental changes in tissues, e.g. low pH, high temperature, 
or noxious stimuli [48] and [49]. These changes are likely present in ischemic tissue. The 
finding that NOD activates TRPV1 may explain its renoprotective properties in the setting 
of  ischemia-induced AKI [50], yet the causality of  this observation and its translation 
to clinical application warrants further supportive evidence. Immune modulation and 
inflammation
The main pharmacological functions of  the endocannabinoid system include 
neuromodulation, controlling motor functions, cognition, emotional responses, homeo-
stasis and motivation. In the periphery, this system is also an important modulator of  
immunity [51].
Several studies have unambiguously demonstrated that endocannabinoids modu-
late proliferation and apoptosis of  T and B lymphocytes, macrophage-mediated killing, 
cytokine production, immune cell activation by inflammatory stimuli, chemotaxis and 
inflammatory cell migration [52, 53]. Most if not all of  these effects have been reported to 
be primarily mediated via CB2 receptors causing inhibition of  the cAMP/protein kinase 
A pathway.
NADs may modulate the immune system in a similar fashion. Yet there are a num-
ber of  biological activities described for NADs related to immune modulation that are 
neither mediated via CB receptors nor via TRPV1. Initially NADs were described as potent 
inhibitors of  5-lipoxygenase [54]. This enzyme catalyses two steps in the biosynthesis of  
leukotrienes (LT), a  group of  lipid inflammatory mediators derived from arachidonic 
acid. LT antagonists are used in  treatment of  asthma; more recently a  potential role 
in neointimal thickening and atherosclerosis has raised considerable interest [55–58]
Cyclooxygenase-2 (COX-2) is an enzyme that plays a key role in inflammatory pro-
cesses. Classically, this enzyme is up-regulated in inflammatory situations and is respon-
sible for the generation of  prostaglandins (PG). One lesser-known property of  COX-2 is 
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its ability to metabolize the endocannabinoids, N‑arachidonoyl ethanolamine and 2-ara-
chidonoyl glycerol, generating PG-glycerol and PG-ethanolamides [59]. Although the 
formation of  these COX-2-derived metabolites of  endocannabinoids has been known for 
a while, their biological effects remain to be fully elucidated. Recently, Alhouayek et al. 
showed that 2-arachidonoyl glycerol through its oxidation by  COX-2 gives rise to the 
anti-inflammatory prostaglandin D2-glycerol ester [60].
Interestingly, Navarrete et  al. found that N‑arachidonoyl dopamine (NADA) acti-
vates a redox-sensitive p38 MAPK pathway that stabilizes COX-2 mRNA resulting in the 
accumulation of  the COX-2 protein [61, 62]. Moreover, they demonstrated that NADA 
inhibits the expression of  microsomal prostaglandin E2 synthase 1 and thus the produc-
tion of  the inflammatory mediator PGE2. This was paralleled by the induction of  lipo-
calin-type prostaglandin D synthase and increased production of  PGD2. Therefore even 
though COX-2 amplifies tissue inflammation, in  conjunction with NADs, in  particular 
NADA, it may redirect PG synthesis towards formation of  PGD2 [62]. The finding of  Patel 
et al. that selective inhibitors of  COX-2 may worsen renal dysfunction and injury in con-
ditions associated with renal ischemia supports this view [63]. Because of  their redox 
active catechol structure NADs have the propensity to inhibit the activation of  redox 
dependent proinflammatory transcription factors, e.g. NF-κB, AP-1 and NFAT [64, 65]
and therefore they largely inhibit the expression of  inflammatory mediators produced 
by endothelial cells [66] and proliferation of  T cells [64–67].
Implementation	of	NAD	in transplantation	
medicine
While the list of  compounds that show beneficial effects at the pre-clinical stage is steadily 
increasing, only a  limited number of  such compounds will find a  clinical use. The lack 
of  venture capital for entering clinical phase studies is among others why only a small 
percentage of  promising compounds will proceed, let alone will obtain FDA approval.
The multitude of  beneficial effects of  NADs warrants careful considerations on the 
application mode, e.g. donor or recipient treatment, additive to preservation solutions, 
and their associated ethical hurdles. Particularly donor pre-treatment may raise ethical 
concerns as to whether written informed consent of  the recipient is required. Waiving 
informed consent of  the recipient in  the randomized donor dopamine treatment trial 
was justified because it was (1) strictly observational in the recipient; (2) the intervention 
was limited to the deceased donor and (3) limited to a fully approved drug. Clearly, as FDA 
approval for the use of  NADs in human does not exist, similar studies with the use of  
NADs are not possible. Although NADs may also have the propensity to protect allografts 
when used as additive to the organ preservation solution, there is no supportive evidence 
using whole organs, albeit that it has been reported for experimental models that addition 
of  dopamine to the preservation solutions is protective to liver [23] and renal allografts 
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[25]. Also the type of  NADs for implementation in  transplantation medicine requires 
careful considerations since some of  the beneficial effects of  NADs are meditated by the 
fatty acid tail and therefore not present in all NADs.
Concluding remarks
This review has summarized the potential protective properties of  NADs on transplan-
tation relevant entities. Based on their propensity to act as agonist of  CB receptors and 
TRPV1 channels, to act as anti-oxidant and to inhibit inflammatory mediators including 
those derived from arachidonic acid, NADs may find clinical implementation in trans-
plantation medicine as a  mean of  pre-conditioning to prevent brain death-induced 
inflammation and to prepare donor organs to cold ischemia. Yet it should be emphasized 
that most of  the potential benefits of  NADs mainly have been studied in vitro and only to 
a limited extent in transplantation relevant in vivo models. Nonetheless their potential 
as new expedient drugs should be further explored using relevant transplantation mod-
els. The composition of  the NADs, i.e. the type of  fatty acid that is required for a specific 
in vivo biological effect, as well as the pharmacokinetic of  these compounds should be 
implemented in future studies.
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N‑octanoyl dopamine (NOD) treatment improves renal function when applied to brain 
dead donors and in the setting of  warm ischemia induced acute kidney injury (AKI). 
Because it also activates transient receptor potential vanilloid type 1 (TRPV1) chan-
nels we first assessed if  NOD conveys its renoprotective properties in warm ischemia 
induced AKI via TRPV1 and secondly if  renal transplant recipients also benefit from 
NOD treatment. 
We induced warm renal ischemia in Lewis, wild type and TRPV1-/- Sprague Dawley 
rats by clamping the left renal artery for 45 min. Transplantations were performed in allo-
geneic and syngeneic donor recipient combinations (Fisher to Lewis, Lewis to Lewis) with 
a cold ischemia time of  20 h. Treatment was instituted directly after restoration of  organ 
perfusion. Renal function, histology and perfusion were assessed by serum creatinine, 
microscopy and magnetic resonance imaging (MRI) using arterial spin labelling (ASL).
NOD treatment significantly improved renal function in Lewis rats after warm 
ischemia induced AKI. It was however not effective after prolonged cold ischemia. The 
renoprotective properties of  NOD were only observed in Lewis or WT-, but not TRPV1-/- 
Sprague Dawley rats. Renal inflammation was significantly abrogated by NOD. MRI-ASL 
showed a significantly lower cortical perfusion in ischemic as compared to non-ischemic 
kidneys. No overall all differences were observed in renal perfusion between NOD and 
NaCl treated rats.
NOD treatment reduces renal injury in warm ischemia but is not effective in renal 
transplant in our experimental animal models. The salutary effect of  NOD appears to be 




Acute kidney injury (AKI) is recognized as a major complication in intensive care unit 
patients [1-4]. Approximately thirteen percent of  hospital-acquired AKI patients will 
progress to end stage renal disease within 3 years [5]. Innovative interventions beyond 
supportive therapy are currently not available for AKI patients; emphasizing the clinical 
need for new therapeutic approaches. 
Delayed graft function (DGF) is a manifestation of  AKI with attributes unique to 
transplantation. The diagnosis of  DGF is complicated by a variety of  definitions based on 
a range of  clinical criteria depending on the local transplant centre, region, and country 
[6, 7]. Along with an increased use of  marginal donors the incidence of  DGF has increased 
over time, translating to a fourty percent decrease in long-term graft survival [8, 9]. Cold 
ischemia time is strongly associated with DGF, with a twenty-three percent increase in 
the risk of  DGF for every 6 h of  cold ischemia [10, 11].
We have recently designed N‑octanoyl dopamine (NOD) as a possible drug candi-
date to overcome the limitations of  dopamine treatment in brain dead donors, i.e. tachy-
cardia and high blood pressure, which was observed in approximately twelve percent of  
treated donors in our prospective, randomized clinical trial to assess the salutary effect 
of  donor dopamine treatment on DGF [12]. In contrast to dopamine (DA), NOD does 
not affect mean arterial blood pressure in vivo [13], yet also improves renal function in 
recipient rats that received a renal allograft from a NOD treated brain dead donor [14, 
15]. NOD protects cultured cardiomyocytes, endothelial and renal epithelial cells against 
cold inflicted injury, much better as compared to dopamine. In addition to this, NOD has 
a profound anti-inflammatory action as it inhibits a subset of  pro-inflammatory genes 
via impaired NFκB trans-activation [16], thus making NOD a promising drug candidate 
beyond its intentional use in donor management.
Indeed we have reported that NOD also has renoprotective properties in the setting 
of  warm ischemia-induced AKI, when applied shortly before and after the induction of  
AKI [17]. Although in vitro experiments have indicated that NOD is an agonist of  the tran-
sient receptor potential vanilloid type 1 channel (TRPV1) [17], it, is currently not clear if  
the renoprotective properties of  NOD are mediated via TRPV1. Yet, other TRPV1 agonists 
have shown a beneficial effect on ischemia reperfusion (I/R) injury in different organs 
[18-20]. Activation of  TRPV1 may result in the release of  calcitonin gene related peptide 
(CGRP) and substance P (SP) [21-23] from sensory nerves, possibly causing local vasodila-
tion in end-organs [19, 24-27].
In the present study we hypothesize that the renoprotective effect of  NOD in warm 
ischemia-induced AKI is TRPV1 dependent. TRPV1 activation will increase renal per-
fusion and thus improves restoration of  renal function. Because TRPV1 activation may 
also occur in renal allografts after prolonged static cold storage, we speculated that NOD 
treatment of  renal allograft recipients would also benefit from NOD. 





Male Fisher (F344/DuCrl), Lewis (LEW/Crl) rats and Sprague Dawley (CD® IGS) rats 
weighting 200 g – 220 g were obtained from Charles River (Sulzfeld, Germany). TRPV1-/-
Sprague Dawley rats were obtained from SAGE Labs (Boyertown, PA, US). Lewis rats were 
used in warm ischemia-induced AKI model to demonstrate that the NOD treatment after 
onset of  ischemia is equally protective as the combination of  pre-and post-treatment in 
previous study [17]. Since TRPV1-/- rats were bred on the Sprague Dawley background, WT 
Sprague Dawley were used as control. For renal transplantation the allogeneic Fisher to 
Lewis and syngeneic Lewis to Lewis models were used. Animals were kept under stan-
dard conditions and fed standard rodent chow and water ad libitum. All procedures 
were performed according to the Guide of  the Care and Use of  Laboratory Animals pub-
lished by the National Academy of  Sciences and were approved by the local authorities 
(Regierungspräsidium Karlsruhe AZ: 35-9185.81/G – 19/12, 35-9185.81/G – 229/12). 
Experimental protocol
Ischemia-induced acute kidney injury (AKI) and renal 
transplantation (Tx)
All surgical procedures were performed under general anaesthesia using ketamine 
(100 mg/mL; Ketamin®, Intervet Deutschland GmbH, Unterschleißheim, Germany) and 
xylazine (6 mg/mL; Rompun®, Bayer Health Care, Leverkusen, Germany) intraperitoneal. 
AKI was induced by clamping the left renal artery for 45  min in unilateral nephrecto-
mized rats. For ASL measurements the contralateral kidney was not removed but served 
as non-ischemic control.
Allogeneic and syngeneic renal transplantations were performed as described 
previously [28, 29]. After explantation, donor kidneys were stored at 4° C in University 
of  Wisconsin solution for 20 h, before transplantation into bilaterally nephrectomized 
recipients. 
Osmotic minipump (Alzet® 2 mL1, 10 µL/hr, Charles River Laboratories, Sulzfeld, 
Germany) filled with 40 µM NOD (Novaliq GmbH, Heidelberg, Germany) or NaCl (NaCl 
0.9 percent Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany) were implanted 
subcutaneously directly after induction of  AKI or after transplantation as described [28, 
29]. Each group consisted of  a minimum of  eight animals. No immunosuppression was 





Group 1: Control; ischemia time 45 min; NaCl treatment for 5 days
   1A: AKI in Lewis rats
   1B: AKI in wild type (WT) Sprague Dawley rats (sd)
   1C: AKI in TRPV1-/- Sprague Dawley rats 
1D: AKI (left kidney) in Lewis rats, right kidney was not removed and served as control for 
renal perfusion experiments 
Group 2:  NOD; ischemia time 45 min; NOD treatment for 5 days
   2A: AKI in Lewis rats
   2B: AKI in wild type (WT) Sprague Dawley rats
   2C: AKI in TRPV1-/- Sprague Dawley rats 
2D: AKI (left kidney) in Lewis rats, right kidney was not removed and served as control 
for renal perfusion experiments 
Transplantation (Tx):
Allogeneic (Allo):   Graft from Fisher donors transplanted into bilaterally nephrecto-
mized Lewis recipients
Group 3: Allo-Tx – control; post Tx treatment with NaCl for 7 days
Group 4: Allo-Tx – NOD; post Tx treatment with NOD for 7 days
Syngeneic(Syn):    Graft from Lewis donors transplanted into bilaterally nephrecto-
mized Lewis recipients
Group 5: Syn-Tx – control; post Tx treatment with NaCl for 7 days
Group 6: Syn-Tx – NOD; post Tx treatment with NOD for 7 days




Renal function was assessed by serum creatinine (s-crea) and serum urea (s-urea), mea-
sured on days 0, 1, 3, 5 (and 7 in Tx models) after surgery. s-crea and s-urea are expressed 
as mean in mg/dl ± SD.
Immunohistochemistry
The kidneys were harvested and on day 5 after AKI and on day 7 after Tx and immuno-
histochemical staining were performed as described before [30]. Quantification of  ED1 
staining was performed by morphometric analysis using software (Cell^F 5.1, Olympus 
Soft Imaging Solutions GmbH, Münster, Germany). For each section 20 random high 
magnification (400x) microscopic fields were analyzed, the results are expressed as per-
cent ED1 stained area per microscopic field ± SD.
Real-time quantitative PCR
Total RNA was isolated from renal tissue using Trizol-Reagent (Life Technologies, Inc., 
Rockville, MD, USA). After DNase treatment, (RNase free DNase I, Ambion, Wood-
ward, Austin, TX, USA) 1 µg of  total RNA was reverse-transcribed into cDNA using the 
High-Capacity cDNA Reverse Transcription Kit (Life Technologies). TaqMan™ real-time 
polymerase chain reaction was used for quantitative measurement of  mRNA expression 
of  CXCL1 (Rn00578225_m1), E-Selectin (Rn00594072_m1), ICAM (Rn00564227_m1), 
IL-6 (Rn99999011_m1), TNF-alpha (Rn99999017_m1), VCAM1 (Rn00563627_m1). All 
samples were measured in triplicate. Gene expression was normalized to the housekeep-
ing gene beta-actin (Rn006677869_m1) and expressed as fold change relative to control 
native kidney and calculated with the ΔΔCT method [31].
Live-cell calcium imaging
Preparation of  acutely dissociated dorsal root ganglion (DRG) neurons and imaging were 
done as described before [32]. A cell was considered an excitable neuron and then eval-
uated only when significantly responding to application of  capsaicin and/or depolariza-
tion by high potassium solution (140 mM). Each single slide investigated was regarded as 
an independent experiment. Five independent experiments were performed on acutely 
dissociated DRG neurons obtained from three different male WT or TRPV1-/- rats.
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Arterial Spin Labelling-Magnetic Resonance Imaging (ASL-MRI)
Renal perfusion was measured with MRI using a flow-sensitive alternating inversion 
recovery (FAIR)-ASL technique [33, 34]. In brief, to acquire a perfusion-weighted image, 
arterial blood is labelled by inverting its magnetization. After an inflow time (inversion 
time) TI which allows the labelled blood to flow into the tissue of  interest, it is imaged 
with an appropriate readout sequence. When using FAIR, the labelling is alternating 
between a global inversion (tag image) and a slice-selective inversion (control image). 
Several tag-control pairs and additional M0 images, without prior labelling are recorded. 
All ASL perfusion measurements were performed following the protocol and parameters 
described in Zimmer et al. [35]. A 3 T whole-body MR scanner (Magnetom Tim Trio, Sie-
mens Healthcare Sector, Erlangen, Germany) was used. The total measurement time for 
30 tag-control pairs and 30 M0 images was 9 min. ASL perfusion maps were calculated by 
analysing the acquired data with an in-house written MATLAB (Version 7.10, The Math-
Works, Natick, MA, USA) script. Renal perfusion was expressed in mL/100g/min. 
Statistical Analysis
Data are shown as means ± standard deviation (SD). For the calcium imaging data are 
shown as means ± standard error of  the mean (SEM). For comparison of  two nonpara-
metric independent groups, Wilcoxon Rank Sum test was applied. For comparison of  
two parametric independent groups two-sample-t-test was performed (JMP 10.0.0; SAS 
Institute Inc, Cary, NC, USA). Statistical significance was defined as a p-value < 0.05.
Results
NOD treatment improves renal function after warm ischemia 
NOD treatment significantly improved renal function in Lewis rats after induction of  
warm renal ischemia (s-crea NOD vs. NaCl ): day 1 – 2.42 ± 0.36 vs. 3.02 ± 0.52, p = 0.0406; 
day 3 – 1.04 ± 0.60 vs. 3.52 ± 1.70, p = 0.0038; day 5 – 0.46 ± 0.10 vs. 2.04 ± 1.63, p = 0.0032// 
s-urea NOD vs. NaCl: day 3 – 198.11 ± 106.64 vs. 503.05 ± 231.94, p = 0,01; day 5 – 89.75 ± 32.69 
vs. 387.44 ± 293.78, p = 0.0054) (Figure 1A). While NaCl treated rats displayed a significant 
body weight loss, this was not observed with NOD treated rats (Figure 1B). Also the num-
bers of  infiltrated ED1 + cells assessed at day 5 were significantly decreased in NOD treated 
rats (Figure 1C and D). There was no difference in cytokine mRNA expression except for 
TNFα; IL-6 was not statistically significant Fold change TNF-α: 1.16 ± 0.4 vs 0.69 ± 0.19; Fold 
change IL6: 6.60 ± 2.3 vs 10.52 ± 3.91; not significant; p = 0.0128; NaCl vs NOD treatment).
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Figure	1.	NOD	treatment	improves	renal	function	and	ameliorates	inflammation	in	AKI (A) Serum 
creatinine (mg/dl) (graph to the left) and serum urea (mg/dl) (graph to the right were assessed on day 0, 
1, 3, 5 after induction of  AKI. The animals were treated with NOD (bold line) or NaCl (dotted line) via 
osmotic mini pumps over the whole experimental period. Serum creatinine was significantly lower in 
NOD treated rats on all days of  measurements. Serum creatinine: *p = 0.041 (day 1), **p = 0.004 (day 3), 
**p = 0.003 (day 5). Serum urea: p = 0.344 (day 1), **p = 0,010 (day 3), **p = 0,005 (day 5). (B) Body weight 
of  each of  the animals was assessed directly prior to induction of  AKI and 5 days thereafter. The body 
weight prior to AKI induction was set at 100 percent. In the NaCl treated rats a significant mean body 
weight loss of  ~ 15 percent was observed, while in the NOD treated rats no significant differences were 
noticed in body weight before and 5 days after induction of  AKI. (C) Renal infiltrated ED1  + cells were 
assessed by immunohistochemistry as described in materials and methods. Quantification of  ED1 + was 
performed by quantitative morphometric analysis. For each animal at least 2 sections were evaluated 
using 10 randomly chosen high power (400⨯ magnification) microscopic fields. The results are expressed 
as mean percent ED1 + stained area per microscopic field ± SD. (D) Representative sections obtained from 
kidneys of  the NaCl or NOD treated rats are depicted.
Chapter 3
54
The salutary effect of NOD treatment in ischemia-induced AKI is 
mediated via TRPV1
We assessed the role of  TRPV1 activation in the renoprotective properties of  NOD by 
using TRPV1-/- Sprague Dawley rats. To assure that TRPV1 responses were absent in the 
TRPV1-/- Sprague Dawley rats, dorsal root ganglion cells (DRG) were isolated from wild 
type (WT) Sprague Dawley and TRPV1-/- Sprague Dawley rats and subsequently stimu-
lated with either capsaicin or NOD. As determined by live-cell calcium imaging, neither 
capsaicin (10  µM, 100  µM) nor NOD (30  µM, 100  µM) were able to activate TRPV1 in 
DRG isolated from TRPV1-/- Sprague Dawley rats, while this was clearly observed in WT 
Sprague Dawley rats (Figure 2). 
Warm ischemia-induced AKI was induced in WT Sprague Dawley and 
TRPV1-/- Sprague Dawley rats as described for Lewis rats. Impairment of  renal function 
was observed to a similar extent in NaCl treated WT Sprague Dawley and TRPV1-/- Sprague 
Dawley rats, indicating that the absence of  TRPV1 does not influence renal function in 
the course of  AKI (Figure 3A). While NOD treatment was significantly improving renal 
function in the WT Sprague Dawley rats (Figure 3A, graph to the left), it was not effective 
in TRPV1-/- Sprague Dawley rats (Figure 3A, graph to the right). Loss of  body weight 5 days 
after AKI was significantly lower in NOD treated WT Sprague Dawley rats as compared 
to NaCl treatment. This was not observed in TRPV1-/- Sprague Dawley rats (Figure 3B). 
Irrespective of  treatment, TRPV1-/-  Sprague Dawley rats displayed less infiltration of  
ED1  +  cells as compared to WT Sprague Dawley rats. Only in WT Sprague Dawley rats 
NOD treatment significantly reduced the amount of  infiltrated ED1 + cells (Figure 3C and 
3D). No difference were observed in cytokine expression in renal tissue 5 days after AKI 
between the NOD treated and control group except for IL-6 which was significantly higher 
in treated WT Sprague Dawley rats (Table 1) and TRPV1-/- Sprague Dawley rats. Cytokine 
expression was significantly lower in the TRPV1-/- Sprague Dawley rats as compared to 
WT Sprague Dawley rats (Figure 3E).
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Figure	2.	NOD	does	not	activate	DRG	from	TRPV1-/- rats. Live cell calcium imaging was performed 
on DRG isolated from wild type (WT) Sprague Dawley and TRPV1-/- Sprague Dawley rats. Images were 
recorded at baseline and after stimulation of  DRG with 30 µM and 100 µM NOD, capsaicin 10 µM (1) for 
WT and 100 µM (2) for KO, 140 mM potassium chloride and 10 µM ionomycin subsequently. The ratio 
340/380 at 510 nm is a measure proportional to free intracellular calcium. The images are false colour 
coded according to the amount of  intracellular calcium (graph at the top where warmer colours indicate 
increasing calcium values). The graphs at the bottom show the mean trace ± SEM of  at least 60 regions of  
interest (ROI) with each ROI containing 1 cell. SEM is depicted as dotted gray line.
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Figure	3.	The	renoprotective	effect	of	NOD	is	abrogated	in	TRPV1-/- Sprague	Dawley	rats. (A) Serum 
creatinine (mg/dl) from WT Sprague Dawley (graph to the left) and TRPV1-/- Sprague Dawley rats (graph 
to the right) were assessed on day 0, 1, 3, 5 after induction of  AKI. The animals were treated with NOD 
(bold line) or NaCl (dotted line) via osmotic mini pumps over the whole experimental period. Serum cre-
atinine was significantly lower in NOD treated rats on all days of  measurements in the WT rats, while in 
the TRPV1-/- Sprague Dawley rats no differences were found between NOD and NaCl treated rats. Serum 
creatinine/WT: *p = 0.038 (day 1), **p = 0.002 (day 3), **p = 0.004 (day 5). Serum creatinine/TRPV1-/- Sprague 
Dawley : p = 0.267 (day 1), p = 0.722 (day 3), p = 1.0 (day 5). (B) Body weight was measured 5 days after AKI in 
WT Sprague Dawley and TRPV1-/- Sprague Dawley rats. The results are expressed as mean percent body 
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Table	1.	Quantification of  mRNA for various cytokines was done in renal tissue obtained 5 
days after AKI.
WT Sprague Dawley rats TRPV1-/- Sprague Dawley rats
Cytokines	↓	/Treatment→ NaCl NOD NaCl NOD
CxCL1 6.43 ± 1.29 7.36 ± 1.02 1.55 ± 0.58 2.02 ± 0.44
E-SEL 2.65 ± 0.20 2.77 ± 0.23 1.45 ± 0.38 2.13 ± 0.31
ICAM 2.48 ± 0.23 3.34 ± 0.41 2.27 ± 0.15 2.45 ± 0.35
IL-6 21.81 ± 1.94 41.06 ± 5.42† 11.88 ± 2.04 25.99 ± 4.11**
TNF-α 2.29 ± 0.26 2.44 ± 0.19 0.86 ± 0.20 1.61 ± 0.15***
VCAM 0.49 ± 0.03 0.49 ± 0.04 0.46 ± 0.07 0.59 ± 0.08
Results are expressed as Relative quantity ± SEM relative to untreated native kidney.  
(† p = 0.0094; **p = 0.0062, ***p = 0.0096)
weight loss relative to the body weight immediately before AKI induction. In WT Sprague Dawley rats NOD 
treatment significantly mitigates body weight loss (p = 0.0041). No difference was found in TRPV1-/- Sprague 
Dawley rats. (C) Representative sections obtained from kidneys of  NaCl or NOD treated WT and TRPV1-
/- Sprague Dawley rats are depicted. (D) Renal infiltrated ED1 + cells were assessed by immunohistochem-
istry. Quantification of  ED1  + was performed by quantitative morphometric analysis. For each animal at 
least 2 sections were evaluated using 10 rando mLy chosen high power (400⨯ magnification) microscopic 
fields. The results are expressed as mean percent ED1 stained area per microscopic field ± SD. (E) The mRNA 
expression for different inflammatory cytokines was performed by qPCR on renal tissue harvested 5 days 
after AKI induction. Result expressed as Relative quantity ± SEM relative to untreated native kidney.
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Is renal perfusion influenced by NOD?
We assessed if  the renoprotective effect of  NOD was associated with improved renal per-
fusion. Renal cortical perfusion in the ischemic kidney was measured 5 days after warm 
ischemia-induced AKI using ASL. The non-ischemic kidney served as control. Renal 
cortical perfusion was significantly lower in the ischemic kidney, as reported previously 
[35]. NOD treatment did not influence cortical perfusion neither in the ischemic, nor in 
the non-ischemic control kidney (Figure 4).
Figure	4	Renal	perfusion	after	AKI	and	NOD	treatment.	Renal cortical perfusion was measured by 
ASL-MRI in a total of  10 rats. AKI was induced as described in the materials and method section. In 
each animal renal cortical perfusion was compared to the non-ischemic kidney (A). Exemplary illus-
trations of  ASL perfusion MRI of  two rats with left side AKI either treated with NOD (lower row) or 
NaCl (upper row) are depicted. Axial morphological images of  the kidneys as recorded during the ASL 
measurement (M0 images) are displayed on the left. The according maps of  absolute perfusion values in 
units of mL/100g/min are shown on the right. (B)	Renal cortical perfusion was quantified and expressed 
as perfusion in mL/100g/min ± SD. 
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NOD does not affect renal function in NOD treated transplant 
recipients
We next assessed if  the renoprotective effect of  NOD treatment was also noted after 
prolonged cold ischemia and transplantation NOD treatment of  the recipients did not 
significantly influence renal function, yet there was a trend observed towards a minor 
improvement (Figure 5A). Similarly, NOD did not influence body weight loss, renal 
inflammation (Figure 5B, C and D) or cytokine mRNA expression (data not shown). To 
exclude that an anti-Fisher allo-response or intrinsic strain differences have were under-
lying the failure of  NOD to act renoprotective also syngeneic renal transplantations were 
performed. Similar as observed in the allogeneic transplantation model, recipient NOD 
treatment was not renoprotective (Figure 5E) or influenced body weight (Figure 5F). This 
was unlikely due to the susceptibility of  TRPV1 expressing sensory nerves to prolonged 
cold preservation since isolated DRG that were either or not subjected to cold preserva-
tion reacted in a similar fashion to both NOD and capsaicin (Figure 5G).
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Figure	5.	NOD treatment of  renal allograft recipients does not improve renal function. (A) Serum creat-
inine (mg/dl) (graph to the left) and serum urea (mg/dl) (graph to the right) were assessed on day 0, 1, 3, 5 
and 7 after transplantation of  allogeneic Fischer renal allografts in Lewis recipients. The renal allografts 
NOD treatment exerts reno-protective properties in AKI but not in renal allograft recipients 
61
3
were subjected to 20 h of  cold preservation in UW solution. The recipients were treated with NOD (bold 
line) or NaCl (dotted line) via osmotic mini pumps over the whole experimental period. No differences 
in renal function between the groups were noted. Serum creatinine: p = 0.494 (day 1), p = 0.129 (day 3), 
p = 0.470 (day 5), p = 0.086 (day 7). Serum urea: p = 0.119 (day 1), p = 0.494 (day 3), p = 0.939 (day 5), p = 0.939 
(day 7). (B) Body weight loss was measured on day 7 after allogeneic renal transplantation. The result is 
expressed as mean body weight loss in percent relative to the body weight on day 0. No differences in loss 
of  body weight were found in both transplantation models. (C) Renal infiltrated ED1 + cells were assessed 
by immunohistochemistry. Quantification of  ED1 + was performed by quantitative morphometric anal-
ysis. For each animal at least 10 sections were evaluated using 20 rando mLy chosen high power (400⨯ 
magnification) microscopic fields. The results are expressed as mean percent ED1 stained area per micro-
scopic field ± SD. (D) Representative sections obtained from kidneys of  the NaCl or NOD treated recipient 
rats. (E) Serum creatinine (mg/dl) (graph to the left) and serum urea (mg/dl) (graph to the right) were 
assessed on day 0, 1, 3, 5 and 7 after transplantation of  syngeneic Lewis renal allografts in Lewis recipi-
ents. The renal allografts were subjected to 20 h of  cold preservation in UW solution. The recipients were 
treated with NOD (bold line) or NaCl (dotted line) via osmotic mini pumps over the whole experimental 
period. No differences in renal function between the groups were noted. Serum creatinine: p = 0.713 (day 
1), p = 0.6 (day 3), p = 0.96 (day 5), p = 0.792 (day 7). Serum urea: p = 0.227 (day 1), p = 0.431 (day 3), p = 1.0 (day 
5), p = 0.674 (day 7). (F) Body weight loss was measured on day 7 after syngeneic renal transplantation. 
The result is expressed as mean body weight loss in percent relative to the body weight on day 0. No 
differences in loss of  body weight were found in both transplantation models. (G) Live cell calcium imag-
ing was performed on freshly isolated DRG or on DRG that were subjected to 18 h of  cold preservation. 
DRGs were subsequently stimulated with 30 µM NOD, 10 µM capsaicin, 140 mM potassium chloride and 
10 µM ionomycin. Mean traces ± SEM of  200 regions of  interest (ROI) with each ROI containing one cell 
is depicted. SEM is depicted as dotted line.
Discussion
In the present study we further explored the renoprotective effect of  NOD in the setting 
of  warm ischemia induced AKI in more details and assessed if  renal allograft recipients 
may also benefit from NOD treatment. The major findings of  this study are as follows. 
Firstly, NOD treatment improves renal function in warm ischemia induced AKI, even 
when treatment is started after renal ischemia. Improved renal function was not asso-
ciated with large changes in renal perfusion. Secondly, the renoprotective properties 
of  NOD are completely lost in TRPV1-/- Sprague Dawley rats. Thirdly, NOD treatment of  
renal transplant recipient rats does not improve renal function. TRPV1 responsiveness 
was not lost as a consequence of  cold preservation since both NOD and capsaicin were 
able to activate DRG that were subjected to cold preservation. 
Our study is in good agreement with previous publications on the protective prop-
erties of  TRPV1 activation in the setting of  ischemia reperfusion injury in kidney [18, 
36], lung [20] and heart [37] models. Nonetheless the finding that NOD treatment did not 
improve kidney function in renal allograft recipient rats was unexpected. In our previous 
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studies on NOD and AKI, NOD was applied as bolus therapy shortly before and directly 
after induction of  warm ischemia induced AKI. Because we intuitively reasoned that 
pre-treatment of  the recipient would not influence the function of  the donor allograft, 
we first demonstrated that pre-treatment per se is not required for the renoprotective 
effect of  NOD in the warm ischemia-induced AKI model. Hence both the AKI and trans-
plantation models were similar in the sense that treatment was started after the inciting 
event. It could be argued that cold preservation of  renal grafts is causing more damage 
to the kidney as compared to warm ischemia and therefore NOD might not be protective 
under the former condition. Yet this was not reflected by serum creatinine levels which 
even showed a trend towards a faster recovery of  renal function in the transplantation-as 
compared to the warm ischemia-induced AKI model. As this was observed in both 
syngeneic and allogeneic donor recipient combinations, intrinsic strain differences in 
susceptibility to tissue ischemia also cannot explain these results. We did not study the 
expression of  TRPV1 in renal tissue after cold storage and thus it cannot be excluded that 
cold storage affects the expression of  TRPV1 and consequently the efficacy of  NOD to 
improve renal function. However cold storage of  isolated DRG did not impair the efficacy 
of  capsaicin or NOD to activate TRPV1. 
The renal pelvis, pelvi-ureteric junction, and ureter are heavily innervated by 
TRPV1-positive sensory nerves located between the layers of  smooth muscles and epithe-
lia [38, 39]. The sensory nerve endings contain amongst others vasoactive neuropeptides, 
e.g. calcitonin gene-related peptide (CGRP) and substance P (SP), which are released 
upon TRPV1 activation [40, 41]. Because CGRP and SP are vasoactive neuropeptides 
TRPV1-positive sensory nerve fibers may regulate local renal blood flow [42]. 
Mizutani et al [25] have reported that denervation of  primary sensory nerves 
before renal ischemia/reperfusion aggravates the inflammatory response in the kidney 
and worsens renal function. Accordingly they postulate that TRPV1 expressing sensory 
nerves are activated in the pathologic process of  warm ischemia/reperfusion-induced 
AKI and that such activation reduces acute renal injury by attenuating inflammatory 
responses. The finding that no significant difference in renal function impairment was 
found between WT and TRPV1-/-  Sprague Dawley rats that were subjected to ischemia 
induced AKI and the finding that in kidneys of  the latter rats consistently less infiltra-
tion of  ED1  + monocytes/macrophages was present argues against this hypothesis. The 
expression of  a number of  chemokines was also reduced in the TRPV1-/- as compared to 
the WT Sprague Dawley rats, albeit that this might equally well be explained by a reduced 
number of  infiltrated monocytes/macrophages. A recent study by Chen et al [43] also 
demonstrated that TRPV1 activation improves AKI while the absence of  TRPV1 or inhi-
bition of  these channels did not further deteriorate renal function in the setting of  AKI. 
Although our data are in good agreement with this study, it remains to be assessed why 
the expression of  pro-inflammatory cytokines are significantly reduced in TRPV1-/- rats. 
Cytokine expression has been addressed in the study by Chen et al [43]. These finding also 
suggest that the inflammatory response in the course of  AKI might not be a major critical 
factor that determines renal function. Also, despite the fact that in vitro studies clearly 
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have demonstrated the anti-inflammatory properties of  NOD [44], with the exception 
of  a reduction in infiltrating ED1 + cells NOD treatment did not have a major influence on 
the expression of  pro-inflammatory cytokines in the kidney following AKI. In fact, we 
observed that the expression of  IL-6 was increased by NOD in WT and TRPV1-/- Sprague 
Dawley as well as in Lewis rats, albeit that this did not reach statistical significance in the 
latter strain.
Although our study unambiguously demonstrates that the renoprotective effect of  
NOD in warm ischemia-induced AKI is strictly depending on TRPV1 expression, there are 
some limitations that warrant further studies. In such studies also the influence of  NOD 
on early inflammatory parameters needs to be implemented. At present it is not clear 
why TRPV1 activation in warm ischemia-induced AKI models translates into improved 
renal function. Even though capsaicin leads to vasodilation in the renal vasculature 
[42], we were not able to demonstrate differences in renal perfusion in NOD treated rats 
using ASL. However it cannot be excluded that NOD treatment slightly increases renal 
perfusion not detectable by the ASL-MRI method [35]. Secondly, it is not clear why renal 
recipients do not benefit from NOD treatment. This seems not to be related to allogeneic 
differences, cold preservation or intrinsic differences in kidney from different strains, yet 
the role of  renal denervation in NOD mediated renoprotection and kidney expression of  
TRPV1 over time in AKI has not been addressed. Thirdly, renoprotective effect conveyed 
by NOD in the warm ischemia induced AKI model cannot be extrapolated to other causes 
of  AKI. Although, NOD treatment in pre and post bolus combination, and as continuous 
treatment directly after the inciting event show a protective effect, it still needs to be 
assessed if  NOD treatment would impart protection once the degree of  injury is large and 
manifested by already increased serum creatinine levels. Apart from this, NOD improves 
renal function in allograft recipients when used in BD donors [14], yet whether this is also 
mediated by TRPV1 is currently not known. An intriguing question which arises is as to 
whether donor NOD treatment can improve organ quality of  renal allograft with already 
impaired donor renal function. 
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We studied the chemical entities within N-octanoyl dopamine (NOD) responsible for the 
activation of  transient-receptor-potential channels of  the vanilloid-receptor subtype 1 
(TRPV1) and inhibition of  inflammation. The potency of  NOD in activating TRPV1 was 
significantly higher compared with those of  variants in  which the ortho-dihydroxy 
groups were acetylated, one of  the hydroxy groups was omitted ( N-octanoyl tyramine), 
or the ester functionality consisted of  a bulky fatty acid ( N-pivaloyl dopamine). Short-
ening of  the amide linker (ΔNOD) slightly increased its potency, which was further 
increased when the carbonyl and amide groups (ΔNODR) were interchanged. With the 
exception of  ΔNOD, the presence of  an intact catechol structure was obligatory for the 
inhibition of  VCAM-1 and the induction of  HO-1 expression. Because TRPV1 activation 
and the inhibition of  inflammation by  N-acyl dopamines require different structural 





N-acyl dopamines (NADs) are condensation products of  fatty acids linked to dopamine 
at the amino group. They show agonistic properties at the transient receptor potential 
channel of  the vanilloid receptor subfamily subtype 1 (TRPV1), are capable of  activating 
the cannabinoid receptors CB1 and CB2 and show anti-inflammatory and immune mod-
ulatory effects[1–4]. TRPV1 is mainly expressed in unmyelinated C-and thinly myelinated 
Aδ-afferent nerve fibers[5, 6] and significantly contributes to the generation of  pain sig-
nals, i.e. nociception. It is essential for selective modalities of  pain sensation, e.g. tissue 
injury-induced thermal hyperalgesia [7] as observed in  the course of  inflammation [8], 
incision-induced postoperative pain [9], visceral nociception [10] or neuropathic pain 
conditions [11, 12].
There is growing evidence that supports a prominent role for inflammation in the 
development and maintenance of  neuropathic pain. TRPV1 activation by NADs has been 
reported to modulate nociceptive signaling in  inflammatory pain[13–15]. Independent 
hereof, NADs also exhibit anti-inflammatory properties on  their own through inhibi-
tion of  transcription factors involved in inflammation, e.g. NFκB, NFAT and AP-1 [1, 2]. 
We have previously demonstrated that N-octanoyl dopamine (NOD), a synthetic NAD, 
strongly inhibits Tumor necrosis factor alpha (TNFα) mediated vascular cell adhesion 
molecule-1 (VCAM-1) expression along with a  variety of  inflammatory chemo-and 
cytokines [16]. Moreover, like other catechol containing structures NOD induces the 
expression of  heme oxygenase-1 (HO-1), as a consequence of  Nrf-2 activation[17]. These 
properties make NOD an interesting molecule to ameliorate tissue damage, either caused 
by inflammation or oxidative stress as inciting events. Indeed we have shown that NOD 
has a salutatory effect on ischemia induced acute kidney injury (AKI) in rats [18] and that 
its use in brain dead donor rats improves renal function in recipient rats[19].
In analogy to capsaicin (CAP), an archetypic TRPV1 agonist, NADs can be structur-
ally divided into three parts, i.e. the aromatic moiety (A-region), the linker region con-
taining the amide bond (B-region) and the hydrophobic aliphatic side chain (C-region)
[20–22]. NOD differs from CAP in structure as it contains a catechol instead of  a vanilloid 
moiety (the A-region), is one methylene group longer (the B-region) and contains a com-
pletely saturated aliphatic chain (the C-region) (Figure 1A).
In this study we try to assess what structural elements impart NADs TRPV1 agonis-
tic properties and what structural components confer its anti-inflammatory properties. 
We used NOD as a lead compound and subsequently made changes in the A-, B-and C-re-
gion to delineate to what extent this affects TRPV1 activation and its anti-inflammatory 
properties in terms of  inhibiting TNFα mediated VCAM-1 and HO-1 induction.





General	procedures	for	chemical	synthesis. All reagents and solvents were purchased 
from commercial suppliers and were used without further purification unless otherwise 
specified. NMR spectra were recorded on a 250 MHz Bruker AC250, a 300 MHz Varian 
Mercury Plus and a 500 MHz Varian NMR System spectrometer (Palo Alto, CA). Chem-
ical shifts (δ) are given in  ppm and are referenced to the residual solvent resonance 
signals relative to (CH3)4Si (1H, 13C). Mass spectra were obtained on a Bruker Daltonics 
microflexTM MALDI-TOF mass spectrometer (Bremen, Germany). Preparative column 
chromatography was performed on  Merck silica gel 60. Reactions were monitored 
by  thin-layer chromatography (TLC) on  Merck silica gel F254 aluminum plates, with 
visualization under UV (λ = 254    nm). If  necessary, the purity was determined by  high 
performance liquid chromatography (HPLC). Purity of  all final compounds was 95 per-
cent or higher (Supplementary Table S2). HPLC was performed on  a  Dionex UltiMate 
3000 HPLC system (Thermo Scientific, Dreieich, Germany), equipped with a  reverse 
phase column (Merck Chromolith RP-18e; analytical: 100x4.6 mm plus a guard column 
10x4.6mm; semipreparative: 100x10 mm plus a guard column 10x10 mm) and a UV-diode 
array detector (210   nm, 254   nm). The solvent system used was a gradient of  acetoni-
trile:water (containing 0.1 percent TFA) (0–8 min: 0–100 percent MeCN) at a flow rate of  
4 mL/min unless otherwise stated.
N-acyl dopamine synthesis N-octanoyl dopamine (NOD), N-pivloyl dopamine 
(NPiD) and N-octanoyl tyramine (NOT) were prepared from commercially available 
precursors as described previously [23]. The compounds were purified by two fold recrys-
tallization from dichloromethane, and purity of  the compounds was confirmed by HPLC. 
Briefly, octanoic acid was converted to its mixed anhydride derivative by reaction with 
ethyl chloroformate in  the presence of  N-ethyl diisopropylamine. The crude mixed 
anhydride was incubated with dopamine hydrochloride in N,N-dimethylformamide and 
N-ethyl diisopropylamine to form NOD. After aqueous preparation and evaporation 
of  the organic solvent NOD is obtained in an overall yield of  sixty percent. The sample 
investigated by  NMR (Bruker AC250) yielded spectra in  accordance with the expected 
structure.
N-(3,4-dihydroxyphenethyl)pivalamide (NPiD). Analytical HPLC: tR = 1.50 min 
( > 97 percent). 1H NMR (250 MHz, CDCl3): δ = 8.69 (s, 2H, 2xOH), 7.46 (t, 3J = 6.6  Hz, 1H, 
NH), 6.62 (d, 3JH5,H6 = 7.9 Hz, 1H, H-5), 6.55 (dd, 3JH5,H6 = 7.9 Hz, 4JH2,H6 = 1.9 Hz, 1H, H-6), 6.41 (d, 
4JH2,H6 = 1.9 Hz, 1H, H-2), 3.14 (dt, 3JH,H = 7.4 Hz, 3JNH,H = 6.6 Hz, 2H, NCH2), 2.50 (d, 3J = 7.4 Hz, 
2H, BnCH2), 1.07–1.04 ppm (m, 9H, 3xCH3).
4-(2-Octanamidoethyl)-1,2-phenylene	diacetate	(A-NOD). Acetylation of  NOD 
was performed by suspending NOD (2 g, 7.16 mmol) of  in acetic anhydride (5 mL) under 
magnetic stirring. When two drops of  sulphuric acid were added, the suspension turned 
clear and stirring was continued for one hour. Diluted hydrochloric acid (5 mL) was added 
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and 30 min later the reaction mixture was poured into 200 mL ice water. The precipi-
tated product was collected by vacuum filtration and dried under vacuum to yield pure 
A-NOD, confirmed by HPLC. Analytical HPLC: tR = 3.38 min ( > 97 percent). 1H NMR (250 
MHz, CDCl3): δ = 7.12 (d, 3JH5,H6 = 8.1 Hz, 1H, H-5), 7.06 (dd, 3JH5,H6 = 8.1 Hz, 4JH2,H6 = 2.0 Hz, 1H, 
H-6), 7.01 (d, 4JH2,H6 = 2.0 Hz, 1H, H-2), 3.49 (dt, 3JH,H = 7.5 Hz, 3JNH,H = 6.7 Hz, 2H, NCH2), 2.81 (d, 
3J = 7.5 Hz, 2H, BnCH2), 2.89 (s, 6H, 2xAcCH3), 2.13 (t, 3J = 7.7 Hz, 2H, H-α), 1.63–1.56 (m, 2H, 
H-β), 1.33–1.19 (m, 8H, H-γ,δ,ε,ζ), 0.89–0.86 ppm (m, 3H, CH3).
N-(3,4-Dihydroxybenzyl)octanamide (ΔNOD). To a stirring solution of  3,4-dihy-
droxybenzylamine hydrobromide (300 mg, 1.36 mmol) and NaHCO3 (377 mg, 4.49 mmol) 
in H2O (5 mL), CHCl3 was added after 30 min and after 15 min a fresh solution of  octanoyl 
chloride (232 µL, 1.36 mmol) in CHCl3 (1 mL) was added and the solution was stirred at 
40° C for 18 h. Water was added (10 mL) and the solution was extracted 3⨯ with CHCl3 
(10 mL). The organic phase was washed with 0.5 M HCl (10 mL) and brine (10 mL) and 
dried with MgSO4. The CHCl3 was removed and the crude product was purified by semi 
preparative HPLC (0–75 percent MeCN in  H2O + 0.1 TFA within 6 min at 4  mL/min). 
The fractions containing the product were collected and lyophilized to give ΔNOD as 
colorless powder (66  mg, 34 percent). RF = 0.36 (EA:CH 2:1). 1H NMR (300  MHz, CDCl3): 
δ = 6.87 (d, 4JH2,H6 = 2.0 Hz, 1H, H-2), 6.80 (d, 3JH5,H6 = 8.1 Hz, 1H, H-5), 6.62 (dd, 3JH5,H6 = 8.1 Hz, 
4JH2,H6 = 2.0 Hz, 1H, H-6), 4.31 (d, 3J = 8.1 Hz, 2H, BnCH2), 2.23 (t, 3J = 7.7 Hz, 2H, H-α), 1.67–1.57 
(m, 2H, H-β), 1.27–1.22 (m, 8H, H-γ,δ,ε,ζ), 0.87–0.85 ppm (m, 3H, CH3). 13C NMR (75 MHz, 
CDCl3): δ = 174.3 (C = O), 144.5 (C-3), 144.1 (C-4), 130.1 (C-1), 119.9 (C-6), 116.9 (C-2), 114.8 (C-5), 
43.5 (BnCH2), 36.7 (C-α), 31.6 (C-ε), 29.1 (C-γ), 28.9 (C-δ), 25.8 (C-β), 22.6 (C-ζ), 14.0 ppm 
(CH3). MS (MALDI-TOF): m/z ( percent) 266 (100) [M + H] + . Analytical HPLC: tR = 2.69 min 
( > 96 percent). See supplementary figure 4 for NMR signal assignment.
2-(3,4-Dihydroxyphenyl)-N-octylacetamide (ΔNODR). (Compound 4g from 
Walpole et al.[24], no NMR data) To a solution of  3,4-dihydroxyphenylacetic acid (300 mg, 
1.78 mmol) in dry THF (8 mL) under an argon atmosphere, Et3N (249 µL, 1.78 mmol) and 
ethyl chloroformate (165 µL, 1.78 mmol) were added and stirred 3 h in the dark at ambi-
ent temperature. Then octylamine (296 µL, 1.78 mmol) was added and the solution was 
stirred for 18 h. To the solution was added EA and the organic phase was washed with 
brine and dried with MgSO4. The solvent was removed and the crude product was puri-
fied by column chromatography (CH → CH:EA 4:1 → 1:1) to obtain the product ΔNODR 
as colorless solid (138 mg, 28 percent). RF = 0.24 (EA:CH 1:1). 1H NMR (500 MHz, CDCl3): 
δ = 6.83 (d, 3JH5,H6 = 8.1 Hz, 1H, H-5), 6.75 (d, 4JH2,H6 = 1.7 Hz, 1H, H-2), 6.48 (dd, 3JH5,H6 = 8.1 Hz, 
4JH2,H6 = 1.7 Hz, 1H, H-6), 3.40 (s, 2H, BnCH2), 3.24 (dd, 3JH,H = 13.5 Hz, 3JNH,H = 6.7 Hz, 2H, H-α), 
1.52–1.46 (m, 2H, H-β), 1.28–1.22 (m, 10H, H-γ,δ,ε,ζ,η), 0.87–0.84  ppm (m, 3H, CH3). 13C 
NMR (126 MHz, CDCl3): δ = 175.2 (C = O), 144.7 (C-3), 144.3 (C-4), 124.3 (C-1), 121.2 (C-6), 
116.5 (C-5), 115.9 (C-2), 41.2 (BnCH2), 40.7 (C-α), 31.7 (C-ζ), 29.1 (C-ε), 29.0 (C-δ), 28.6 (C-β), 
26.8 (C-γ), 22.6 (C-η), 14.1 ppm (CH3). MS (MALDI-TOF): m/z ( percent) 279 (100) [M + H] + . 
Analytical HPLC: tR = 3.12 min ( > 98 percent).




pound 1 from Goto et al. [25], no NMR data) To a solution of  natural Capsaicin (162 mg, 
0.53  mmol) and K2CO3 (220  mg, 1.59  mmol) in  CH2Cl2 (30  mL), a  1 M solution of  BBr3 
in CH2Cl2 (1.32 mL) was slowly added at-18° C within 5 min and the mixture was stirred 
for 60  min to reach-16°  C. Water (20  mL) was added for quenching them reaction and 
the mixture was extracted with CH2Cl2 (1x) and EA (1x). The combined organic phases 
were washed with brine (20 mL) and dried with MgSO4. The solvent was removed and 
the crude product was purified by column chromatography (CH → CH:EA 4:1 → 2:1 → 1:1) 
to obtain a  yellow oil (117  mg, 76 percent). The yellow oil was further purified by  semi 
preparative HPLC (0–50 percent MeCN in H2O + 0.1 TFA within 8 min at 4 mL/min). The 
fractions containing the product were collected and lyophilized to give Cap-OH as color-
less powder (45 mg, 29 percent). RF = 0.33 (EA:CH 2:1). 1H NMR (500 MHz, CDCl3): δ = 6.85 
(s, 1H, H-5), 6.79 (s, 1H, H-2), 6.60 (d, 3JH5,H6 = 8.0 Hz, 1H, H-6), 5.37–5.25 (m, 2H, HC = CH), 
4.29 (s, 2H, BnCH2), 2.26 (t, 3J = 7.6 Hz, 2H, H-α), 1.95 (dd, 3J = 13.9 Hz, 4J = 7.0 Hz, 1H, CH), 
1.67–1.59 (m, 2H, H-δ), 1.38–1.23 (m, 4H, H-β,γ), 0.94 (s, 3H, CH3), 0.93 ppm (s, 3H, CH3). 13C 
NMR (126 MHz, CDCl3): δ = 174.6 (C = O), 144.4 (C-3), 144.1 (C-4), 138.5 (C-ζ), 129.7 (C-1), 126.2 
(C-ε), 119.9 (C-6), 115.0 (C-5), 114.9 (C-2), 43.7 (BnC), 36.4 (C-α), 32.1 (C-δ), 30.9 (C-η), 29.1 
(C-γ), 25.3 (C-β), 22.6 ppm (2xCH3). MS (MALDI-TOF): m/z ( percent) 292 (100) [M + H] + . 
Analytical HPLC: tR = 3.08 min ( > 95 percent).
General procedures for in vitro experiments
Chemicals
All chemical reagents were purchased from Sigma Aldrich (Sigma-Aldrich Chemie 
GmbH, Munich, Germany) unless otherwise indicated.
Site directed mutagenesis
A pcDNA3-rTRPV1 construct was used to generate rTRPV1-R491A (5'-gca gga aat att gaa 
tcc ctg cga aga aga agt aga ctc ctc-3'; 5'-gag gag tct act tct tct tcg cag gga ttc aat att tcc tgc-3); 
T511A (5'-gta caa aga aaa gta tct cac tgg cgc tgt cca caa aca aac tct tga-3', 5'-tca aga gtt tgt ttg 
tgg aca gcg cca gtg aga tac ttt tct ttg tac-3'); S512A (5'ctg tac aaa gaa aag tat ctc ata ggc gct gtc 
cac aaa caa act-3', 5'-gag ttt gtt tgt gga cag cgc cta tga gat act ttt ctt tgt aca-3'); T550A (5'-gta 
gag cat gtt ggc cca gcc cat ggc ca-3', 5'-tgg cca tgg gct ggg cca aca tgc tct ac-3'); and E570A 
(5'-ctg tac aaa gaa aag tat ctc agc gta gct gtc cac aaa caa act c-3', 5'-gag ttt gtt tgt gga cag cta 
cgc tga gat act ttt ctt tgt aca g-3') mutations using QuikChange Site-Directed Mutagenesis 
Kit (Agilent Technologies) as per manufactures’ protocol. Sequence of  all the clones was 
verified by  using BigDye® Terminator v3.1 Cycle Sequencing Kit at the Department of  




HEK293 cells (obtained from ATCC, LGC Standards, Teddington, UK) were cultured 
in  T25cm2 flasks with Dulbecco’s modified Eagle’s medium (DMEM; PAA, Pasching, 
Austria) supplemented with 10 percent fetal calf  serum (FCS Gold, ;PAA), 100 U/l peni-
cillin and 100 µg/mL streptomycin (PAA) at 37° C in a five percent CO2 humidified atmo-
sphere. 24 h prior to transfection, 4.0 ⨯ 105 cells per well were plated on  poly-L-lysine 
(10 µg/mL) coated round (Ø 15 mm) coverslips, transfected with 1 µg pcDNA3-rTRPV1 or 
the mutated constructs using 3 µL Metafectene (metafectene® pro-Biontex Laboratories 
GmbH) and incubated at 34° C in a 5 percent CO2 humidified atmosphere.
Human umbilical vein endothelial cells (HUVECs) were isolated from the freshly 
available umbilical cord. Cells were grown in basal endothelial cell growth medium (Pro-
vitro GmbH, Berlin Germany), supplemented with 2 percent fetal bovine serum, without 
antibiotics at 37ºC in a 5 percent CO2 humidified atmosphere and experiments were con-
ducted at approximately 80–90 percent visual confluence.
Calcium Imaging
48 h post transfection cells were transferred into extracellular solution containing NaCl 
137.6 mM, KCl 5.4 mM, MgCl2 0.5 mM, CaCl2 1.8 mM, glucose 5 mM and HEPES 10 mM 
(Roth, Karlsruhe, Germany), loaded with the fluorescent dye FURA-2AM (3 µM; Biotrend, 
Köln, Germany) and 3 µM Pluronic F-127 for 45 min at RT in dark. Followed by 20 min 
washout in extracellular solution, fluorescence was measured using an inverted micro-
scope (IX-81 with Cell^R, Olympus, Hamburg, Germany) and an ORCA-R2 CCD camera 
(Hamamatsu Corp., Bridgewater, NJ, USA). After alternating excitation with light of  
340  nm and 380  nm wavelength, the ratio of  the fluorescence emission intensities at 
510 nm (340 nm/380 nm [510 nm]) was digitized at 0.5 Hertz and calculated. This fluores-
cence ratio is a relative measure of  intracellular calcium concentration[26]. The concen-
tration range at which calcium transients appeared upon stimulation with each of  the 
compounds was established by  application of  increasing concentration of  compounds 
for 1 min in a single coverslip of  rTRPV1 transfected HEK293 cells followed by a washout 
for 1  min (inter-stimulus interval: 5  min). For EC50 determination a  minimum of  nine 
concentrations of  each compound based on this range were used. Only one concentration 
per coverslip and a  minimum of  three separate coverslips for each concentration was 
used. The compound was applied to the cells for 1 min followed by 1 min washout using 
perfusion and 2 min rest. Repetitive application of  30 µM NOD was used to investigate 
tachyphylaxis. Additionally, 30 s before the second stimulus vehicle or 30 µM of  the com-
petitive TRPV1 antagonist Capsazepine was applied to block the receptor. At the end of  
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each experiment 10 µM CAP was used to select transfected cells. Analysis was done using 
cell^R software (Olympus). Each coverslip was considered as an independent experiment. 
Absolute change in ratio was determined by subtracting baseline value from the peak.
Protein isolation and Western blotting
HUVECs were lysed in 20 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, one percent Triton 
X-100, 0.5 percent sodium deoxycholate, 1  µM dithiothreitol (DTT) buffer containing 
proteinase and phosphatase inhibitors. Protein concentrations were measured using 
Coomassie-Reagent (Pierce, Rockford, USA). 15 µg of  protein per condition was loaded 
on  10  percent SDS-polyacrylamide gel. Human anti-VCAM-1 (1:2000, BBA19, R&D 
Systems, Germany) or Human anti-HO-1 (1:2000, ADI-SPA-896-F, Enzo, Biochem Inc.) 
antibodies were used to probe the membrane. Since these compounds do not influence 
expression of  β-Actin, equal protein loading was confirmed by stripping and re-probing 
membranes with monoclonal human anti-β-actin antibody (1:10,000, Abcam plc, UK). 
Anti-goat IgG-HRP, anti-rabbit IgG-HRP, anti-mouse IgG-HRP conjugated secondary 
antibodies (1:2500, Santa Cruz Biotechnology) were used. Image J ver1.5e was used for 
densitometry analysis. All the lanes were normalized to β-Actin. Inhibition of  VCAM-1 is 
expressed as percentage relative to that of  TNFα; induction of  HO-1 is expressed as fold 
increase relative to that of  cells grown in normal culture medium.
Luminol Assay
The redox activity of  the compounds was measured using luminol assay. Serial dilutions 
of  the compounds were prepared in distilled water, added to the luminol reaction mix 
(luminol 2.5 mM, p-Coumaric acid 0.9 mM and 0.3 percent H2O2). HRP (0.1 µg/µL) and 
quenching of  chemiluminescence was measured immediately using infinite® 200 PRO – 
Tecan microplate reader. The measurements were performed in triplicates.
Molecular modeling
Because of  structural similarity between NOD and CAP the structure of  TRPV1 PDB 
3J5R[27], in  which the TRPV1 forming complex with CAP is modelled, was taken. This 
structure is a reconstruction of  the above mentioned complex by single particle cryo-mi-
croscopy[28]. The protein structure was processed with the Protein Preparation Wizard 
in the Schrödinger Suite 2005 (Maestro, Version 9.0, 2007; Schrödinger, LLC: New York, 
NY, USA), two chains are needed for delimiting the binding site, denoted as chain A and 
B in the manuscript. Hydrogen atoms were added followed by the adjustment of  bond 
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orders. The protonation states for protonable residues were adjusted to match pH = 7.4. 
After this, the protein was subjected to geometry optimization by using OPLS_2005 force 
field [29]. The structures of  the different NADs were sketched by using the chemical edi-
tor at Maestro and were prepared using LigPrep (two-dimensional representations were 
converted into three-dimensional ones and partial charges were assigned).
Glide software was used for performing docking analyses[30]. The grid box for 
molecular docking was centered in the middle of  the pocket, close to Y511, including the 
amino acids of  chain A and B present in the binding site. The extra precision (XP) Glide 
mode was used. Glide XP has empirical scoring functions and also imposes desolvation 
penalties for burial of  protein or ligand polar and charged groups. The method adds 
explicit water molecules to poses selected in previous steps, counts them, and uses these 
counts for performing comparisons with analogous groups in known active compounds. 
This process reduces false positives and increases reliability of  the docking energy values. 
In our approach, the best docked position for each complex was determined by consider-
ing the total energy value after five runs.
Statistical analysis
All data are expressed as the means ± SEM from at least three independent experiments. 
Statistical significance of  results was assessed by  one-or two-way ANOVA followed 
by LSD (Prism 6 for Windows Version 6.01, p < 0.05 was considered to be significant. For 
comparison, data were normalized to the respective first response.
Results
Generation of structural derivatives of NOD
To assess the molecular entities within NOD that are required for TRPV1 activation, we 
used NOD as a lead structure. We synthesized compounds that slightly differ from NOD at 
the aromatic moiety (A-region), the linker region (B-region) or the aliphatic chain (C-re-
gion). These changes included acetylation of  the catechol structure, (A-NOD), omitting 
one hydroxyl functional group from the benzene nucleus (N-octanoyl tyramine (NOT)), 
exchanging octanoyl for the branched pivaloyl as aliphatic chain (N-pivaloyl dopamine 
(NPiD)), and shortening of  the linker region by one methylene group. The later was made 
in two variants in which the positions of  the carbonyl group were interchanged relative 
to the position of  the amide group (ΔNOD and ΔNODR) (Figure 1B). In addition the vanil-
loid moiety of  CAP was changed to a catechol structure (CAP-OH) (Figure 1C). We chose 
a different way for synthesis of  CAP-OH as Goto et al [25]. Natural capsaicin was reduced 
and yielded saturated and unsaturated compounds with and without CH3O-group. Only 
purification via semi-preparative HPLC led to the pure CAP-OH.
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Figure	1.	Chemical	structures	of	the	studied	compounds. (A) CAP and NOD are shown with sche-
matic representation of  the different regions (A, B and C regions are shown with the dotted line). (B) 
Chemical structure of  compounds used in the study, the structural region in which they vary from NOD 
is mentioned on the left side of  the structure. NOD variants were synthesized by modifying the A-, B-and 
C-region region relative to that of  NOD. (C) CAP-OH was synthesized by changing A region of  CAP.
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Figure	 2.	 NOD	 like	 Capsaicin	 (CAP)	 activates	 rTRPV1	 (A).	A  representative experiment showing 
increases in free [Ca + + ]i in rTRPV1 transfected cells in response to 1 nM, 100 nM and 10 µM of  CAP and 
NOD. The ratio 340/380 at 510 nm – a measure proportional to free [Ca + + ]i – is false color coded where 
warmer colors indicate increasing calcium values. (B) Dose response curves of  CAP (filled) and NOD 
(open circles). rTRPV1 expressing HEK293 cells were stimulated once with each concentration with at 
least three different measurements per concentration. The results are expressed as average ratio 340/380 
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NOD derivatives have differential TRPV1 activation properties
TRPV1 activation by the synthetic NADs was assessed using calcium microfluorimetry 
on  rTRPV1 transfected HEK293 cells. Neither the synthetic NADs nor CAP induced 
change of  intracellular calcium concentrations ([Ca + + ]i) in  untransfected HEK293 cells 
(Supplementary Figure 1).
Even though NOD dose dependently increased [Ca + + ]i in  rTRPV1 transfected 
HEK293 cells (Figure 2A), it was significantly less potent and effective as compared to 
CAP (Figure 2 B) NOD EC50 5.572 µM versus CAP EC50 0.3 µM (Table 1).
The application of  30  µM NOD led to a  significant increase in  [Ca + + ]i (p < 0.03) 
compared to vehicle control, and these cells also responded to the specific TRPV1 ago-
nist capsaicin CAP. With repetitive NOD application, calcium influx displayed marked 
tachyphylaxis and decreased to 60 ± 6.3 percent from the first to the fifth response (Figure 
2C-D; p < 0.001). Application of  TRPV1 antagonist Capsazepine (CPZ) 30 sec before the 
second NOD stimulus, significantly reduced responses (to 78 ± 3.4 percent of  1st versus 
35 ± 5.1 percent of  1st without/with CPZ p < 0.001). Interestingly, under these conditions 
NOD-evoked responses were persistently reduced after wash-out of  CPZ, while capsaicin 
CAP responsiveness of  these cells was not changed (Figure 2 C and D; p = 0.89).
All synthetic NOD derivatives were able to activate TRPV1 in a concentration-de-
pendent manner (Figure 3). ΔNODR was the most and A-NOD the least efficacious at 
TRPV1. EC50 for A-NOD, ΔNOD and ΔNODR were 20.82 µM, 2.86 µM and 0.06 µM respec-
tively (Table 1). CAP-OH also activated TRPV1 in a dose dependent manner. Although it 
retained agonistic properties at TRPV1 CAP-OH has an EC50 value of  0.736 µM, nearly two 
times higher than that of  CAP EC50 0.3 µM (Table 1).
at 510 nm ± SEM of  all measurements. The EC50 value of  CAP was about 0.87 µM and for NOD 5.93 µM 
(indicated as dotted lines). Two-way ANOVA indicates substance differences; **p < 0.01 and *** and 
p < 0.001 LSD post-hoc test. (C) A series of  representative experiments showing increases in free [Ca + + ]i 
in rTRPV1 transfected cells in response to repetitive application of  30 µM NOD. The response displayed 
marked tachyphylaxis from stimulus to stimulus (black trace). Application of  equimolar concentration 
of  the competitive TRPV1 antagonist Capsazepine before and during the 2nd stimulus (CPZ; grey trace) 
abolished the NOD response further confirming that NOD acts as a  full agonist at TRPV1. The ratios 
340/380 at 510  nm – a  measure proportional to free [Ca + + ]i – was averaged from three independent 
experiments per condition and are shown as mean ± SEM (depicted as dotted line) (D) Bar graph shows 
the maximum increases in free [Ca + + ]i upon response to repetitive application of  30 µM NOD with or 
without equimolar concentration of  CPZ; repeated application of  NOD induced tachyphylaxis of  subse-
quent responses, CPZ largely blocked NOD responses – both phenomena are also known for capsaicin at 
TRPV1. ***p < 0.001, LSD post-hoc test vehicle versus CPZ group; + p < 0.05, + + p < 0.01, + + + p < 0.001 versus 
preceding application within treatment group.
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Because NOT and NPiD precipitated at high concentrations (1 mM) at which calcium 
transients were only 38 percent and 51 percent of  the CAP response, EC50 values could not 
be determined. It should be mentioned however that slight calcium transients for NOT 
and NPiD were observed at 100 and 500 µM respectively.
Figure	3:	Dose	response	curves	obtained	with	different	NADs	rTRPV1	transfected	HEK293	cells	
were	stimulated	only	once	and	 for	each	concentration	at	 least	3	different	measurements	were	
done.	The results are expressed as average ratio 340/380 at 510  nm ± SEM of  all measurements with EC50 
values (indicated as dotted lines) of  5.93 µM (NOD, open circles), 18.69 µM (A-NOD, grey circles), 3.69 µM 
(ΔNOD, filled circles) and 0.06 µM (ΔNOD R, triangles). n.s. p > 0.2, + + p < 0.01, + + + p < 0.001 ANOVA with LSD 
post-hoc test between substances.




used	in the	study. For TRPV1 activation and Luminol Assay – the EC50 value defined as the 
concentration of  the compound needed to evoke the response corresponding to the 50 per-
cent of  the maximum produced by that compound. The increase in ratio was fitted in equation 
to obtain LogEC50 values. For TRPV1 activation assay-bottom was constrained to 0 since the 
baseline was subtracted from the response. Top in the equation refers to the platue observed 
in the dose response experiments and provides the efficacy i.e. maximum strength of  TRPV1 
activation.The anti-inflammatory property of  the compounds was assessed at 100  µM via 
their ability inhibit TNFα induced VCAM-1 expression or induction of  HO-1at protein level. 
Western blot data quantification was performed by  densitometry. Inhibition of  VCAM-1 
is expressed as relative to that of  TNFα (10ng/mL), induction of  HO-1 is expressed as fold 
increase relative to that of  cells grown in normal culture medium. For each experiment and 
for each quantification chemiluminescence signal was normalized using ß-actin. Statistical 
analysis was performed using a  one way-ANOVA with Fisher’s LSD test, VCAM-1 inhibi-


















Capsaicin 0.87 6.06 ± 0.19 6.09 ± 0.34 1.13 ± 0.18 2.81 ± 0.31 Not mea-
sured
NOD none 5.93 5.23 ± 0.08 2.34 ± 0.08 0.40 ± 0.05**** 10.12 ± 3.06**** 9.15
A-NOD A 18.69 4.73 ± 0.25 1.06 ± 0.19 0.53 ± 0.08*** 6.11 ± 1.95* 14.80
ΔNOD B 3.69 5.43 ± 0.21 4.39 ± 0.32 0.79 ± 0.07** 3.66 ± 0.72 6.78
ΔNODR B 0.06 7.22 ± 0.13 3.14 ± 0.26 0.43 ± 0.07**** 6.98 ± 1.49**** 7.70
NOT A  > 100  > -4 N.D 0.76 ± 0.07** 1.44 ± 0.52  > 1000
NPiD C  > 500  > -3.3 N.D 0.53 ± 0.12*** 5.93 ± 1.55* 10.44
CAP-OH 4.93 5.31 ± 0.25 7.81 ± 0.66 0.46 ± 0.11**** 4.86 ± 0.97* 37.52
(n.s. non-significant, *p < 0.05, **p < 0.001, ***p < 0.0001)
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NOD, CAP and the NOD derivatives use similar amino acids for 
their TRPV1 interaction
Based on  the electron cryo-microscopy structure of  the rTRPV1 ion channel [27], we 
performed docking studies with NOD, CAP, and the NOD derivatives to understand the 
interaction between the agonist and the channel. We observed potential hydrogen bond 
interactions for CAP with three amino acids Y511, T550 and E570 (Figure 4A) in the TRPV1 
binding pocket. For NOD, two of  these interactions were the same, i.e. T550 and E570, 
while no hydrogen bond interaction with Y511 was suggested (Figure 4B).
The NOD derivatives established hydrogen bond interactions with the same resi-
dues (Figure 4D-H), with the exception of  A-NOD, which is oriented differently because 
the lack of  OH substituents in its catechol group (Figure 4C). The hydrogen bond distances 
obtained from the docking positions of  the studied compounds (without considering 
A-NOD) are shown in  the Supplementary Table S1. It is possible to observe that NOD, 
CAP, and the NOD derivatives form one or two hydrogen bond interactions with the res-
idue E570. Meanwhile, all the compounds, with the exception of  NPiD, form hydrogen 
bond with T550. Finally, the compounds CAP, ΔNODR, NPiD and CAP-OH are hydrogen 
bonded to Y511.
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Figure	4:	Docking	of	capsaicin,	NOD,	and	NOD	derivatives	in TRPV1	channel.	Conformations of  
the studied compounds within the binding pocket of  TRPV1 for CAP (A), NOD (B), A-NOD (C), NOT (D), 
ΔNOD (E), ΔNODR (F), NPiD (G), and CAP-OH (H). Chain A of  the protein is represented in yellow, where 
amino acids with hydrogen bond contributions Y511, T550 and E570 are in stick representations. Chain 
B of  the protein is represented in orange, where amino acids with VDW contributions are also in stick 
representations. Glide XP scoring energy values are at the top-left corner of  each docking pose picture 
(A-H). Correlation between these values and experimental logEC50 values are in (I).
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The docking method Glide XP yielded a  scoring energy value for each compound 
reported in Figure 4. Despite docking methods are not so reliable in calculating binding 
energy values [31] a  good correlation between the Glide XP scoring energy values and 
experimental logEC50 values was found with correlation coefficient R2 = 0.63 (Figure 4I). 
This result confirms that the selected electron cryo-microscopy structure is a good model 
for studying the affinities of  TRPV1 ligands, and gives confidence in  the ability of  the 
Glide XP method to describe the relationship between the chemical interactions of  the 
ligands in the binding site and their differential affinities. It is possible to extract per-res-
idue coulombic, hydrogen bond, and van der Waals (VDW) components from the Glide XP 
scoring energy to get more insight in the most relevant TRPV1 amino acids involved in the 
differential activities (Supplementary Figure 2). The analysis of  the coulombic compo-
nents indicates that E570 has the major contribution, which is better when both catechol 
hydroxyl groups are available. The analysis of  the hydrogen bond components shows that 
the residues Y511, T550 and E570 have different energy contributions for each compound. 
Finally, the analysis of  the VDW contributions is more complex due to multiple residues 
involved. The residues with higher VDW contributions were Y511, L515, F522, F543, A546, 
M547, T550, N551, L553, Y554, I569, and I573 from chain A, and F587, F591, I661, L662, 
A665, and L669 from chain B. It is noteworthy to mention that Y511 has not only hydrogen 
bond contribution; it also has an important VDW contribution. This chemical role was 
suggested previously in  the report of  Lee et al.[32]: when the Y511F and Y511A mutants 
were generated, capsaicin EC50 values increased 30 times for the first mutant (where 
hydrogen bond contribution was lost and VDW contribution was kept), and 500 times for 
the second (where both hydrogen bond and VDW contributions were lost).
To evaluate the interactions revealed by  the docking model and previously pub-
lished anchor residues S512 and R491[33] for the CAP TRPV1 interactions, all putative 
interacting amino acids in rTRPV1 were changed to alanine by site-directed mutagenesis. 
The effect of  these mutations on  TRPV1 activation was studied at three different con-
centrations of  CAP (300 nM, 1 µM, and 10 µM; Figure 5A) and NOD (15 µM, 50 µM and 
200 µM; Figure 5B) corresponding to approximately 2.5, 9 and 36 (for NOD) or 1, 3 and 
30 (for CAP) times the EC50 value. For the Y511A and E570A rTRPV1 variants the calcium 
responses were completely lost at the two lower concentrations of  CAP or NOD and 
remained significantly diminished even when using excessively high concentrations of  
CAP or NOD (Figure 5 A-B). Also the T550A significantly diminished TRPV1 activation, 
which seemed to be more pronounced in the case of  NOD stimulation at 15 µM (two times 
EC50) and at 200 µM (three times EC50). While in HEK cells expressing the S512A TRPV1 
variant CAP was not able to evoke calcium responses when tested over a range of  concen-
tration (Supplementary figure 3), mutation of  R491 to A did not affect TRPV1 activation 
by CAP or NOD.




sensitivity	to	capsaicin	(CAP)	and	NOD.	HEK293 cells were transfected with different mutants of  the 
rTRPV1 receptor. Cells were challenged with different concentrations of  either capsaicin (300 nM, 1 µM, 
10 µM; A) or NOD (15 µM, 50 µM, 200 µM; B). Y511A, and E570A are important for the binding of  both 
capsaicin and NOD. Regarding T550A the effect is more pronounced after NOD application. A minimum 
of  3 independent experiments were done. Statistical analysis was performed using two way-ANOVA with 
Fisher’s LSD test wild-type tested versus mutated rTRPV1 at the same concentration (n.s. non-signifi-
cant, *p < 0.05, **p < 0.001, ***p < 0.0001).
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Figure	 6:	 Anti-inflammatory	 property	 is	 not	 solely	 governed	 via	 catechol	 structure.	 Anti-in-
flammatory	property	is	not	solely	governed	via	catechol	structure.	 (A)	HUVECs were stimulated 
overnight with – TNF-α (10 ng/mL) in the presence of  100 µM various compounds. The expression of  
VCAM-1 and HO-1 was determined by western blotting and quantified by densitometry. VCAM-1 expres-
sion is presented as fold change relative to TNFα (T) and HO-1 expression is presented as fold change 
relative to medium (M) (B-D) Dose-response experiments for direct comparison of  NOD vs NOT (B), 
Capsaicin (CAP) vs. CAP-OH (C) and ΔNOD vs. ΔNODR (D). For all the blots equal loading of  protein was 
ensured with ß-actin. Representative blots are shown, a total of  at least 3 independent experiments were 
performed. Statistical analysis was performed using a one way-ANOVA with Fisher’s LSD test, VCAM-1 
inhibition-TNFα versus treatment, HO-1 induction medium versus treatment (n.s. non-significant, 
*p < 0.05, **p < 0.001, ***p < 0.0001).
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The anti-inflammatory property of NADs is not defined solely 
by Redox activity
To assess if  the structural changes in  the synthetic compounds would also affect their 
anti-inflammatory properties, we screened all compounds for down-regulation of  TNFα 
mediated VCAM-1 expression and induction of  HO-1 in  HUVECs (Fig. 7A). Except for 
ΔNOD all catechol containing structures were able to inhibit TNFα mediated VCAM-1 
expression, while this was neither observed for CAP nor for NOT. Inhibition of  VCAM-1 
expression was paralleled by  a  concomitant induction of  HO-1 expression. Dose-re-
sponse experiments for direct comparison of  NOD vs NOT, CAP vs CAP-OH and ΔNOD 
vs. ΔNODR are depicted in  figure 6 B-C. In considering that catechols contain a  high 
redox activity which may contribute to the anti-inflammatory effects of  NADs[16], we 
assessed for each compound the quenching properties in a peroxidase mediated luminol 
chemiluminescence reaction (Table 1). All compounds except for NOT were able to quench 
chemiluminescence in the luminol assay.
Discussion
We previously demonstrated that apart from TRPV1 activation, NOD exerts profound 
cyto-protective properties including prevention of  cold inflicted injury [23, 34, 35], 
down-regulation of  inflammatory mediators [16] and inhibition of  platelet function[35]. 
In the present study we sought to dissect the molecular entities within NOD that gov-
ern TRPV1 activation and are responsible for the anti-inflammatory effect as defined 
by  down-regulation of  TNFα mediated VCAM-1 expression and induction of  HO-1. 
The major findings of  this study are as follows: firstly, NOD is an agonist at rTRPV1 
in  a  HEK293 heterologous expression system but activates TRPV1 with lesser potency 
than CAP. Alterations in  the A-, B-and C-regions of  NOD may all affect the potency 
to stimulate TRPV1. While shortening of  the linker region by  one methylene group 
improved ability of  NADs to activate TRPV1 (NOD EC50 = 5.57  µM, ΔNOD EC50 = 2.87  µM, 
ΔNODR EC50 = 0.06 µM) the use of  a short branched fatty acid in the C-region (NPiD) or 
omission of  a hydroxyl group in the A region (NOT) profoundly deteriorated TRPV1 acti-
vation. Acetylation of  both hydroxyl groups in the A-region (A-NOD) impaired TRPV1 
activation to a much lesser extent. Secondly, docking studies suggested that amino acids 
(AA) Y511, E570 and T550 in  TRPV1 may form hydrogen bond interactions with CAP, 
while only E570 and T550 form this interaction with NOD. In addition to these putative 
interacting AA, site directed mutagenesis also revealed the importance of  S512 for TRPV1 
activation by CAP or NOD. Thirdly, the anti-inflammatory effects of  the compounds were 
not significantly affected by changes in the A-, B-and C-regions of  NOD as long as the cat-
echol moiety in the A-region was maintained. Acetylation of  the ortho-dihydroxy groups 
(A-NOD) was equally effective as compared to NOD. Moreover attainment of  catechol 
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structure imparted CAP-OH better anti-inflammatory property as compared to CAP. The 
only exception found in this study was ΔNOD which did not inhibit VCAM-1 expression 
despite the fact that it carries an intact catechol structure.
The CAP-bound TRPV1 structure was recently resolved by making use of  cryo-EM[27, 
28] and iterative computation in  conjunction to systematic site-specific functional 
tests[36]. From these data it has been postulated that CAP takes a  ‘tail-up, head-down’ 
configuration in  which the vanillyl and amide groups form specific interactions with 
residues T550 and E570 by hydrogen bonds to anchor to its bound position. The aliphatic 
chain interacts with the channel through nonspecific VDW forces and contributes to the 
binding affinity. This is followed by a series of  structural rearrangements to stabilize the 
activated conformation mainly by ‘pulling’ at E570 through hydrogen bonding and VDW 
forces. The Y511 residue seems not to play a role in hydrogen binding but closes the mouth 
of  the binding pocket and thereby cradling the CAP molecule inside[36]. This model thus 
explains why the Y511A mutation leads to impaired TRPV1 activation, but does address 
the importance of  S512 for TRPV1 activation by CAP [33] and NOD. Although S512 is not 
directly present in the binding pocket, it might contribute to the shape of  the binding 
pocket and thus might be indirectly required for attaining the appropriate binding pocket 
configuration for the interaction with TRPV1 agonists. This might explain why we did 
not achieve TRPV1 activation by any of  the TRPV1 agonist in cells expressing the S512A 
TRPV1 mutant. Our docking studies suggest similar interactions for NOD and TRPV1 as 
described for CAP, i.e. interaction of  the catechol group with E570 and interaction of  the 
amide with T550.
Acetylation of  both hydroxyl groups in the A-region (A-NOD) yielded loss of  TRPV1 
activation potency and significantly lower 340/380-ratio for A-NOD as compared to 
NOD. It should be emphasized that our docking studies suggest that A-NOD would not fit 
in the TRPV1 pocket unless it is converted to NOD via intracellular esterases. This might 
as well explain why the 340/380-ratio was lower for A-NOD. Both NPiD and NOT were 
extremely poor TRPV1 agonists. According to docking experiments, the former does not 
fit in the hydrophobic region of  the TRPV1 pocket because of  the short bulky fatty acid 
tail or the short bulky fatty acid tail does not provide sufficient VDW forces in the interac-
tion with the hydrophobic core of  the channel[36]. On the other hand, NOT enters in the 
TRPV1 pocket but only allows one hydrogen bond with E570, as opposed to two bonds for 
NOD. This results in a relative loss of  binding affinity and thus in impaired TRPV1 acti-
vation. Shortening of  the linker region on the contrary, increased the potency of  NADs 
to activate TRPV1 (ΔNOD EC50 = 2.87 µM and ΔNODR EC50 = 0.06 µM). In fact, ΔNODR was 
even more potent than CAP (EC50 = 0.305 µM) in activating TRPV1. Although our TRPV1 
docking model did not predict any difference between ΔNODR and CAP with respect to 
the total energy value, the coulombic and hydrogen bond contributions of  E570 and the 
hydrogen bond contribution of  Y511 are suggested as the more important chemical char-
acteristics for explaining ΔNODR’s lower EC50 value.
Analyses of  Synthetic NADs Revealing Different Structural Requirements for Their Anti-inflammatory and TRPV1-Activating Properties
89
4
ΔNOD and ΔNODR also behaved differently with respect to the anti-inflammatory 
properties. These properties seem to depend on  the presence of  the catechol structure 
which acts as an anti-oxidant able to inhibit NFĸB [16] and to activate the Nrf2-keap1 path-
way[17]. In line with this, it was found that CAP-OH is more superior to CAP in inhibiting 
VCAM-1 and inducing HO-1 expression. Yet, despite having an intact catechol structure 
and high redox activity ΔNOD completely failed to inhibit TNFα mediated VCAM-1 and 
to induce HO-1. This underlines that redox activity alone is not determining anti-inflam-
matory property.
Conclusion
In conclusion, it was demonstrated that the molecular entities that govern TRPV1 activa-
tion by NOD, and presumably NADs in general, are different from the ones that provide 
NADs their anti-inflammatory properties. In keeping with the close relation between 
inflammation and pain, compounds that can desensitize TRPV1 and have anti-inflam-
matory properties, may offer new therapeutic avenues for the treatment of  inflammatory 
pain. Topical application of  CAP has long been clinically used to treat persistent pain, 
such as osteoarthritic pain, post-herpetic neuralgia of  the trigeminal nerve, migraine 
prophylaxis, diabetic neuropathy, HIV-associated distal sensory neuropathy, and intrac-
table pain in  cancer patients[37–41]. Nonetheless its use is associated with complete 
denervation and impaired nerve regeneration [42] as a  consequence of  strong TRPV1 
activating properties. Moreover, it may not, or only indirectly, address the inflammatory 
component of  pain. Our findings may thus provide a framework for the rational design 
of  moderate TRPV1 agonists with improved anti-inflammatory properties for the treat-
ment of  inflammatory pain.
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To mitigate pre-transplantation injury in organs of  potential donors N-octanoyl dopa-
mine (NOD) treatment might be considered as it does not affect hemodynamic param-
eters in braindead (BD) donors. To better assess optimal NOD concentrations for donor 
treatment we report on the fast and facile radiofluorination of  the NOD-derivative [18F]
F-NOD [18F] compound	5 for in vivo assessment of  NOD’s elimination kinetics by means 
of  PET imaging. [18F] compound	5 was synthesized with reproducible high radiochemical 
yield and purity (> 98 percent) as well as high specific activities (> 20 GBq/µMol). Stability 
tests showed no decomposition of  [18F]5 over a period of  120min in rat plasma. In vitro, 
low cell association was found for [18F] compound	5	indicating no active transport mecha-
nism. In vivo, [18F] compound	5 exhibited a fast blood clearance, predominantly eliminated 
by liver. Although these data suggest that also NOD might be subjected to a fast clearance, 




Current evidence suggests that low dose dopamine treatment of  braindead (BD) donors 
improves transplantation outcome in  recipients of  renal and heart allografts [1–3]. 
Although the salutary effect of  donor dopamine treatment has not been completely delin-
eated, it has been suggested that the hemodynamic properties of  dopamine do not play 
an essential role herein.[4, 5] In vitro studies have identified three putative mechanisms 
by  which dopamine may convey its protective properties in  transplantation settings. 
Firstly, dopamine can protect cells against cold inflicted injury as tested in vitro on endo-
thelial cells, renal epithelial cells and cardiomyocytes. [6],[7, 8] Secondly, dopamine is able 
to activate the transcription factor Nrf2 which regulates the expression of  the tissue pro-
tective protein Heme oxygenase 1 (HO-1).[9] Thirdly, dopamine has anti-inflammatory 
properties, reflected by down-regulation of  adhesion molecules and chemokines.[9–11]
Even though both prospective and retrospective studies have advocated the use of  
dopamine in BD donors as a meaningful modality to improve transplantation outcome 
[1, 2], it has not been implemented in  general guidelines for donor management. Cur-
rently dopamine is used in  donor management to stabilize blood pressure, albeit that 
in clinical practice (nor)adrenaline is more frequently used for blood pressure stabiliza-
tion of  BD donors. In approximately 12 percent of  treated donors dopamine treatment 
needs to be discontinued as a consequence of  tachycardia or hypertension. Moreover, the 
potential impact of  inotropic agents on cardiomyocytes, i.e. increased cytosolic calcium 
concentration [12, 13] and opening of  the mitochondrial permeability transition pore 
[14, 15], may raise further concerns on the use of  such agents in donor management.[16, 
17] This underscores the need for dopamine-like compounds that are devoid of  hemo-
dynamic action and yet have a  similar or higher efficacy to protect organ allografts 
from pre-transplantation injury. By N-acylation of  dopamine, which largely abrogates 
adrenoceptor and dopaminergic receptor binding, a class of  synthetic compounds was 
developed lacking hemodynamic actions while retaining the protective properties of  
dopamine.[3, 8] As representative of  N-acyl dopamines we have shown that N-octanoyl 
dopamine (NOD) is superior to dopamine in vitro [18, 19] and is highly effective in vivo to 
protect rat kidneys from ischemia induced acute kidney injury (AKI).[20, 21] The latter 
seems to be a consequence of  the interaction with the transient receptor potential cation 
channel subfamily V member 1 (TRPV1) [22] as NOD was not renoprotective in TRPV1-/-
rats.[23] Recently it was also demonstrated that NOD treatment of  BD donor rats reduced 
inflammation in the donor kidney and improved renal function when such grafts were 
transplanted into allogeneic recipients [24].
Although these pre-clinical findings are promising tissue distribution and phar-
macokinetics of  NOD have not been addressed so far. As a first step we developed in the 
present study a NOD based radiotracer to study the in vivo tissue distribution and elimi-
nation kinetics of  NOD by means of  PET imaging.
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In this work, we developed a fluorinated derivative of  NOD, 2-fluoro-N-octanoyl 
dopamine 5 (F-NOD) and compared the in vitro behaviour of  F-NOD with NOD in various 
assays in order to prove whether F-NOD could act as an analogue to NOD. In brief, we 
compared the induction of  HO-1, redox activity, TRPV1 activation and EC50. Further we 
performed a catechol O-methyl transferase (COMT) assay with NOD and F-NOD in order 
to investigate the cell intern metabolism. We developed a precursor 10 for radiofluori-
nation in order to obtain the radiotracer [18F]F-NOD. Next, we performed an in vitro cell 
assay with [18F]F-NOD at HUVECs for the determination of  cell association. After this, we 
evaluated the in vivo behaviour of  radiolabelled [18F]F-NOD in three Lewis rats.
Experimental Section
General	procedures. All reagents and solvents were purchased from commercial suppli-
ers and were used without further purification unless otherwise specified. NMR spectra 
were recorded on a 300 MHz Varian Mercury Plus and a 500 MHz Varian NMR System 
spectrometer (Palo Alto, CA). Chemical shifts (δ) are given inppm and are referenced to the 
residual solvent resonance signals relative to (CH3)4Si (1H, 13C) and the internal standard 
CFCl3 (19F). Mass spectra were obtained on a Bruker Daltonics microflexTM MALDI-TOF 
mass spectrometer (Bremen, Germany). Preparative column chromatography was per-
formed on Merck silica gel 60. Reactions were monitored by thin-layer chromatography 
(TLC) on Merck silica gel F254 aluminium plates, with visualization under UV (λ = 254nm) 
or by evaluation using ninhydrin and heating. If  necessary, the purity was determined 
by high performance liquid chromatography (HPLC). Purity of  all final compounds was 
95 percent or higher. Analytical (radio-)HPLC was performed on a Dionex UltiMate 3000 
HPLC system (Thermo Scientific, Dreieich, Germany), equipped with a reverse phase col-
umn (Merck Chromolith® RP-18e; 100x4.6 mm plus a guard column 10x4.6mm), a UV-di-
ode array detector (210nm, 254nm) and a scintillation radiodetector Gabi Star (Raytest, 
Straubenhardt, Germany). The solvent system used was a gradient of  acetonitrile:water 
(containing 0.1 percent TFA) (0–8min: 0–100 percent MeCN) unless otherwise stated 
at a flow rate of  4 mL/min. All radioactive compounds were identified using analytical 
radio-HPLC by  comparison of  the retention time of  the reference compound and also 
by  co-injection with the reference substance. A  difference of  0.11min between UV and 
γ-trace occurs as a  function of  the HPLC setup. Decay-corrected RCYs were quantified 
by calculation from QMA-eluted activity against C18-eluted activity with respect to the 
purity of  the final product in radio-HPLC and radio-TLC using a radio-TLC scanner (BAS-
2500, Raytest). Catridge purification was performed with Waters C18 light cartridges. [18F]




Human umbilical vein endothelial cells HUVECs were isolated from the freshly avail-
able umbilical cord. Cell were grown in basal endothelial cell growth medium (Provitro 
GmbH, Berlin, Germany), supplemented with 2 percent fetal bovine serum and antibi-
otics. Cultures were maintained at 37ºC in a 5 percent CO2 humidified atmosphere and 
experiments were conducted on cells at approximately 80–90 percent confluence.
HEK293 cells were cultured in  T25cm2 flask with DMEM supplemented with 10 
percent FCS, 1 percent Penicillin Streptomycin at 37° C with 5 percent CO2 humidified 
atmosphere.
Calcium Imaging and data analysis
HEK293 cells were seeded on 15 mm round glass coverslips in 12 well plates. 24 hours post 
plating, cells were transfected with rTRPV1 using Metafectane (metafectene® pro-Biontex 
Laboratories GmbH, Germany). 48 hours post transfection, cells were transferred into 
extracellular solution containing 137.6 mM NaCl, 5.4 mM KCl, 0.5 mM MgCl2, 1.8 mM 
CaCl2, 5 mM glucose, and 10 mM HEPES (Roth, Karlsruhe, Germany), loaded with the 
fluorescent dye FURA-2AM (1 µM; Biotrend, Cologne, Germany). Fluorescence was mea-
sured using an inverted microscope (IX-81 with Cell^R, Olympus, Hamburg, Germany) 
and an ORCA-R2 CCD camera (Hamamatsu Corp., Bridgewater, NJ, USA). After alternat-
ing excitation with light of  340nm and 380nm wavelength, the ratio of  the fluorescence 
emission intensities at 510nm (340nm/380nm [510nm]) was calculated and digitized 
at 0.5 Hertz. This fluorescence ratio is a relative measure of  intracellular calcium con-
centration [25]. Analysis was done using cell^R software (Olympus). All the cells that 
responded to Capsaicin were taken as region of  interest and each coverslip was taken as 
an independent experiment. To determine the absolute change in ratio, the baseline value 
was subtracted from the peak. The data was analyzed using 2-way ANOVA with fixed 
effects for substance and concentration (STATISTICA Vs. 4.5, StatSoft, Inc.), LSD post-hoc 
test was used to identify substance differences at a given concentration.
Protein isolation and Western Blotting
HUVEC cell lysates were generated by lysing in lysis buffer consisting of  10 mM Tris-
HCl, 150 mM NaCl, 5 mM EDTA, 1 percent Triton X-100, 0.5 percent sodium deoxycho-
late, 1 µM dithiothreitol (DTT), proteinase inhibitor cocktail and phosphatase inhibitor. 
Protein concentration was measured using Coomassie-Reagent (Pierce, Rockford, USA). 
Samples (15 μg protein extract) were heated to 95° C for 5mins, loaded and separated 
on 10 percent SDS-polyacryamide gels followed by semi-dry blotted onto PVDF mem-
branes (Roche, Mannheim, Germany). The membranes were incubated with 5 percent 
w/v non-fat dry milk in TBS/Tween 0.5 percent to block unspecific background staining 
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and hereafter incubated overnight at 4°  C with anti-VCAM-1-(AF643, R&D Systems, 
Wiesbaden, Germany) or anti-HO-1-antibodies (ADI-SPA-895, Enzo, Biochem Inc, 
USA). Subsequently, the membranes were thoroughly washed with TBS-Tween 0.1 per-
cent and incubated with the appropriate horseradish peroxidase conjugated secondary 
antibody, followed by five wash steps in TBS/Tween 0.1 percent. Proteins were visual-
ized using enhanced chemiluminescence technology, according to the manufacturer’s 
instructions (Pierce, Rockford, IL, USA). To confirm equal protein loading, membranes 
were stripped and re-probed with monoclonal anti-β-actin antibody (clone AC-74, asci-
tes fluid, Sigma Aldrich, USA).
Luminol Assay
The redox activity of  the NOD and F-NOD was measured using luminol assay. Serial 
dilutions of  the compounds were prepared in distilled water and added to Luminol reac-
tion mix (luminol 2.5mM, p-Coumaric acid 0.9 mM and 0.3 percent H2O2). HRP (0.1  µg/
µL) was added to the reaction mix and quenching of  chemiluminescence was measured 
immediately using infinite® 200 PRO – Tecan microplate reader. The measurements were 
performed in triplicates.
COMT assay (for hydrophilic substrate-dopamine)
The assay is performed with manufacturer specifications. In brief, the assay solution con-
sists of 1 mM SAM in 100 µL of  20 mM tracepure HCl mixed with 100 µL of  10 mM MgCl2 
in tracepure water and 100 µL of  5 mM dithiothreitol in tracepure water and 200 µL of  
0.5 M Tris buffer (pH 8.0 at 37° C). The substrate (10 mM dopamine) is added in 200 µL 
tracepure water. 100 µL of  this assay solution were mixed with 100 µL freshly prepared 
COMT-solution (10units) in 1 percent BSA (bovine serum albumin) and incubated at 37° C 
for 1 hr. Afterwards, 100 µL of  HCl conc. were added and the mixture was cooled on ice for 
5mins, centrifuged and the supernatant was analysed with analytical HPLC.
COMT assay (for hydrophobic substrate).
The assay solution consists of  100 µL of  10 mM MgCl2 in tracepure water and 100 µL of  
5 mM dithiothreitol in tracepure water and 500 µL of  0.5 M Tris buffer (pH 8.0 at 37° C). 
100 µL of  this assay solution were mixed with 10 µL Tween20 and 20 µL of  14.6 mM SAM 
(300nmol). 3 µL (300nmol) of  the substrate (100mM NOD or F-NOD in EtOH) is added 
and finally 100  µL freshly prepared COMT-solution (75units) in  1 percent BSA (bovine 
serum albumin) is added. The assay mixture is incubated at 37° C for 2–4h. Afterwards, 
the mixture was cooled on ice for 5mins, centrifuged and the supernatant was extracted 
3⨯ with CHCl3. The organic solvent is removed in vacuum and the residue is dissolved 




Cells were incubated with ~450 kBq [18F]5 per well on a six-well plate for different time 
points at 37°  C under normal atmosphere. Therefore, 9.11 MBq [18F] compound	 5	was 
added to 20 mL cell medium, mixed and 1 mL from that solution was added to every well 
containing cells. After incubation, the supernatant was collected, the cells were washed 
three times with 1 mL PBS and the third washing solution was collected and finally 50 µL 
lysis buffer was added to the cells and cells were scratched from the bottom of  the well 
and collected for gamma counting.
Animal experiments and data analysis
Lewis rats (LEW/Crl, Charles River Laboratories, Sulzfeld, Germany), aged 10 weeks and 
with a  weight of  270–280  g, were employed for the initial PET experiments. The rats 
were anesthetized by isoflurane (2–2.5 percent delivered at 3.5L/min) and a catheter was 
implanted in  the V. femoralis for administration of  the radiotracer. First experiments 
were set-up as terminal experiments in  order to assess the biodistribution after injec-
tion of  different doses of  [18F]F-NOD (4.8, 5.9 and 13.2 MBq, in 0.9 percent NaCl solution, 
150 µL, respectively).
All experiments were performed in compliance with the National Guidelines for Ani-
mal Protection, Germany, and the approval of  the animal care committee. Small-animal 
PET experiments were conducted on the Albira PET System (Bruker Biospin MRI GmbH, 
Ettlingen, Germany). On injection of  the radiotracer a 120-min dynamic scan was initiated. 
The protocol comprised 31 frames (10⨯ 60, 10⨯ 120, 5⨯ 300, and 6⨯ 600 sec). Reconstruction 
was performed using maximum likelihood expectation maximization (MLEM) algorithm 
with a matrix size of  20⨯20 and a pixel size of  0.5 mm (12 iterations) with the Albira Suite 
Reconstructor (Bruker Biospin MRI GmbH, Ettlingen, Germany) with the data output 
in kBq/cc. For data analysis volumes of  interests (VOI) were drawn in PMOD (version 3.608) 
to quantify the injected dose (PMOD Technologies Ltd, Zurich, Switzerland).
Materials
(E)-1-Fluoro-4,5-dimethoxy-2-(2-nitrovinyl)benzene	 (2). 3,4-Dimethoxy-2-fluoro-
benzaldehyde (1, 552  mg, 3.00  mmol) and ammonium acetate (58  mg, 0.75  mmol) were 
dissolved in nitromethane (5 mL) and the mixture was stirred at 80° C for 6 h. After cooling 
to room temperature (r. t.) excess nitromethane was removed and substituted with Et2O. 
This solution was washed with water (2⨯ 10 mL), dried with MgSO4 and the yellow prod-
uct (555 mg, 81 percent) was crystallized from a solution of  Et2O/petroleum ether (PE) 1:1. 
The purity of  2	was > 97 percent and the product was used without further purification. 
RF = 0.47 (Et2O:PE 1:1). 1H NMR (500 MHz, CDCl3): δ = 8.04 (d, 3JH,H = 13.7Hz, 1H,-HC = CH-NO2), 
7.64 (d, 3JH,H = 13.7Hz, 1H,-HC = CH-NO2), 6.87 (d, 4JH,F = 6.7Hz, 1H, H-6), 6.71 (d, 3JH,F = 11.7Hz, 1H, 
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H-3), 3.93 (s, 3H, 4-OCH3), 3.90ppm (s, 3H, 5-OCH3). 13C NMR (126 MHz, CDCl3): δ = 157.6 (d, 
1JC,F = 251.9Hz, C-1), 153.7 (d, 3JC,F = 10.5Hz, C-4), 146.0 (d, 4JC,F = 2.2Hz, C-5), 137.1 (d, 3JC,F = 10.5Hz, 
C-3), 132.6 (d, 5JC,F = 1.0Hz, C = C-NO2), 111.1 (d, 4JC,F = 4.4Hz, C = C-NO2), 100.5 (d, 2JC,F = 27.9Hz, 
C-6), 56.5ppm (2xOCH3). 19F NMR (282 MHz, CDCl3): δ = -114.6ppm. MS (MALDI-TOF): m/z 
( percent) 228 (30) [M + H] + , 250 (30) [M + Na] + . See Figure 1 for NMR signal assignment.
Figure	1.	F-NOD 7 as an example for NMR signal assignment.
2-(2-Fluoro-4,5-dimethoxyphenyl)ethan-1-amine	(3). To a solution of  2	(2.43 g, 
10.69  mmol) in  anhydrous THF (40  mL) under an N2 atmosphere, a  fresh solution of  
LiAlH4 (1.02  g, 26.9  mmol) in  THF (40  mL) was slowly added at 0°  C. The mixture was 
stirred for 15min and the reaction was quenched with ice-cold water. THF was removed 
under reduced pressure at 30° C, brine was added and the aqueous phase was extracted 
with ethyl acetate (EA) (3⨯ 50  mL). The organic phase was dried with MgSO4, concen-
trated and the crude product 3	was obtained as yellow oil (2.11 g, 99 percent). RF = 0.16 (EE). 
1H NMR (300 MHz, CDCl3): δ = 6.68 (d, 4JH,F = 7.1Hz, 1H, H-6), 6.61 (d, 3JH,F = 11.0Hz, 1H, H-3), 
3.85 (s, 3H, 5-OCH3), 3.84 (s, 3H, 4-OCH3), 2.98 (t, 3J = 6.1Hz, 2H, NCH2), 2.77 (t, 3J = 6.9Hz, 
2H, CCH2), 2.33ppm (br s, 2H, NH2). 13C NMR (75 MHz, CDCl3): δ = 155.2 (d, 1JC,F = 237.8Hz, 
C-1), 148.4 (d, 3JC,F = 9.9Hz, C-4), 145.1 (d, 4JC,F = 2.6Hz, C-5), 116.2 (d, 2JC,F = 17.5Hz, C-1), 113.3 
(d, 3JC,F = 6.5Hz, C-6), 100.2 (d, 2JC,F = 28.5Hz, C-3), 56.5 (OCH3), 56.1 (OCH3), 42.0 (NCH2), 
31.9ppm (CCH2). MS (MALDI-TOF): m/z ( percent) 223 (100) [M + Na] + .
N-(2-Fluoro-4,5-dimethoxyphenethyl)octanamide	 (4). To a  solution of  3	
(2.07 g, 10.40 mmol) in CH2Cl2 (20 mL), a solution of  octanoyl chloride (1.6 mL, 9.36 mmol) 
in CH2Cl2 (25 mL) was slowly added at 0° C. To the resulting dark orange suspension Et3N 
(2.2 mL, 15.6 mmol) was added and the mixture was stirred for 15min at 0° C. The resulting 
pale yellow solution was washed with water and brine and dried with MgSO4. The sol-
vent was removed and the crude product was purified by column chromatography (PE → 
PE:EA 10:1 → 5:1 → 4:1 → 1:1) to obtain compound 4 as pale yellow solid (1.41 g, 42 percent). 
RF = 0.33 (PE:EA 1:2). Hot petroleum ether was used for recrystallization of  4. 1H NMR (500 
MHz, DMSO‑d6): δ = 6.66 (t, 4JH,F = 7.1Hz, 1H, H-6), 6.61 (d, 3JH,F = 11.0Hz, 1H, H-3), 5.49 (s, 1H, 
NH), 3.85 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.48 (dt, 3JH,H = 6.8Hz, 3JNH,H = 6.1Hz, 2H, NCH2), 
2.79 (t, 3J = 6.9Hz, 2H, CCH2), 2.13 (t, 3J = 7.6Hz, 2H, H-α), 1.62–1.56 (m, 2H, H-β), 1.31–1.23 (m, 
8H, H-γ,δ,ε,ζ), 0.89–0.86ppm (m, 3H, CH3). 13C NMR (126 MHz, DMSO‑d6): δ = 173.2 (C = O), 
155.1 (d, 1JC,F = 237.7Hz, C-2), 148.4 (d, 3JC,F = 9.9Hz, C-4), 145.2 (d, 4JC,F = 2.7Hz, C-5), 116.1 (d, 
2JC,F = 17.4Hz, C-1), 113.0 (d, 3JC,F = 6.4Hz, C-6), 100.1 (d, 2JC,F = 28.5Hz, C-3), 56.4 (OCH3), 56.4 
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(OCH3), 39.7 (NCH2), 36.9 (C-α) 31.7 (C-ε), 29.2 (C-γ), 29.0 (C-δ), 28.8 (CCH2), 25.7 (C-β), 22.6 
(C-ζ), 14.1ppm (CH3). 19F NMR (282MHz, CDCl3): δ = -126.1ppm. MS (MALDI-TOF): m/z ( 
percent) 326 (100) [M + H] + . Analytical HPLC: tR = 4.54min.
N-(2-Fluoro-4,5-dihydroxyphenethyl)octanamide	 (5). To a  solution of  4	
(734  mg, 2.26  mmol) in  CH2Cl2 (100  mL), a  solution of  BBr3 (11.3  mL, 11.3mmol, 1M) 
in  CH2Cl2 was slowly added at-12°  C within 5min. The mixture was stirred for 135min 
at-10° C and was allowed to reach r. t. for 60min. Water (30 mL) was added for quenching 
the reaction and the mixture was extracted with CH2Cl2 (1x) and EA (2x). The combined 
organic phases were dried with MgSO4, concentrated under reduced pressure and the 
crude product was purified by column chromatography (PE → PE:EA 1:1) to obtain com-
pound 5 as pale yellow solid (602mg, 90 percent). RF = 0.44 (PE:EA 1:3), 0.85 (methanol). 1H 
NMR (300 MHz, DMSO‑d6): δ = 9.09 (s, 1H, OH), 8.72 (s, 1H, OH), 7.81 (t, 3J = 5.7Hz, 1H, NH), 
6.54 (d, 4JH,F = 7.8Hz, 1H, H-6), 6.48 (d, 3J H,F = 10.9Hz, 1H, H-3), 3.18–3.11 (m, 2H, NCH2), 2.52 
(t, 3J = 7.3Hz, 2H, CCH2), 2.01 (t, 3J = 7.2Hz, 2H, H-α), 1.48–1.43 (m, 2H, H-β), 1.27–1.23 (m, 
8H, H-γ,δ,ε,ζ), 0.88–0.83ppm (m, 3H, CH3). 13C NMR (75 MHz, DMSO‑d6): δ = 171.9 (C = O), 
153.3 (d, 1JC,F = 233.2Hz, C-2), 144.2 (d, 3JC,F = 11.2Hz, C-4), 141.3 (d, 4JC,F = 2.3Hz, C-5), 116.5 (d, 
3JC,F = 6.0Hz, C-6), 115.0 (d, 2JC,F = 17.2Hz, C-1), 102.8 (d, 2JC,F = 26.4Hz, C-3), 39.0 (NCH2), 35.3 
(C-α) 31.1 (C-ε), 28.5 (C-γ), 28.4 (C-δ), 28.1 (CCH2), 25.2 (C-β), 22.0 (C-ζ), 13.9ppm (CH3). 19F 
NMR (282 MHz, DMSO‑d6): δ = -129.7ppm. MS (MALDI-TOF): m/z ( percent) 298 (100) 
[M + H] + . Analytical HPLC: tR = 3.96min.
4-(2-Aminoethyl)-5-nitrobenzene-1,2-diol	 (8). 6-Nitrodopamine compound	 8 
was prepared according to the literature.[26] In brief, to a solution of  dopamine hydro-
chloride (1.50g, 7.91mmol) in water (45 mL) at 0° C NaNO2 (1.89g, 27.39mmol) was added 
and the mixture was stirred for 15min. To the pale yellow solution an ice-cold solution of  
20 percent H2SO4 (3.5 mL) was slowly added. The yellow product starts to precipitate from 
the brown solution. The product was filtered, washed with cold water and methanol and 
dried with high vacuum to obtain compound	8 as yellow solid (1.21g, 77 percent). NMR 
and MS analyses were consistent with the literature.[26]
4-Nitro-5-(2-octanamidoethyl)-1,2-phenylene	 dioctanoate	 (9). To a  solution 
of  compound	8	(500 mg, 2.52 mmol) in CH2Cl2 (10 mL), a solution of  octanoyl chloride 
(1.19 mL, 6.98mmol) in CH2Cl2 (3 mL) was slowly added at 0° C. Et3N (1.23 mL, 8.82mmol) 
was added and the mixture was stirred at r. t. for 16h. CH2Cl2 was removed and the residue 
was redissolved in EA (20 mL) and washed with brine. The organic phase was dried with 
Na2SO4, concentrated under reduced pressure and the crude product was purified by col-
umn chromatography (PE → PE:EA 5:1 → 3:1) to obtain compound 9 as pale yellow solid 
(431mg, 33 percent). RF = 0.59 (PE:EA 1:1). Hot acetonitrile was used for recrystallization 
of  compound	9. 1H NMR (500 MHz, CDCl3): δ = 7.89 (s, 1H, H-3), 7.21 (s, 1H, H-6), 5.79 (s, 
1H, NH), 3.61–3.57 (dt, 3JH,H = 6.8Hz, 3JNH,H = 6.4Hz, 2H, NCH2), 3.12 (t, 3J = 6.8Hz, 2H, CCH2), 
2.55 (t, 3J = 7.5Hz, 2H, 2-O(CO)CH2), 2.54 (t, 3J = 7.5Hz, 2H, 1-O(CO)CH2), 2.17 (t, 3J = 7.7Hz, 2H, 
N(CO)CH2), 1.70–1.63 (m, 4H, O(CO)CH2CH2), 1.56–1.50 (m, 2H, N(CO)CH2CH2), 1.44–1.22 
(m, 24H, 3xH-γ,δ,ε,ζ), 0.92–0.85ppm (m, 9H, 3xCH3). 13C NMR (126 MHz, CDCl3): δ = 173.7 
(NC = O), 170.5 (2-OC = O), 170.2 (1-OC = O), 146.0 (C-1), 145.8 (C-2), 140.9 (C-4), 133.2 (C-5), 
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127.5 (C-6), 120.9 (C-3), 39.7 (NCH2), 36.6 (N-C-α), 34.0 (2-O-C-α), 33.9 (1-O-C-α), 32.8 
(CCH2), 31.7 (N-C-ε), 31.6 (2xO-C-ε), 29.0 (6xC-γ,δ), 25.6 (N-C-β), 24.8 (2xO-C-β), 22.6 (3xC-
ζ), 14.0ppm (3xCH3). MS (MALDI-TOF): m/z ( percent) 577 (60) [M + H] + . Analytical HPLC: 
tR = 7.75min.
N-(4,5-Dihydroxy-2-nitrophenethyl)octanamide	 (10). Compound	 9 (150  mg, 
0.26 mmol) was dissolved in acetonitrile (25 mL) at 30° C. The mixture was cooled to 0° C 
and a solution of  0.1M NaOH (2.6 mL, 0.26 mmol) was added dropwise. The mixture was 
then stirred for 4 h at 50° C. Water was added and the mixture was extracted with EA 
(2x). The organic phase was dried with MgSO4, concentrated under reduced pressure and 
the crude product was purified by  column chromatography (PE → PE:EA 1:1) to obtain 
compound 10 as yellow solid (83 mg, 99 percent). RF = 0.20 (PE:EA 1:1). 1H NMR (500 MHz, 
DMSO‑d6): δ = 10.33 (s, 1H, OH), 9.81 (s, 1H, OH), 7.84 (t, 3J = 5.7Hz, 1H, NH), 7.48 (s, 1H, H-6), 
6.68 (s, 1H, H-3), 3.27–3.23 (m, 2H, NCH2), 2.88 (t, 3J = 7.1Hz, 2H, CCH2), 1.99 (t, 3J = 7.5Hz, 2H, 
H-α), 1.47–1.41 (m, 2H, H-β), 1.28–1.17 (m, 8H, H-γ,δ,ε,ζ), 0.87–0.84ppm (m, 3H, CH3). 13C 
NMR (126 MHz, DMSO‑d6): δ = 171.9 (C = O), 151.7 (C-5), 143.9 (C-4), 139.0 (C-2), 128.1 (C-1), 
118.1 (C-6), 111.9 (C-3), 39.7 (NCH2), 35.3 (C-α) 32.8 (C-ε), 31.0 (CCH2), 28.5 (C-γ), 28.3 (C-δ), 
25.1 (C-β), 22.0 (C-ζ), 13.8ppm (CH3). MS (MALDI-TOF): m/z ( percent) 325 (100) [M + H] + . 
Analytical HPLC: tR = 4.06min.
N-(4-Hydroxy-3-methoxyphenethyl)octanamide	 (12). 3-Methoxytyramine 
(3-MT) (50mg, 0.25  mmol) was mixed with octanoic acid (40  µL, 0.25mmol) and BOP 
(110mg, 0.25mmol) in  2  mL anhydrous THF. The solution was cooled to 0°  C and Et3N 
(105  µL, 0.75mmol) dissolved in  400  µL THF was added dropwise within 15min. The 
reaction was allowed to stir at r. t. for 16h. THF was substituted with 10 mL Et2O and the 
organic phase was washed 3⨯ with HCl (3 mL, 1 M), 2⨯ with NaHCO3-solution (5 mL, 1 
M) and 2⨯ with brine (5  mL). The organic phase was dried with MgSO4 and the prod-
uct was recrystallized in Et2O/hexane to obtain a pale yellow solid (70 mg, 95 percent). 
RF = 0.30 (PE:EE 1:2). 1H NMR (500 MHz, CDCl3): δ = 6.85 (d, 3J = 7.9Hz, 1H, H-2), 6.71–6.66 
(m, 2H, H-5,6), 5.50 (s, 1H, NH), 3.88 (s, 3H, OCH3), 3.49 (t, 3J = 6.8Hz, 2H, NCH2), 2.74 (t, 
3J = 6.9Hz, 2H, CCH2), 2.21 (d, 3J = 2.9Hz, 1H, OH), 2.13 (t, 3J = 7.6Hz, 2H, (CO)CH2), 1.63–1.54 
(m, 2H, N(CO)CH2CH2), 1.32–1.22 (m, 8H, H-γ,δ,ε,ζ), 0.89–0.86ppm (m, 3H, CH3). 13C NMR 
(126 MHz, CDCl3): δ = 173.1 (NC = O), 146.6 (C-3), 144.3 (C-4), 140.9 (C-1), 121.3 (C-6), 114.4 
(C-5), 111.1 (C-2), 55.9 (OCH3), 40.6 (NCH2), 36.9 (CCH2), 35.4 (C-α), 31.7 (N-C-ε), 29.2 (C-γ), 
29.0 (C-δ), 25.8 (C-β), 22.6 (C-ζ), 14.1ppm (CH3). MS (MALDI-TOF): m/z ( percent) 294 (70) 
[M + H] + . Analytical HPLC: tR = 6.13min (0–8min: 0–50 percent MeCN).
Radiochemistry
N-(2-[18F]Fluoro-4,5-dihydroxyphenethyl)octanamide[18F]5. No-carrier-added aque-
ous [18F]fluoride (3.43GBq) was trapped on a Waters QMA cartridge, which was precon-
ditioned with 1M NaHCO3 (5 mL) and tracepure H2O (10 mL). [18F]Fluoride was eluted with 
a freshly prepared Kryptofix®-solution (12.5mg K2.2.2, 800 µL MeCN, 200 µL tracepur 
H2O, 10 µL 1M K2CO3) into the reaction vessel and dried via azeotropic distillation with 
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a gentle stream of  helium (2 mL/min) at 100° C for 4min at 600mbar, followed by addi-
tion of  anhydrous acetonitrile (2 × 0.8 mL;3min at 600mBar) and 4min at full vacuum. 
Afterwards, compound	 10 (1.5mg, 4.62  µMol) dissolved in  anhydrous DMSO (500  µL) 
was added, and the reaction mixture was stirred at 120°  C for 30min. Water (15  mL) 
was added, the solution was passed through a SepPak® tC18 plus light cartridge (145 mg 
sorbent, preconditioned with 5 mL Et2O), the cartridge was washed with water (10 mL, 
cartridge kept wet) followed by elution of  [18F]5 with diethylether (3 mL, the first yellow 
1.1 mL were discarded until the eluted fraction was colourless). The solvent was evap-
orated at 80° C at 900mbar in a gentle stream of  helium for 4–5min to afford 880MBq 
(RCY = 45 percent, d.c.) [18F]5 with a RCP > 99 percent within approx. 90min and a specific 
activity = 28 ± 6GBq/µMol (n = 5). Radio-HPLC: tR = 4.07min. Radio-TLC: RF = 0.85 (metha-
nol). For injection purposes, [18F]5 is redissolved in a suitable amount (0.4 – 1.0 mL) of  
0.9 percent NaCl solution for injection + 0.9 percent EtOH and purified by a sterile filter 
(0.22 µM) with a final pH 7.57 ± 0.3.
Results and discussion
Synthesis of F-NOD
F-NOD was synthesized from 3,4-dimethoxy-2-fluorobenzaldehyde compound	 1	 as 
outlined in  Scheme 1. It was successfully converted to the β-nitrostyrene derivative 
compound	2 by the method of  Milhazes et al.[27] To this end, nitromethane was used as 
solvent and ammonium acetate as base for generation of  compound	2 (yield > 81 percent), 
which was subsequently reduced with LiAlH4 to the corresponding amine 3. This was fol-
lowed by introduction of  an octanoyl group at the primary amine using octanoyl chloride 
in excess and selective removal of  both methoxy groups with 5 eq. BBr3 at-12° C [28].
Scheme	1.	Synthesis pathway of  the non-radioactive reference compound 5.
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In vitro studies with F-NOD and NOD
Several in  vitro studies were conducted to test if  F-NOD compound	 5	displayed similar 
relevant biological properties as NOD compound	7, i.e. inhibition of  TNFα mediated vas-
cular cell adhesion molecule 1 (VCAM-1) expression, induction of  HO-1, redox activity 
[29, 30] and the ability to activate TRPV1. [31] At higher concentrations both NOD 7 and 
F-NOD compound	 5 inhibited VCAM-1 expression almost to a  similar extent, while at 
low concentrations F-NOD compound	5 seemed to be less effective. This was more pro-
nounced for induction of  HO-1 (Figure 2A). We have previously demonstrated that the 
redox activity of  NOD compound	 7 is crucial for its ability to inhibit VCAM-1 expres-
sion.[32] In essence this redox activity is provided by the ortho dihydroxy moiety on the 
benzene structure. Since these functional groups are also present in F-NOD compound 
5, this largely explains its ability to inhibit VCAM-1 expression and induce HO-1. We 
made use of  peroxidase based luminol reaction, to assess if a difference existed in redox 
activity of  the compounds Dose response experiments revealed highly significant effects 
of  concentration (F(15,559) = 194.42, p < 0.001; two-way ANOVA, fixed effects) as well as 
of  substance F(1,559) = 26.78, p < 0.001. Although both NOD 7	and F-NOD	5 were able to 
completely quench chemiluminescence, for NOD 7	 (EC50 : 12.12 µM) it was achieved at 
lower concentration as compared to F-NOD compound	5 (EC50 : 32.6 µM) (Figure 2B Inter-
action: F(15,559) = 5.98, p < 0.001 two-way ANOVA, fixed effects). This suggests a  small 
difference in redox activity between both compounds and might explain why F-NOD 5 is 
less efficiently inhibiting VCAM-1 and inducing HO-1 expression at low concentrations. 
In agreement with their redox activity it was found that both compounds were able to 
protect endothelial cells against cold inflicted injury (Figure S1).
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Figure	2.	In vitro F-NOD 5 shows similar biological activities as NOD 7: (A) Influence of  F-NOD and NOD 
on  TNFα mediated VCAM-1 expression and induction of  HO-1. Cells were stimulated overnight with 
TNFα 10ng/mL in the presence of  different concentrations of  F-NOD 5 or NOD (0–100 µM). Cell lysates 
were prepared and 15 µg of  total protein was loaded on a 10 percent SDS PAGE. The gel was blotted and 
stained for VCAM-1 and HO-1. Equal loading of  protein was confirmed with ß-Actin. Note that at higher 
concentrations inhibition of  VCAM-1 and induction of  HO-1 are comparable but not at lower concen-
trations to NOD in terms of  its anti-inflammatory properties. (B) Redox activity of  NOD and F-NOD: 
F-NOD 5 similar to NOD 7 was able to quench the luminol assay. Serial dilutions of  NOD 7 or F-NOD 5 
were added to 100 µL of  reaction mixture containing 0.005U of  horseradish peroxidase (HRP), 2.5 mM 
luminol and 0.9 mM p-Coumaric acid. Chemiluminescence was measured directly after addition of  0.03 
percent H2O2. The ability to quench peroxidase mediated chemiluminescence was tested and results are 
expressed as relative to the control to which neither NOD nor F-NOD was added along with ± SEM of  all 
measurements. For each concentration and for each compound at least 3 independent measurements 
were performed. EC50 of  NOD 7 was determined to be 12.12 µM and EC50 of  F-NOD 5 32.60 µM indicated 
by dashed lines, *p < 0.05, ***p < 0.001 ANOVA with LSD post-hoc test.
The TRPV1 activating properties were assessed in  a  heterologous cell assay. 
F-NOD compound	5	like NOD compound	7 was able to activate TRPV1 (Figure 3A). Dose 
response experiments revealed highly significant effects of  concentration (F (11,137) = 17.86, 
p < 0.001; two-way ANOVA, fixed effects) as well as of  substance (F (1,137) = 12.38, p < 0.001). 
Thus, both substances were able to activate TRPV1 in a concentration dependent manner 
but NOD (EC50 = 7.10  µM [-5.15 ± 0.08]) was much more effective as compared to F-NOD 
(EC50 = 45.94 µM [-4.34 ± 0.12]) (Figure 3B).
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Figure	 3.	 TRPV1	 activation	 by  F-NOD	 and	 NOD: (A) Representative images of  a  calcium imaging 
experiment using rTRPV1 transfected HEK293 cells (Left panel). The ratio 340/380 at 510nm – a mea-
sure proportional to free intracellular calcium – is false colour coded where warmer colours indicate 
increasing calcium values. Average time course traces are shown on  the right panel. Cells were first 
either stimulated with 10 µM NOD compound 7 or 10 µM of  F-NOD compound 5, followed by 10 µM 
capsaicin to select rTRPV1 transfected cells and to see maximum response after washing away of  the first 
substance; (B) rTRPV1 transfected HEK293 cells were stimulated with different concentrations of  NOD 
compound 7 or F-NOD compound 5: For each concentration and for each compound at least 3 indepen-
dent measurements were performed. The results are expressed as average ratio 340/380 at 510nm ± SEM 
of  all measurements (n = 3 to 13). EC50 of  F-NOD compound 5 was determined to be 45.94 µM and EC50 
of  NOD compound 7 7.10 µM; EC50 values (NOD 7: 7.10 µM and F-NOD 5: 45.94 µM) indicated by dashed 
lines, *p < 0.05, ***p < 0.001 ANOVA with LSD post-hoc test.
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It was further investigated, whether F-NOD also interacted with TRPV1 binding 
pocket in similar fashion as NOD via computational molecular modelling. No differences 
in putative interactions with amino acids inside the TRPV1 binding pocket were found 
between NOD compound 7 and F-NOD compound	 5	 (Figure S2). The 6-fold increase 
in EC50 value of  F-NOD for TRPV1 activation could be explained by the insertion of  flu-
orine as substituent in  the aromatic ring. Fluorine might exert an inductive (-I) effect, 
thereby reducing the negative charge density in  the aromatic ring, which in  turn may 
influence the ability of  F-NOD to access the TRPV1 binding site [33].
Radiochemistry
For radiolabelling purposes we initially tried to synthesize the precursor 10 by introduc-
tion of  a nitro group into NOD 7 (Scheme 2). Although synthesis of  NOD compound	7	was 
successful [34], the subsequent nitration step to generate precursor compound	10	failed 
under various conditions.[26, 35–37] This was most likely due to the acidic conditions 
during the nitration, which caused hydrolysis of  the octanoyl group yielding only small 
amounts (< 10 percent) of  nitro dopamine 8. Therefore precursor compound	10 was syn-
thesized from 5-nitrified dopamine compound	8, which was subsequently reacted with 
an excess of  octanoyl chloride in order to maximize the yield of  compound	9	(Scheme 2). 
The O-octanoyl groups of  compound 9 were removed selectively by NaOH.
Scheme	2.	Synthesis pathway of  precursor	10.
The optimization procedure for radiolabelling of  precursor compound	 10 (0.5–
1.8  mg) was performed at 20–120oC in  CH3CN, DMF or DMSO (0.5–1.0  mL) for 20–60 
minutes, respectively, using [18F]KF/K2.2.2/K2CO3 (Table 1). Scheme 3 depicts the best 
radiolabelling conditions, which were obtained with 1.5  mg compound	 10 in  0.5  mL 
DMSO for 30min reaction time at 120° C (radiochemical yield (RCY) = 45 percent (decay 
corrected – d.c.) (Figure 4A); specific activity 21.9–34.5GBq/µMol for [18F]F-NOD [18F]5). 
Purification was performed by  tC18 light cartridges resulting in  a  radiochemical purity 
(RCP) > 99 percent and absolute amount of  activity of  880MBq after 90min (starting from 
3.43 GBq [18F]fluoride) (Figure 4B). The identity of  the product was checked by compari-
son of  retention times on HPLC and TLC with that of  the reference compound 5.
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Scheme	3.	Radiosynthesis scheme of  radiotracer [18F]F-NOD [18F]5.
Radiolabelling with acetonitrile as solvent resulted in a comparable RCY (38 per-
cent, d.c.) but under formation of  a more lipophilic side product (> 29 percent). Removal 
of  this side product was only possible by semi-preparative HPLC which ended in pro-
longed overall synthesis time and lower product activity. Radiolabelling utilizing DMF 
resulted in much lower RCY (6 percent, d. c.) (Table 1).
Figure	4.	Synthesis and purification of  [18F]F-NOD: (A) Representative chromatogram of  the radiola-
belling reaction and 18F-incorporation (tR = 0.65min) into [18F]F-NOD (tR = 4.07min) after 30min at 120° C 
in DMSO; (B) Representative chromatogram of  the purity of  [18F]F-NOD (tR = 4.07min) after purification 
with SepPak light cartridge: γ-trace (thick line) is depicting the radiochemical purity > 99 percent, 
UV-trace at 210nm (dashed line) is depicting the chemical purity > 96 percent.
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Table	1.	Optimization of  the radiolabelling of  precursor 10 reaction time, temperature, sol-











1.5 MeCN 0.5 20 30 10 25
1.5 MeCN 0.5 100 10 19 42
1.8 MeCN 0.5 100 40 18 55
1.8 MeCN 1.0 100 60 38 61
1.5 DMF 0.5 100 40 6 65
0.5 DMSO 0.5 110 40 16 83
1.5 DMSO 0.5 100 40 33 58
1.5 DMSO 0.5 120 40 45 69
*Unless otherwise stated RCYs are all corrected for decay
Lipophilicity and in vitro stability tests of [18F]F-NOD
The lipophilicity of  a  pharmacologically active compound is a  fundamental physico-
chemical parameter. Hence, logP/logD determinations are of  utmost importance and 
relevance to evaluate structure-activity relationships in medicinal chemistry as well as 
in radio pharmacy.[38] The lipophilicity (logD) of  [18F] compound	5 was determined at pH 
7.5 to be 3.35  ± ± 0.04 (n = 3) using PBS and n-octanol according to the shake-flask method 
(OECD guideline).[39] Next, the stability of  [18F] compound	5 was elaborated in vitro. To 
this end, a solution of  [18F]5 in PBS/3 percent EtOH (100 µL) was incubated with rat plasma 
(200 µL) and shaken for at least 120min at 37° C. Radio-TLC as well as radio-HPLC analy-
ses were performed after 30, 60 and 120min, respectively, and showed no decomposition 
or radiodefluorination of  [18F]5	 (RCP ≥ 98 percent) in  the supernatant fraction, which 
showed a recovery rate of  [18F] compound	5	of  77–85 percent after precipitation of  the 
incubation solution (100 µL) with acetonitrile (100 µL) at 0° C. The precipitate contained 
15–23 percent of  the remained activity.
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Cell uptake and stability studies
Cell uptake studies were performed with HUVECs to assess to what extent [18F] compound 
5	is taken-up by the cells, and if so whether it is further metabolized. As depicted in Figure 
5A [18F] compound	5	cell associated activity was approximately 0.14–0.21 percent of  the 
applied dose (ID) after 120 minutes of  incubation at 37° C. HPLC analysis of  the cell lysate 
extracts revealed only one radioactive peak at tR = 4.07min, corresponding to the intact 
[18F] compound	5, indicating that [18F] compound	5	was not metabolized intracellularly 
within the time-frame of  the experiment.
In order to investigate the stability of  [18F] compound	5	 in more detail, a catechol 
O-methyl transferase [40] (COMT) assay was performed [41] to assess if  [18F]5	 is a  gen-
uine substrate for COMT. COMT is a  ubiquity intracellular enzyme which deactivates 
catechols by addition of  a methyl group to one of  the hydroxyl groups.[42] The assay was 
optimized using dopamine as gold standard, which is converted to 3-methoxythyramine 
(3-MT) compound (11) (Scheme 4).
Scheme	4.	Synthesis for O-methylated metabolite compound	12 of  NOD in COMT assay.
Because of  the high lipophilicity of  both NOD and F-NOD, 10 µL of  Tween20 was 
added and higher concentrations of  the methyl donor S-adenosyl-l-methionine (SAM) 
and COMT were used with elongated reaction times (120–240min) in order to allow the 
formation of  3-MNOD compound	12 and (OMe)2-F-NOD compound	4. Figure 5 displays 
the HPLC chromatograms of  combined injections of  different NOD and F-NOD deriva-
tives (Figures 5 B,D) and the performed COMT assay (Figures 5 C,E) at different time points.
The conversion to the methylated derivatives proceeded slower in comparison to 
dopamine which was totally converted to 3-MT after 120 minutes using low concentration 
of  SAM and COMT. Methylation of  NOD and F-NOD occurred at both hydroxy groups 
resulting in  double methylated derivatives. The rate of  conversion to the methylated 
derivatives of  F-NOD was slightly faster in comparison to NOD (see chromatograms C 
and E at 180 minutes in Figure 5). This might be explained by the strong negative induc-






Figure	5.	 (A) Uptake of  [18F]5 by endothelial cells over a period of  120 min at 37° C (values represent 
means  ±  SD of  three independent experiments); Representative chromatograms of: (B) NOD and its 
derivatives; (C) COMT assay for NOD, indicating a new more lipophilic peak (16 percent) at the same 
retention time like 3 - O - methoxy N - octanoyl dopamine compound 12; (D) F - NOD and its derivative; 
(E) COMT assay for F - NOD; HPLC condition: 0 – 50 percent MeCN + 0.1 percent TFA within 8 minutes.
In vivo evaluation of [18F]5
For assessment of  the elimination kinetics of  [18F] compound	5 in three Lewis rats dif-
ferent amounts of  activity (4.8, 5.9 and 13.2 MBq) were injected to find the optimal dose 
for PET imaging (13.2MBq). Elimination of  [18F] compound	5 was characterized by a fast 
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blood clearance and substantial renal and hepatobiliary elimination (Figure 6A) com-
parable with lipophilic radiotracers.[43, 44] The activity is flowing through the kidneys 
without higher accumulation of  activity within 5–10 minutes (SUVbw = 8 ± 5g/mL) which 
was subsequently reallocated from the renal pelvis into the bladder within 30min. Most 
of  the injected activity accumulated in the liver after 8min (SUVbw = 21 ± 10g/mL) possibly 
because of  the lipophilic nature of  [18F] compound	5. It seems that in the liver might be 
substantial oxidative defluorination [45] of  [18F]5 by rat specific dehalogenase [46, 47] as 
reflected by  a  gradual accumulation of  activity in  bones starting at 60 minutes. After 
120 minutes most of  the activity was found in the bladder (SUVbw = 38.5 g/mL) and bones 
(SUVbw = 9.8g/mL). Time-activity curves of  different organs are illustrated in  Figure 6B. 
The activity remains at a certain level (SUVbw = 8g/mL) within the renal pelvis and slowly 
eliminates into the bladder after 30 minutes. The liver activity is higher but also shows 
a faster elimination then the renal pelvis with no formation of  a plateau.
A
B
Figure	6.	(A) PET images (MIP - maximal intensity projection) of  Lewis rat with injected 13.2 MBq [18F]5; 
(B) Distribution of  [18F]5 within 120 min (n=3). Most of  activity accumulates in liver. Some of  the activity 




In summary, we compared the in vitro behavior of  F-NOD compound	5 with NOD com-
pound 7 in various assays in order to prove, whether F-NOD compound	5 could act as an 
analogue to NOD compound	7. The results of  F-NOD compared to NOD were similar at 
induction of  HO-1, redoxactivity, TRPV1 activation and EC50. NOD and F-NOD are both 
substrates for COMT. At both derivatives O-methylation takes place but in comparison 
to dopamine, NOD and F-NOD have a higher stability. This might be due to the higher 
lipophilicity of  compound	5 and compound	7, which hinders the O-methylation by the 
enzyme. These data suggested that the radiolabelled [18F]F-NOD could act as a  tool for 
further determination of  the behaviour of  NOD. In vitro cell assay with [18F]F-NOD at 
HUVECs revealed low cell association (0.14–0.21 percent), which means that there is no 
active transport mechanism into the cell. The cell experiment suggests, that the concen-
tration of  NOD must be at least 500⨯ higher in order to get a 1⨯ concentration inside the 
cell after 2 h.
The in  vivo experiments reveal a  fast renal and hepatobiliary clearance of  [18F]
F-NOD. Since the concentration of  the radiotracer is very low, the metabolism of  such 
small doses can be faster in  comparison to a  higher concentration of  non-radioactive 
NOD. Due to the fast clearance it is recommended to use a high concentration of  NOD as 
bolus injection or semi-high in continuous injection in order to reach a renoprotective 
level in the kidneys for transplantation purposes.
In conclusion, we herein report on  the fast and facile radiofluorination of  the 
NOD-derivative [18F]F-NOD [18F] compound	5	for in vivo assessment of  NOD’s elimination 
kinetics by means of  PET imaging. We demonstrated that F-NOD 5 and NOD 7 behave 
similar in different in vitro assays and that both are substrates for COMT. [18F] compound	5	
was synthesized with reproducible high radiochemical yield and purity (> 98 percent) as 
well as high specific activities (> 20 GBq/µMol). After a synthesis time of  approximately 
90 minutes, the radiotracer was ready for injection. Stability tests show no decomposition 
of  [18F]5	over a period of  120 minutes in rat plasma. Fast blood clearance and a predom-
inant Elimination by liver and kidneys was found for [18F] compound	5	in vivo. Although 
these data suggest that also NOD might be subjected to a  fast clearance, further phar-
macokinetic evaluation is warranted. However, [18F] compound	5 is useful for studying 
pharmacokinetics via biodistribution for period up to 30 minutes, due to the fast renal 
and hepatobiliary elimination and degradation in  vivo between 30–60min. [18F]5 might 
not be suitable for elongated pharmacokinetics and biodistribution studies in rodents as 
it likely underlies oxidative defluorination after 60min.
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N-acyl dopamines (NAD) are gaining attention in the field of  inflammatory and neuro-
logical disorders. Due to their hydrophobicity, NADD may have access to the endoplasmic 
reticulum (ER). We therefore investigated if NAD induce the unfolded protein response 
(UPR) and if this in turn influences cell behaviour.
Genome wide gene expression profiling, confirmatory qPCR and reporter assays 
were employed on  human umbilical vein endothelial cells (HUVEC) to validate induc-
tion of  UPR target genes and UPR sensor activation by  N-octanoyl dopamine (NOD). 
Intracellular ATP, apoptosis and induction of  thermo tolerance were used as functional 
parameters to assess adaptation of  HUVEC.
NOD, but not dopamine dose dependently induces the UPR. This was also found for 
other synthetic NAD. Induction of  the UPR was dependent on the redox activity of  NADD 
and was not caused by selective activation of  a particular UPR sensor. UPR induction did 
not result in cell apoptosis, yet NOD strongly impaired cell proliferation by attenuation 
of  cells in  the S-G2/M phase. Long-term treatment of  HUVEC with low NOD concen-
tration showed decreased intracellular ATP concentration paralleled with activation of  
AMPK. These cells were significantly more resistant to cold inflicted injury.
We provide for the first time evidence that NAD induce the UPR in vitro. It remains 
to be assessed if UPR induction is causally associated with hypometabolism and thermo-
tolerance. Further pharmacokinetic studies are warranted to address if the NAD concen-




The endoplasmic reticulum (ER) can be considered as the gatekeeper for protein synthe-
sis, assuring appropriate protein folding and maturation of  secreted and transmembrane 
proteins. These functions are highly regulated and require checkpoint for allowing that 
only correctly folded proteins can leave the ER. Whenever the folding capacity of  the ER 
is too low to meet the cellular demand for newly synthesized proteins, unfolded or mis-
folded proteins start to accumulate in the ER, which in turn, triggers a set of  responses 
known as the unfolded protein response (UPR) [1–4].The function of  the UPR can be 
divided into two major objectives, i.e. restoration of  ER homeostasis and secondly induc-
tion of  apoptosis if the first objective fails. The UPR accomplishes its function by increas-
ing the expression of  chaperone proteins to assist in protein folding, transient inhibition 
of  mRNA translation to decrease protein influx into the ER, increasing ER associated 
degradation to remove misfolded proteins and induction of  apoptotic genes to eliminate 
cells that are beyond repair.
The UPR consist of  three different branches, each of  which containing a  specific 
transmembrane ER sensor protein that, upon activation, sets a  series of  responses 
in motion resulting in the transcription of  typical UPR target genes [3, 4]. These so called 
UPR sensor proteins are the inositol requiring kinase 1 (IRE1), double-stranded RNA-ac-
tivated protein kinase (PKR)-like ER kinase (PERK) and activating transcription factor 6 
(ATF6)[1–3], all of  which are associated with the ER chaperone glucose-regulated protein 
BiP. If  misfolded proteins accumulate, BiP dissociates from the ER sensors, leading to 
their activation [1–3, 5]. UPR sensor activation is characterized by cleavage of  X-box-bind-
ing protein 1 (Xbp1) mRNA (IRE1), phosphorylation of  the translation initiation factor 2 
α subunit (eIF2α) (PERK) and processing of  ATF6 in the Golgi apparatus[6–12].The UPR 
has been implicated in  a  variety of  diseases including cancer, metabolic, neurodegen-
erative and inflammatory disease [13]. In addition it might be an integral part of  the 
protective strategies used by hibernating mammals for long term survival in a state of  
cold torpor[14]. Signalling components of  the UPR are emerging as potential targets for 
intervention and treatment of  human disease[15].
Long chain polyunsaturated fatty acids are able to form conjugates with amines, 
e.g. ethanolamine, serotonin or dopamine. Since these conjugates can influence a vari-
ety of  biological systems, they are gaining increased attention as promising new leads 
in the field of  inflammatory and neurological disorders and for other pharmacological 
applications[16]. Endogenous N-acyl dopamines (NAD), e.g. N-arachidonoyl-, N-oleoyl-, 
N-palmitoyl-and N-stearoyl-dopamine are present in  brain tissue and are known to 
modulate the endocannaboid system. It has also been reported that NAD are able to 
activate transient receptor potential (TRP) vanilloid subfamily member 1 (TRPV1) [16, 17]. 
We recently described N-octanoyl-dopamine (NOD), a short synthetic NAD, as a potent 
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protective compound in  acute kidney injury [18]. In addition it prevents hypothermic 
preservation injury[19, 20] strongly inhibits platelet function [21] and impairs NFκB 
activation [22]. Yet, it should be underscored that its increased hydrophobicity, as com-
pared to dopamine, may allow NOD to cross intracellular membranes much easier where 
it may severely change the redox milieu within subcellular compartments [19]. Changes 
in redox milieu are either caused by donation of  reduction equivalents as a consequence 
of  quinone formation or by the iron chelating properties of  the catechol structure[23]. 
In keeping with the importance of  redox homeostasis in  the ER for oxidative protein 
folding [24, 25], the present study was conducted to assess if synthetic N-acyl dopamine 
derivatives are able to activate the UPR. In addition we sought to identify the structural 
entities within NOD that might be important for UPR activation. To this end we made use 
of  synthetic NAD that were either changed at the aromatic ring or in the aliphatic chain. 
We also sought to address if activation of  the UPR by NOD compromises cell viability or 
if it represents a protective response, allowing cells to adapt to more aggravating condi-
tions such as hypothermic preservation.
Materials and Methods
Reagents
Reagents were obtained from the sources as indicated: endothelial cell culture medium 
(Provitro, Berlin, Germany), PBS, trypsin solution, ethanol (GIBCO, Invitrogen, NY, 
USA), FBS Gold (PAA laboratories GmbH, Pasching, Austria), Actinomycin D, β-mer-
captoethanol, tunicamycin, ethidium bromide, EDTA solution, DMSO, Tween 20, pho-
spahatase inhibitor cocktail 2, Igepal 10 percent, collagenase, HEPES, Triton X-100, DTT, 
sodium deoxycholate, Tris-base, ammonium persulphate, SDS, TEMED, glycine, MTT, 
hexadimethrine bromide, acrylamid 40 percent, gelatine (Sigma-Aldrich, Taufkirchen, 
Germany), bovine serum albumin (SERVA, Heidelberg, Germany), protease inhibitor 
cocktail, first strand cDNA synthesis Kit (Roche Diagnostic, Mannheim, Germany), Dual-
Glo Luciferase Assay System (Promega, Mannheim, Germany), Coomassie protein assay 
reagent (Pierce, Rockford, IL, USA), Trizol (Invitrogen, Carlsbad, CA, USA), chloroform, 
isopropanol, tetrahydrofuran, (Merck, Darmstadt, Germany), anti-eIF2α, anti-phos-
pho-eIF2α (Cell Signalling, Boston, USA), anti-β-actin (Sigma, Taufkirchen, Germany), 
Proteostat PDI assay kit (Enzo, Lörrach, Germany), Cignal Lenti ERSE/ATF6/positive 
control Reporter (luc) kit (Qiagen, Düsseldorf, Germany). Chemiluminescence reagent 
was purchased from PerkinElmer LAS Inc. (Boston, MA, USA). Primers and all reagents 
were purchased for TaqMan PCR (ABI, Darmstadt, Germany). Secondary antibodies 
conjugated with horseradish peroxidase, anti-CHOP and anti-phospho-AMPK were 




Human umbilical vein endothelial cells (HUVECs) were purchased from Promo Cell, 
Heidelberg, Germany and cultured in basal endothelial medium supplemented with 10 
percent fetal bovine serum (FBS), essential growth factors and antibiotics. Cultures were 
maintained at 37° C, 5 percent CO2 humidified atmosphere and experiments were con-
ducted on cells in passage 2–6 at approximately 80–90 percent confluence.
Synthesis of N-acyl dopamines (NAD)
N-octanoyl dopamine (NOD), N-pivloyl dopamine (NPiD) and N-octanoyl tyramine 
(NOT) were synthesized from commercially available precursors as previously described 
[19]and purified by  twofold recrystallization from dichloromethane as demonstrated 
by  thin layer chromatography (TLC). Octanoic or pivalic acid were converted to their 
mixed anhydride derivate by  reaction with ethyl chloroformate in  the presence of  
N-ethyl diisopropylamine. The crude mixed anhydrides were incubated with dopamine 
hydrochloride (Sigma-Aldrich, Taufkirchen, Germany) in  N,N-dimethylformamide and 
N-ethyl diisopropylamine to form NOD or NPiD. NOT was synthesized according to NOD 
using the analog mixed anhydride coupled to tyramine as reaction component. After 
aqueous preparation and evaporation of  the organic solvent NOD in an overall yield of  
approximately 60 percent is obtained. The sample investigated by NMR (Bruker AC250) 
yielded spectra in accordance with the expected structure. Acetylation of  NOD (A-NOD) 
was performed by suspending two grams of  NOD in 5 mL acetic anhydride under mag-
netic stirring. When two drops of  sulphuric acid were added, the suspension turned clear 
and stirring was continued for one hour. Diluted hydrochloric acid (5 mL) was added and 
30 min later the reaction mixture was poured into 200  mL ice water. The precipitated 
product was collected by vacuum filtration and dried under vacuum to yield A-NOD, pure 
as judged by thin layer chromatography (TLC).
Gene expression profiling
Sample preparation and processing was performed according to the Affymetrix GeneChip 
Expression Analysis Manual (http://www.Affymetrix.com). Total RNA was isolated from 
HUVECs using Trizol-Reagent (Life Technologies, Inc., Rockville, MD, USA). DNase treat-
ment was carried out, using RNase free DNase I (Ambion, Woodward, Austin, TX, USA). 
RNA concentration and quality were assessed by RNA 6000 nano assays on a Bioanaly-
ser 2100 system (Agilent, Waldbronn, Germany). 5 µg of  RNA was converted into cDNA 
using T7-(dT)24 primers and the SuperScript Choice system for cDNA synthesis (Life 
Technologies, Inc., Rockville, MD, USA). Biotin-labelled cDNA was prepared by  in vitro 
transcription using the BioArray high yield RNA transcript labeling kit (Enzo Diagnostics, 
Farmingdale, NY, USA). The resulting cDNA was purified, fragmented and hybridized to 
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U133A gene chips (Affymetrix, Santa Clara, CA, USA). After hybridization the chips were 
stained with streptavidin–phycoerythrin (MoBiTec, Goettingen, Germany) and analysed 
on a GeneArray scanner (Hewlett Packard Corporation, Palo Alto, CA, USA).
Microarray processing and statistical analysis
Gene expression profiling was performed using arrays of  HG_U133A 2.0-type from 
Affymetrix. A  Custom CDF Version 13 with Entrez based gene definitions was used to 
annotate the arrays. The Raw fluorescence intensity values were normalized applying 
quantile normalization. Differential gene expression was analysed OneWay-ANOVA 
using a  commercial software package SAS JMP7 Genomics, version 4, from SAS (SAS 
Institute, Cary, NC). A false positive rate of  α = 0.05 with FDR correction was taken as the 
level of  significance. The raw and normalized data are deposited in the Gene Expression 
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/; accession No. GSE-56285).
RNA isolation, PCR and RNA stability
Total RNA was isolated as described above. 1  µg of  total RNA was reverse-transcribed 
into cDNA using the 1st Strand cDNA Synthesis Kit. cDNA was diluted in 20 µL DEPC-
treated water and stored at −20° C until use. qPCR was performed on a ABI-Prism 7700 
sequence detection system using TaqMan universal PCR master mix AmpErase UNG 
(part no. 4324018). The following Taqman assays were used: BiP (part No. Hs00607129_
gH), CHOP (part No. Hs00358796_g1), PDIA4 (part No. Hs00202612_m1), ERO1L (part 
No. Hs00205880_m1) and GAPDH (part No. Hs02758991_g1). Samples were run under 
the following conditions: initial denaturation for 10 min at 95° C followed by 40 cycles 
of  15  s at 95°  C and 1  min at 60°  C. The levels of  gene expression in  each sample were 
determined with the comparative cycle threshold method. PCR efficiency was assessed 
from the slopes of  the standard curves and was found to be between 90 percent and 100 
percent. Linearity of  the assay could be demonstrated by serial dilution of  all standards 
and cDNA. All samples were normalized for an equal expression of  GAPDH. For RT-PCR 
1 µL of  cDNA was amplified in a 20 µL reaction mix containing 2.5 mmol·L–1 dNTPs, 25 
pmol·L–1 of  each primer, 0,125 units Taq polymerase and 0,5 mmol·L–1 MgCl2. The fol-
lowing primers were used: : GAPDH forward: 5′-GTC TTC ACC ACC ATG GAG AA-3′ and 
reserve: 5′-ATC CAC AGT CTT CTG GGT GG-3′, Xbp1 forward: 5′-CCT TGT AGT TGA GAA 
CCA GG-3′ and reverse 5′-GGG GCT TGG TAT ATA TGT GG-3′. The cycling conditions used 
for various primers were as follows: 4 min of  denaturation at 94° C, followed by 30 (Xbp1) 
or 25 (GAPDH) cycles of  amplification, each consisting of  denaturation for 30 s at 94° C, 
annealing for 30 s at 58° C (Xbp1) and 55° C (GAPDH) and extension for 1 min at 72° C. In 
all experiments GAPDH was used as housekeeping gene, no differences were found for 
the conditions tested when β-actin was used. After the last amplification a final extension 
for 10 min at 72° C was performed for each reaction. PCR products were analyzed on a 4 
percent NuSieve agarose gel containing ethidium bromide and run at 50 V for 6 h.
Chapter 6
128
Lentiviral transduction and reporter assays
To evaluate activation of  UPR pathways, cells were transfected with commercially avail-
able reporter constructs as ready-to use transducer lentiviral particles (Qiagen, Düssel-
dorf, Germany). One day before transduction cells were seeded in  96-well plates (104/
well) and cultured overnight. Hereafter, the cells were transduced at an MOI of  5 using 
8 percent polybrene. Five h after transduction 3 volumes of  fresh cell growth medium 
was added and the cells were incubated overnight. Cell growth medium was replaced 
the next day and 24 h hereafter the cells were treated with NAD according to the specific 
experiment. Luciferase activity was evaluated by  a  commercially available luciferase 
assay system (Promega, Mannheim, Germany) according to the manufacturer's protocol.
Protein extraction and Western blot Analysis
HUVEC lysed in  20 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1 percent Triton X-100, 
0.5 percent sodium deoxycholate, 1  µM dithiothreitol (DTT) buffer containing proteinase 
and phosphatase inhibitors. In some experiments, nuclear proteins were isolated as pre-
viously described [26]. Protein concentrations were measured using Coomassie-Reagent 
(Pierce, Rockford, USA). Samples (20 µg protein extract) were heated to 95° C for 5 min-
utes, loaded and separated on 10 percent SDS-polyacryamide gels followed by semi-dry 
blotting onto PVDF membranes (Roche, Mannheim, Germany). The membranes were 
incubated with 5 percent w/v non-fat dry milk or bovine serum albumin in TBS/Tween 
0.5 percent to block unspecific background staining and hereafter incubated overnight 
at 4° C with the specific mono-or polyclonal eIf2α and p-eIf2α (Cell Signalling, Boston, 
USA), anti-CHOP and anti-pAMPK (Santa Cruz, Heidelberg, Germany). Subsequently, 
the membranes were thoroughly washed with TBS-Tween 0.1 percent and incubated 
with the appropriate horseradish peroxidise conjugated secondary antibody (Santa 
Cruz, Heidelberg, Germany), followed by  five times wash in  TBS/Tween 0.1 percent. 
Proteins were visualized using enhanced chemo luminescence technology, according to 
the manufacturer's instructions (Pierce, Rockford, IL). To confirm equal protein loading, 
membranes were stripped and re-probed with monoclonal anti-β-actin antibody (Sigma, 
Taufkirchen, Germany).
PDI activity assay
PDI activity was assessed in a test tube using a commercially available assay ProteoStat 
PDI assay kit (Enzo Life Sciences, Lörrach, Germany). The assay was performed as recom-
mended by the manufacturer.




Cell apoptosis and cell cycle analysis were assessed by FACS. For cell apoptosis HUVEC 
were stimulated with NOD (100    µM) or Tunicamycin (1  µg/mL) for 24 h followed 
by Annexin V/PI staining (Life Technologies, Darmstadt, Germany). For cell cycle anal-
ysis HUVEC were stimulated with NOD (100    µM) for 24 h. After stimulation the cells 
were harvested by  trypsin, washed three times with phosphate-buffered saline (PBS), 
and stained for 15 min at room temperature with 5 µL of  Annexin V–FITC and 10 µL of  PI 
(5 µg/mL) in 1 binding buffer (10 mmHEPES, pH 7.4, 140 mm NaOH, 2.5 mm CaCl2). For cell 
cycle analysis the cells were stained with DRAQ5 (Biostatus Lim., Shephsed, UK) at a final 
concentration of  10    µM according to the supplier's protocol. For all experiments cells 
were analyzed on a FACS Calibur flow cytometer (BD Biosciences, Heidelberg, Germany). 
At least 50,000 gated events were collected per sample and data were analysed by Flowjo 
software (Tree Star, Inc., Ashland, OR, USA).
Proliferation assay
HUVECs were seeded in multiple cell densities (2×103–8×103) in a 96-well plate and cul-
tured in 100 µL of  complete medium for 24 h. Hereafter cells were treated with different 
concentrations of  NOD for 24 h and pulsed with 0.2 µCi of  [6–3H] thymidine/well (Perkin 
Elmer, Groningen, The Netherlands) during the last 16 h of  culture. All conditions were 
tested on  six replicates culture wells. Incorporated 3Hthymidine was assessed by  scin-
tillation counting in  a  liquid scintillation counter (LS 6500, Beckman Coulter, Krefeld, 
Germany).
Intracellular ATP measurement
Cells were cultured from passage 2 till passage 6 in the presence or absence of  NOD (1  µM). 
At passage 6 the cells were seeded in 6-well plates and were cultured for additional 2 days. 
Hereafter cells were harvested by trypsin, counted and 500.000 cells pro condition were 
lysed in 200 µL of  lysis buffer (100 mM Tris, 4 mM EDTA, pH 7.7). Lysates were collected 
and ATP concentrations were assessed directly hereafter using a commercially available 
ATP-driven luciferase assay according to the manufacturer's instruction (Roche Diagnos-
tics, Mannheim, Germany). All experimental conditions were tested in triplicates in at 
least 3 different experiments.
LDH assay
Tolerance to hypothermia associated cell damage was assessed by lactate dehydrogenase 
(LDH) release. To this end, HUVEC were cultured from passage 2 till passage 6 in the pres-
ence or absence of  NOD (1  µM). At passage 6 the cells were seeded in 24-well plates and 
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were cultured for additional 2 or 5 days in the absence of  NOD. Shortly before subjecting 
the cells to cold storage the medium was changed to phenol red free and cells were stored 
for 24 h at 4° C. Cell damage was assessed by LDH release in the supernatant, according to 
manufacturer's instructions (Roche diagnostics, Mannheim, Germany). All experimental 
conditions were tested in triplicate in at least 3 different experiments.
Statistical analysis
All data are expressed as the means  ±  SD from at least three independent experiments. 
Statistical significance was assessed by one-way ANOVA (Dunnett's and Tukey test) and 
p < 0.05 was considered to be significant.
Results
Induction of the UPR by NOD
To investigate if N-octanoyl dopamine (NOD) induces the UPR, we screened by genome 
wide gene expression profiling in HUVECs for genes that were up regulated by NOD. To 
this end, three different primary cultures of  HUVECs were treated with 100   µM NOD 
for 24 h or left untreated. The results of  the top 30 genes that showed up-regulation are 
depicted in Table 1. Thirteen out of  these have been reported to be UPR target genes [3, 11, 
27]. Up-regulation of  the 5 most influenced UPR target genes was confirmed in indepen-
dent experiments by qPCR (data not shown). The raw and normalized data are deposited 
in the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/; accession 
No. GSE-56285).
To further substantiate our affymetrix findings and to confirm that NOD treatment 
induces the UPR we made use of  a cis acting ER-stress response element (ERSE)-contain-
ing luciferase reporter construct. Luciferase expression increased upon NOD treatment 
in lentiviral transduced HUVEC in a dose-dependent fashion (Figure 1a). Since these cis 
acting elements are present in the promoter of  BiP, we assessed the influence of  NOD 
on  BiP mRNA expression. In line with the ERSE reporter assay it was found that BiP 
mRNA transiently increased upon NOD treatment, with maximal expression occurring 
at 8 h of  stimulation (Figure 1b).
NOD did not selectively activate one particular proximal UPR sensor as PERK, IRE1 
and ATF6 were all transiently activated. Phosphorylation of  eIF2α was in most experi-
ments evident after 24 h of  NOD treatment. In some experiments phosphorylation was 
also noted at 8 h, but was persistently absent at later time points (Figure 1c). Similarly, 
IRE1 and ATF6 were transiently activated upon NOD treatment. Xbp1 splicing (Figure 1d) 
and ATF6 induced luciferase expression (Figure 1e) were maximal at 4 and 8 h respec-
tively, with decreasing tendency at later time points.
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Figure	1.	Induction	of	the	UPR	by NOD. (a) HUVECs were transduced by lentiviral particles containing 
either an ERSE-luciferase reporter or a luciferase construct under control of  a CMV driven promoter as 
transduction efficiency control. The cells were stimulated for 8 h with 25 µM, 50 µM and 100 µM of  NOD 
as indicated. Luciferase activity was assessed as described in materials and methods and normalized for 
constitutively expressed luciferase. The results are expressed as normalized ESRE luciferase activity 
relative to untreated (0  µM) cells. Values represent mean ± SD from three independent experiments. 
*p < 0.05, **P < 0.01 vs. untreated control. (b) HUVECs were treated with 100 µM NOD for the indicated 
time periods. Total RNA was isolated and the expression of  BiP and GAPDH was assessed by qPCR. The 
results are expressed as BiP mRNA levels, normalized for GAPDH and relative to cells that were not 
treated. *p < 0.05, **p < 0.01 vs. untreated control. (c) HUVECs were treated with 100 µM NOD for the indi-
cated time periods. Hereafter protein extracts were made and phosphorylation of  eIF2α was assessed 
by Western blotting. The blots were stripped and re-probed with antibodies directed against total eIF2α 
and β-actin to test for equal loading. The results of  a representative blot are depicted, a total of  4 inde-
pendent experiments were performed. (d) HUVECs were treated for 4 and 24 h with 100  µM of  NOD 
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before total RNA was isolated. Cells that were not treated (Med.) served as control. Spliced and unspliced 
xbp-1 mRNA were detected by PCR. The spliced and unspliced amplification products differ by 26 bp. 
(e) Cells were transduced with lentiviral particle containing an ATF-6-driven luciferase reporter or 
a luciferase construct under control of  a CMV driven promoter as transduction efficiency control. The 
cells were stimulated for different time periods with NOD 100 µM. Luciferase activity was assesses as 
described in materials and methods and normalized for constitutively expressed luciferase. The results 
are expressed as normalized ATF6 luciferase activity relative to time point 0. Values represent mean ± SD 
from three independent experiments. **p < 0.01, *p < 0.05 vs. untreated control, ns: no significant.






























a: p-values for the comparison are given as log10 value. UPR target genes are depicted in bold.
NOD treatment of  HUVECs induces the UPR and results in hypo metabolism and tolerance to hypothermia
133
6
Structural requirements of NOD for UPR induction
To assess the structural requirements for UPR induction by NOD we used NOD as lead 
compound and subsequently changed the functional groups at the aromatic ring or 
exchanged the octanoyl-for the more bulky pivaloyl moiety. The changes at the aromatic 
ring included, omission of  one hydroxyl group (N-octanoyl tyramine (NOT) and acetyl-
ation of  the hydroxyl-groups (A-NOD). While NOT has a significant lower redox activity 
compared to NOD, in A-NOD oxidation of  the masked catechol structure can only occur 
intracellular. Moreover acetylation of  the hydroxy groups makes the molecule more polar 
which may facilitate cellular uptake. The presence of  the bulky pivaloyl moiety in N-piv-
aloyl dopamine (NPiD) makes the ester more resistant to hydrolysis [28] (Figure 2).
Figure	2.	Molecular structure of  NAD used in the study.
Chapter 6
134
Figure	3.	Induction	of	the	UPR	by NAD	variants.(a) HUVECs were transduced by lentiviral particles 
containing either an ERSE-luciferase reporter or a luciferase construct under control of  a CMV driven 
promoter as transduction efficiency control. The cells were stimulated for 8 h with 100 µM of  different 
NAD as indicated. Equimolar concentrations of  dopamine were also included to assess if  dopamine 
induces the UPR. ERSE dependent luciferase activity was assessed as described in materials and methods 
and normalized for constitutively expressed luciferase. The results are expressed as normalized ESRE 
luciferase activity relative to untreated (Med.) cells. Values represent mean ± SD from three independent 
experiments, *p < 0.05, **p < 0.01 vs. untreated control, ns: not significant. (b) HUVECs were treated with 
100 µM NAD for 8 h. Cells that were not treated (Med.) served as control. Hereafter total RNA was iso-
lated and the expression of  BiP and GAPDH were quantitated by qPCR. The results are expressed as BiP 
mRNA levels, normalized for GAPDH mRNA expression and relative to cells that were not treated (Med), 
*p < 0.05, **p < 0.01 vs. untreated control, ns: not significant. (c) HUVECs were stimulated for 8 h with 
100 µM of  different NAD, or left untreated (Med). Hereafter protein extracts were made and phosphory-
lation of  eIF2α was assessed by Western blotting. The blots were stripped and re-probed with antibodies 
directed against total eIF2α and β-actin to test for equal loading. The results of  a representative blot are 
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Using the ERSE-containing luciferase reporter construct, it was shown that only the 
redox active compounds NOD, A-NOD and to a lesser extent NPiD were able to increase 
luciferase expression in  lentiviral transduced HUVEC, while the redox inactive NOT 
showed no effect (Figure 3a). In line with these findings, increased BiP mRNA expression 
and ER-sensor activation (Figure 3b–e) only occurred by the redox active NAD variants. It 
should be mentioned however that with exception of  the ATF6 reporter assay, in all other 
assays NPiD was consistently weaker compared to NOD and A-NOD. In contrast to the 
NAD variants, equimolar concentrations of  dopamine were not able to activate the UPR 
(Figure 3a and b).
Since oxidative folding in the ER is catalyzed by protein disulphide isomerase (PDI) 
we assessed in  a  test tube assay if  PDI activity was impaired by  NOD. The known PDI 
inhibitor bacitracin was included to validate the assay and showed inhibition of  65 and 
15 percent at a concentration of  1 and 10 mM respectively (Figure 4a). Although NOD was 
clearly less effective compared to bacitracin, NOD inhibited PDI in  a  dose dependent 
manner with an almost 50 percent inhibition at 10 mM. A-NOD and NPiD did not inhibit 
PDI activity (Figure 4b).
depicted, a total of  4 independent experiments were performed. (d) HUVECs were stimulated for 8 h with 
different NAD (100 µM) before total RNA was isolated. Cells that were not treated (Med.) served as con-
trol. Spliced and unspliced xbp-1 mRNA were detected by PCR. The spliced and unspliced amplification 
products differ by 26 bp. (e) Cells were transduced with lentiviral particle containing an ATF-6-driven 
luciferase reporter or a constitutively expressed luciferase construct. The cells were stimulated for 8 h 
with different NAD (100 µM). Luciferase activity was assessed as described in materials and methods and 
normalized for constitutively expressed luciferase activity. The results are expressed as normalized ATF6 
luciferase activity relative to untreated (Med.) cells. Values represent mean ± SD from three independent 
experiments, *p < 0.05, **p < 0.01, vs. untreated control, ns: no significant.
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Figure	4.	NOD	inhibits	PDI	activity.(a) PDI activity was assessed by monitoring PDI-catalysed reduc-
tion of  insulin in the presence of  Dithiothreitol (DTT) and different concentrations of  NOD. Bacitracin 
in concentrations of  1 and 10 mM was used to validate the assay. (b). Different NAD were tested for inhi-
bition of  PDI activity in a similar manner as described in (a). The results from three independent experi-
ments are expressed as mean percent PDI activity  ±  SD, using PDI activity in the absence of  inhibitors (−) 
as 100 percent, *p < 0.05, **p < 0.01 vs. untreated control, ns: no significant.
NOD does not impair cell viability
In keeping with the fact that induction of  the UPR may result in  apoptosis, we sought 
to address if  NOD treatment affects cell viability. Cell viability was assessed by  means 
of  FACS analysis using Annexin V/7-ADD (Figure 5a). While tunicamycin, a known UPR 
inducer, clearly increased the percentage of  7-AAD single and Annexin V/7-ADD double 
positive cells, this was not observed for NOD (Figure 5a). Interestingly, when HUVEC 
were treated with NOD 3 h prior to the addition of  tunicamycin, the number of  both 
7-AAD single and Annexin V/7-AAD double positive cells decreased (Figure 5a). Transient 
induction of  CHOP mRNA was observed for both NOD and tunicamycin, albeit that 
CHOP mRNA expression was significantly higher for the latter condition (Figure 5b, left 
panel). No significant difference in CHOP mRNA stability was observed between NOD 
and tunicamycin treated cells (Figure 5c, middle panel). However, BiP mRNA was more 
stable in NOD treated cells than tunicamycin-treated cells (Figure 5c, right panel).
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Figure	5.	NOD	does	not	impair	cell	viability.(a) HUVECs were treated for 24 h with NOD (100  µM) or 
tunicamycin (TM, 1 µg/mL). In addition cells were treated for 3 h with 100 µM of  NOD prior to tunica-
mycin treatment. Cells that were not treated (Med.) served as control. Both floating and adherent cells 
were harvested, stained for Annexin V and 7-AAD and analysed by  flow cytometry. (b) HUVECs were 
treated with 100 µM NOD or TM (1 µg/mL) for the indicated time periods. Total RNA was isolated and 
expression of  CHOP mRNA was assessed by qPCR and normalized for GAPDH (left panel). Cells were 
pre-treated either with NOD or with tunicamycin and then chased for 0, 2, 4 and 8 h with AcD 50  ng/mL. 
Total RNA was isolated and the expression of  CHOP (middle panel) and BiP (right panel) mRNA were 
assessed by qPCR and normalized for GAPDH. The results of  three different experiments are expressed 
as mean mRNA levels  ±  SD, **p < 0.01 vs. untreated cells.
Growth arrest, hypometabolism and thermotolerance
In the course of  performing this study we consistently observed that the time to conflu-
ence was much longer when HUVEC were seeded in culture plates and treated with NOD. 
Consequently we assessed if NOD affects cell proliferation. As demonstrated in 3[H] thy-
Chapter 6
138
midine incorporation assays, NOD dose dependently inhibited cell proliferation (Figure 
6a). NOD treatment changed cell cycle phase distribution, with a relative increase of  cells 
in the S-G2/M phase (Figure 6b), suggesting that cell cycle progression was attenuated at 
the S-G2/M phase. Importantly, affymetrix analysis also showed a significant decreased 
mRNA expression for genes involved in S-G2/M progression (table 2), which was con-
firmed by qPCR (Figure 6c).
Figure	6.	NOD	inhibits	cell	proliferation.(a) HUVECs were seeded in different cell densities in 96 well 
plates and the next day treated for 48 h with different concentrations of  NOD. During the last 16 h the 
cells were pulsed with 0.2 µCi 3[H] thymidine and subsequently harvested. The results of  a representa-
tive experiment are depicted and expressed as mean 3H-thymidine incorporation in counts per minute 
(cpm)  ±  SD of  6 replicate wells for each condition. A total of  6 experiments were performed with essen-
tially similar results. Significance was defined as *p < 0.05 and **p < 0.01 compared to untreated cells, 
ns: not significant. (b) In separate experiments HUVECs were stimulated with 100  µM of  NOD or left 
untreated. One part of  the cells was used for cell cycle analysis, for the other part total RNA was isolated 
and the expression of  AUROKA, CCNB1, CCNA2 and CDK1 was assessed by qPCR (c). A total of  three 
experiments were performed. The results in graph (b) are expressed as mean percentage of  cells in G0/1-, 
S-and G2/M-phase. *p < 0.05, NOD vs. untreated. The results in graph (c) are expressed as normalized 
mRNA levels relative to the untreated medium control cells. **p < 0.01 vs. untreated control.
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a :p-values for the comparison are given as log10 value. UPR target genes are depicted in bold.
With exception of  CHOP, all other UPR target genes tested in this study were up-reg-
ulated in a dose dependent manner when HUVEC were treated with low concentrations 
of  NOD (0.1 and 1 µM) form the 2nd passage on until the 6th passage (P2 to P6) (Figure 7a 
and b). In cells that were treated over this long period of  time with NOD, intracellular 
ATP concentrations were significantly lower as compared to cells from a similar passage 
without treatment (Figure 7c). The lower intracellular ATP concentration was paralleled 
by  an increased phosphorylation of  AMPK (Figure 7d), and was still noted when NOD 
was removed from the culture 2 or 5 days prior to analysis. In addition to this apparent 
hypo-metabolic state, cells were also more resistant to cold inflicted injury as determined 




ent primary HUVEC isolations were cultured from P2 until P6 in the absence or presence of  the indicated 
NOD concentrations. (a) BiP mRNA expression for cells cultured in the presence of  0.1 and 1 µM NOD was 
assessed by qPCR. (b) CHOP, BiP, PDI4, and ERO1L mRNA expression for cells cultured in the presence of  
0.1 µM NOD was assessed by qPCR. The results in a and b are expressed as normalized mean mRNA levels 
relative to untreated controls (0, Med)  ±  SD of  3 replicates for each condition and for all 3 HUVEC isola-
tions. **p < 0.01, *p < 0.05 vs. untreated cells. (c) Intracellular ATP concentration was assessed in HUVEC at 
P6 upon long-term culture in the absence (medium) or presence of  NOD (1 µM). The results are expressed 
as mean ATP concentration (pmol/5 ×105 cells) ± SD of  3 replicates for each condition and for all 3 HUVEC 
isolations. **p < 0.01 vs. untreated cells (d,e). In separate experiments NOD (1 µM) containing medium was 
exchanged for normal cell culture medium at P6 and the cells were cultured for 2 (2d) or 5 (5d) days in the 
absence of  NOD. Cells that were continuously cultured in normal cell culture medium (Med.) were used as 
control. In (d) protein extracts were made and assessed for phosphorylation of  AMPK (p-AMPK) by West-
ern blotting. The blots were stripped and re-probed with antibodies directed against β-actin to test for 
equal loading. The results of  a  representative blot are depicted, a  total of  3 independent experiments 
were performed. In (e) the cells were subjected to cold storage (4° C) for 24 h. Hereafter LDH release was 
assessed in the supernatants. Each condition was tested in triplicate in 2 independent experiments. The 
results are expressed as mean LDH release (OD490) ± SD, **P < 0.01 vs. (Med.) control.




In the present study we demonstrate that synthetic NAD transiently activate the UPR. 
This property seems to be dependent on the redox activity of  these compounds. NOD did 
not affect cell viability, but strongly impaired cell proliferation of  HUVEC, most likely 
by attenuation of  cells in the S-G2/M phase. In concordance to this, mRNA expression 
for a number of  genes involved in S-G2/M progression was significantly down-regulated 
by NOD. Interestingly, long-term NOD treatment resulted in hypometabolism and ther-
motolerance, as suggested by a decreased intracellular ATP concentration, activation of  
AMPK and increased resistance to cold inflicted cell injury.
Sensing, responding, and adapting to environmental insults are essential for all 
living organisms and are originating from evolutionarily conserved unique signal trans-
duction pathways. Being one such a pathway, the role of  the UPR is to alleviate ER stress 
and, paradoxically, to activate apoptosis, depending on  the nature and severity of  the 
stressor [29]. NAD are able to activate the UPR mainly due to their redox active catechol 
structure, albeit that at high NOD concentrations (10 mM) PDI activity was also inhibited 
in a test tube assay. The latter seems to be a highly unlikely explanation for UPR induction 
in HUVEC, since low NOD concentrations (25 µM) already induced the UPR. It is therefore 
more conceivable that oxidation of  the catechol containing NAD leads to donation of  
reduction equivalents, thereby changing an oxidizing ER environment to a more reducing 
one. This assumption is supported by the finding that for NOT, which contains a low redox 
active tyramine moiety, UPR induction was not observed. It should also be mentioned that 
the hydrophobic fatty acid of  NAD may facilitate UPR induction by providing an easier 
access to the ER, in line with the observation that despite its catechol structure dopamine 
was not able to induce the UPR. We are aware that no definite proof  that NOD indeed has 
access to the ER is provided. However previous published studies in  which dopamine 
uptake was compared to that of  NOD [19] revealed that both dopamine and NOD were 
found in  the membrane fraction, which predominantly contains the ER compartment, 
as well as in the mitochondrial-and cytosolic fraction. Hence, NOD may also impair the 
redox milieu in other cellular compartments than the ER. It should be emphasized that 
the ER enriched fraction also contained small amount of  mitochondrial proteins, and 
hence formal proof  that NOD has access to the ER compartment is still lacking.
The lower efficacy of  NPiD for UPR induction might reflect a more limited access 
of  NPD to the ER as a consequence of  the bulky pivanoyl fatty acid. Recently, Achard et 
al demonstrated that the long-chain saturated palmitate (C16:0) fatty acid activates the 
UPR [30], questioning as to whether UPR induction as observed in  our study could be 
mediated via intracellular hydrolysis of  NAD. This scenario is however unlikely because 
hydrolysis of  NOT would result in the release of  octanoic acid (C8:0), yet UPR induction 
was not observed when equimolar concentrations of  NOT were applied to HUVEC. The 
concentrations of  palmitate used by Achard et al were significantly higher compared to 
concentration of  NOD at which UPR induction was already noted (750 vs. 25 µM).
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The decision mechanisms for switching the UPR from adaptive response to apop-
tosis have so far been poorly understood. Cojocari et al [31] recently suggested that the 
PERK signaling arm is uniquely important for promoting adaptation and survival during 
hypoxia-induced ER stress. Yet, other reports suggest that UPR mediated cell adaptation 
is not due to selective UPR sensor activation, but most likely reflects changes in protein 
composition or mRNA stability of  adapted cells [32]. Compared to tunicamycin, NOD 
mediated induction of  both CHOP and BiP mRNA was modest, and may explain why 
tunicamicin, but not NOD treated HUVEC went into apoptosis. Interestingly, in  long-
term NOD (1 µM) treated HUVEC CHOP mRNA was down-regulated while that of  BiP was 
persistently up-regulated. This is in line with the observation by Rutkowski et al [32] that 
over a long time course of  low ER stress CHOP up-regulation diminishes, despite per-
sistent up-regulation of  the UPR-responsive ER chaperones BiP. It remains to be assessed 
why prior NOD treatment of  HUVEC, abrogates tunicamycin mediated apoptosis, but it 
may well be a consequence of  altered UPR signalling [32–35].
Similar as reported by  Rutkowski et al for tunicamycin [32], we also observed 
that cell growth was retarded when cells were continuously cultured in the presence of  
low NOD concentrations, as suggested by  an increased time to confluence. It has been 
reported that phenolic compounds significantly affect cell proliferation by arresting cells 
in the G2/M phase [36–39]. Therefore it is at present unclear if growth inhibition by NOD 
is causally related to UPR induction or if this is independent of  the UPR.
AMP-activated protein kinase (AMPK) is a cellular energy sensor that responds to 
low endogenous energy by stimulating fatty acid oxidation. It acts as a low-fuel warning 
system that is activated by depletion of  ATP or, alternatively, by increased levels of  AMP, 
to induce an energy-saving state and to prevent lactate accumulation and cell injury [40]. 
Since long term NOD treatment resulted in decreased intracellular ATP concentrations 
it is conceivable that this might have triggered the activation of  AMPK as observed 
in  our study. More importantly, we also observed that long term NOD treated HUVEC 
were more resistant to cold inflicted injury. This effect was still apparent when NOD was 
removed from the culture medium and cells were grown for additional 2 or 5 days. These 
findings have important implications as pre-conditioning strategies to improve organ 
functioning after cold storage are primarily focused on influencing cellular metabolism 
or energy status and reduction of  inflammation [41]. Mamady H et al, have suggested that 
the UPR might be integral to long term survival in a state of  cold torpor by coordinat-
ing gene expression responses that support the hibernating phenotype [14]. However, it 
would be prudent to be cautious in concluding that the apparent hypometabolism and 
thermotolarance mediated by NOD are linked to UPR induction.
We have previously demonstrated that NOD has therapeutic efficacy in  ischemia 
induced acute kidney injury [18]. Induction of  the UPR has been suggested to be protective 
in a variety of  ischemia/reperfusion models [42–44]. It therefore remains to be assessed 
if therapeutic concentrations of  NOD are able to activate UPR in vivo and to what extent 
this contributes to the reno-protective effect of  NOD in ischemia induced AKI.
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NAD were first described as potent inhibitors of  5-lipoxygenase [45, 46] and 
through the discovery that NAD are highly expressed in brain tissue, subsequent func-
tion have been revealed. Now these conjugates have come to prominence because of  their 
potential roles in the nervous system, vasculature and the immune system and are being 
explored as potential lead compounds in  drug development. The present finding that 
NAD have the propensity to induce hypometabolism and thremotolerance, irrespective 
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Organ donor dopamine treatment is associated with improvements of  the initial graft 
function after the kidney transplantation. NOD is a  synthetic N-acyl dopamine that 
was developed with the aim to create a hydrophobic dopamine derivative that does not 
influence systemic blood pressure for use in organ donor. Due to its anti-inflammatory, 
reno-protective and cytoprotective properties, NOD has become an interesting drug 
candidate for clinical use in  the setting of  ischemia-induced acute kidney injury. The 
main aim of  the thesis was to investigate the relevant chemical and biological proper-
ties that grant NOD reno-protective effects in this context. We studied NOD’s ability to 
activate TRPV1 and NOD’s prominent redox active nature, which may alter the redox 
milieu within intracellular compartments. The experimental studies described in  this 
thesis were performed firstly, to demonstrate that NOD conveys protection in  the set-
ting of  ischemia induced AKI via TRPV1 activation, secondly, to delineate the molecular 
entities within NOD that are required for TRPV1 activation and for its anti-inflammatory 
property, thirdly to study in vivo tissue distribution and the elimination kinetics of  NOD 
and fourthly, to demonstrate that the redox activity of  NOD significantly affects the cell 
behaviour, i.e. NOD induces ER stress and UPR. The potential use of  NADs in transplan-
tation medicine is reviewed in Chapter	2.
Chapter	3 explored the reno-protective effect of  NOD in the setting of  warm isch-
emia-induced AKI. We showed that NOD treatment improves the renal function in warm 
ischemia-induced AKI, even when treatment is started after the renal ischemia. Improved 
renal function was not associated with large changes in the renal perfusion. We showed 
that the reno-protective properties of  NOD are mediated via TRPV1. NOD treatment of  
renal allograft recipient rats did not improve renal function compared to the untreated 
recipient rats. Since both capsaicin and NOD were able to evoke TRPV1-mediated calcium 
transients in cold-stored dorsal root ganglions (DRGs), the lack of  therapeutic efficacy 
in the recipient rats could not be explained by the loss of  TRPV1 responsiveness.
In Chapter	4, we delineated the chemical entities within NOD that mediate TRPV1 
activation and that are responsible for the anti-inflammatory effects. For this, we syn-
thesized compounds by  modifying NOD at the aromatic-, amide linker-and fatty acid 
moieties. Calcium microfluorimetry revealed an EC50 value for TRPV1 activation by NOD 
of  12.7µM. Acetylation of  the ortho-dihydoxy groups (acetylated (A-) NOD) or shorten-
ing of  the amide linker (ΔNOD) decreased the efficacy for TRPV1 activation. For ΔNOD, 
the efficacy further decreased by interchanging the position of  the carbonyl and amide 
groups. The absence of  one hydroxyl group at the aromatic ring (N-octanoyl tyramine 
(NOT) or the use of  a bulky fatty acid as ester functionality (N-pivaloyl dopamine (NPiD) 
significantly impaired TRPV1 activation. Docking studies and site-directed mutagene-
sis revealed similar anchor residues for interactions of  capsaicin or NOD with TRPV1. 
However, mutation of  arginine at position 491 (R491) to alanine only affected TRPV1 
activation by NOD. With exception of  ΔNOD the presence of  an intact catechol structure 
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was mandatory for TNF-α induced the inhibition of  VCAM-1 i.e. to inhibit inflammation 
and for the induction of  heme oxygenase-1 (HO-1) expression. NPiD and A-NOD both 
displayed similar anti-inflammatory properties as NOD.
In the chapter	5, we developed the radiotracer [18F]F-NOD to assess the in vivo elim-
ination kinetics of  NOD. We first established that the biological properties of  F-NOD and 
NOD did not differ, i.e. both inhibited TNF-α-induced vascular cell adhesion protein 1 
(VCAM-1) expression, both induced the expression and activity HO-1, both protected the 
endothelial cells against cold-inflicted injury and both activated TRPV1. [18F]F-NOD was 
efficiently radiolabelled, RCY 45 percent, d. c., and was stable in phosphate buffer and rat 
plasma ( > 99 percent after 120 min at 37° C). In vivo, [18F]F-NOD was cleared rapidly via the 
renal and hepatobiliary system.
Because redox conditions differ between intracellular compartments, and NOD 
participates in redox cycling, we assessed in chapter	6 if synthetic NADs (including NOD) 
activate the unfolded protein response (UPR). NOD dose dependently induces the ER 
stress and UPR. This property seems to depend on the redox activity of  these compounds. 
NOD did not affect cell viability, but strongly impaired cell proliferation of  HUVECs, most 
likely by attenuation of  cells in the S-G2/M phase. In concordance with this, expression of  
several genes involved in S-G2/M progression was significantly downregulated by NOD. 
Interestingly, long-term NOD treatment resulted in hypo metabolism and thermotoler-
ance, as suggested by a decreased intracellular ATP concentration, activation of  AMPK 




N-acyl Dopamines (NADs) are naturally occurring compounds which can be best 
described as dopamine conjugated to an aliphatic chain at the amine side chain. This 
makes NADs a class of  diverse compounds that vary in length and degree of  saturation 
of  the aliphatic chain. In vivo, these are most likely formed through the reaction of  lipid 
hydro peroxides with primary amino groups to form N-acyl-type (amide linkage) dopa-
mine adducts [1]. Lipid hydro peroxides are a consequence of  oxidative stress and can be 
detected in e.g. brain tissue under a variety of  pathological conditions [2, 3]. A number of  
such dopamine adducts have been found in brain tissue [1, 4, 5] in human plasma [6] and 
differ in two aspects from NOD, a synthetic NAD, i.e. the length of  the aliphatic chain and 
the degree of  saturation.
It should be emphasized that NOD was developed to underpin the relationship 
between the hydrophobicity and the efficacy of  catecholamines to protect tissue from 
cold inflicted injury. Various in  vitro and in  vivo studies revealed the unexpected addi-
tional biological properties of  NOD. As such NOD not only displayed cytoprotective 
effects to a  wide variety of  cultured cells when subjected to cold inflicted injury [7, 8], 
but also inhibited TNFα-mediated inflammation [9] and T cell proliferation [10] in vitro. 
In vivo, NOD treatment after transplantation of  organs from the brain dead donor rats, 
improved allograft function in the renal and cardiac graft recipients [11, 12]. A reno-pro-
tective effect of  NOD was also observed in the ischemia-induced AKI model [13]. These 
findings warranted further experimental studies to identify the mechanisms by which 
NOD conveyed each of  these protective effects and to understand how these effects can 
be explained by NODs structure and in vivo bio-distribution.
The studies presented in this thesis have further increased our understanding of  
the working mechanism of  NOD. We identified activation of  TRPV1 as a pivotal mech-
anism in  NOD’s reno-protection after ischemia-induced AKI. Secondly, the molecular 
entities within NOD that are required for TRPV1 activation and for its anti-inflammatory 
property were identified. Thirdly, NOD’s in vivo tissue distribution and elimination kinet-
ics are described. Finally, it describes that NOD induces ER stress response also known as 
the unfolded protein response UPR in vitro due to its redox active nature figure1.
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Figure	1.	A schematic diagram showing major findings of  this thesis.
TRPV1 and inflammation
This thesis provides first report obtained on the bio-distribution of  NOD and shows that 
it has very fast blood clearance i.e within 30 mins by the liver and the kidney. Despite very 
short lifetime inside the organism (rat) the application of  NOD immediately before or 
after the ischemia induced AKI leads to fast recovery of  the renal function. This indicates 
that NOD delivers its reno-protective effect with short exposure time. Furthermore, in 
vitro cellular uptake studies of  NOD shows passive diffusion kinetics for uptake of  NOD 
in  the Human Vein Endothelial cells (HUVECs). These findings along with previously 
conducted the in vitro studies suggests that the reno-protective properties of  NOD in the 
context of  ischemia induced Acute Kidney Injury could be explained either due to – NOD’s 
ability to activate TRPV1 or NOD’s ability to donate reduction equivalence in different cel-
lular compartments to clear ROS regerated during ischemia or both. In this thesis these 
questions were evaluated in vivo in ischemia induced AKI on TRPV1-/- in Sprague Dawley 
rats. NOD treatment in TRPV1-/- Sprague Dawley rats did not improve the renal function 
which zeros down the reno-protective effect of  NOD in ischemia induced AKI in rats to 
TRPV1. This establishes firstly, that the reno-protective property of  NOD in vivo is solely 
due its ability to activate TRPV1. Secondly, this finding also rules out that the redox active 
nature of  NOD which might help clear the ROS produced during reperfusion plays any 
protective role in vivo in ischemia induced AKI.
TRPV1 activation can elicit protective effects in various organs in the IRI models 
in  terms of  restoration of  organ function and limiting inflammation [14], [15], [16] [17]. 
TRPV1 activation in injured tissue causes pain sensation and induces local release of  the 
vasodilators from surrounding neuronal cells causing vasodilation-facilitated perfusion 
155 7
General Discussion
of  blood. The protection might be causally linked to the release of  neuropeptides [18]. 
Although a number of  TRPV1 agonists have been tested in ischemia induced AKI models 
and all have been reported to display therapeutic efficacy [19] [13] in terms of  restoration 
of  the kidney function and limiting inflammation (compared to the saline treated con-
trol) yet, the course of  AKI as such can neither be influenced by TRPV1 inhibition [20] 
nor with genetic ablation of  TRPV1[21]. NOD is a moderately strong TRPV1 agonist. NOD 
treatment pre [13] or post [21] warm ischaemia improves AKI in  a  TRPV1 dependent 
manner. Amongst the endogenous N-acyl dopamines only OLDA has been studied in an 
ex vivo cardiac IRI-model (in mice) and has been described to deliver cardiac protective 
effect [22]. It is worth to mention here that the endogenous N-acyl dopamines NADA and 
OLDA are not only agonists of  TRPV1 but also of  Cannabinoid receptor type 1 (CB1) – 
which evokes an anti-inflammatory effect as described in cerebral ischemia model [23]. 
Whether or not NOD is an agonist of  CB1 is unknown and still needs to be determined. In 
contrast to NOD, hydrolysis of  NADA gives rise to arachidonic acid which may be further 
converted to TRPV1 activating lipoxygenase products [24–26].
Although inflammation is part of  a repair and restoration process that preserves 
tissue functionality, yet inflammation needs to be controlled and needs to go into reso-
lution to prevent excessive responses that may harm the tissue. NOD treatment in itself  
or by virtue of  TRPV1 activation did not influence gene expression of  the inflammatory 
cytokines in  the kidney of  rats undergoing ischemia induced AKI, similar to findings 
of  Tsagogiorgas et. al. Even though Tsagogiorgas et. al also describe a  damping effect 
on NF-kB activation in rats treated with NOD when compared to saline treated control 
rats, it is not conclusive due to small sample size (n = 4) and the heterogeneous effect of  
NFκB activation in  the saline treated control group. TRPV1-/-Sprague Dawley rats irre-
spective of  their treatment (NaCl or NOD) displayed less infiltration of  ED1 + macrophages 
in kidneys of  rats undergoing AKI when compared with WT Sprague Dawley rats.
In certain organ system like heart TRPV1 activation yields anti-inflammatory effects 
and helps restore the organ function. Genetic ablation of  TRPV1 impairs post-ischemic 
recovery in  the isolated perfused heart, exacerbates inflammation, and affects cardiac 
remodelling after myocardial infarction (MI) in  mice [15]. Furthermore, TRPV1 gene 
deletion results in excessive inflammation, disproportional left ventricular remodelling, 
and deteriorated cardiac function after MI, indicating that TRPV1 may prevent the infarct 
expansion and cardiac injury by inhibiting inflammation and abnormal tissue remod-
elling [27]. It seems that the beneficial cardiovascular effects of  the TRPV1 agonists may 
be caused by  an ischemic preconditioning phenomenon, release of  neurotransmitters, 
and inhibition of  platelet aggregation [28]. Contrary to the beneficial effect of  TRPV1 
activation in the heart, in eye TRPV1 activation elicits a neurogenic inflammation in the 
surrounding area aimed to repair injury following a damaging infectious or non-infec-
tious insult. TRPV1 activation in non-neuronal cells of  the eye may lead to phosphory-
lation of  a  variety of  downstream kinases and transcription factors, e.g. transforming 
growth factor β-activated kinase 1 (TAK1), c-jun N-terminal protein kinase 1 (JNK1), 
nuclear factor (NF)-κB. These further contribute to a pro-inflammatory milieu through 
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the upregulation of  transcription of  chemoattractant-encoding genes [29]. However, 
uncontrolled TRPV1 leads to dysregulated and prolonged responses causing opacification 
of  cornea and a decline in visual acuity instead of  restoration of  corneal transparency. 
TRPV1−/− mice regained corneal transparency following an alkali burn, while in wild type 
(WT) littermates the corneas remained inflamed and scarred [30]. Administration of  the 
systemic TRPV1 antagonists also resulted in  restoration of  corneal transparency like 
observed with TRPV1−/− mice. This indicates that limited activation or absence of  TRPV1 
is essential in proper wound healing i.e. resolution of  inflammation and suppression of  
fibrotic processes. In fact, it has been shown that activation of  Cannabinoid receptor type 
1 (CB1) which is also expressed on trigeminal neurons innervating the cornea desensitizes 
TRPV1 in a calcineurin dependent manner [31–33].
From these findings it can be inferred that controlled or limited TRPV1 activation 
has an adaptive benefit and - despite being inflammatory - is pro healing. Thus, locali-
sation of  TRPV1, the extent of  activation and the co-expression of  other receptors are 
important factors in determining the fate of  TRPV1 activation, whether it will lead to an 
uncontrolled or controlled inflammatory process i.e. the microenvironment dictates the 
final inflammatory status.
Oxidative stress and ROS signalling
In vitro, NOD down-regulates inflammatory mediators by impairing NFκB activation, it 
strongly inhibits platelet function [5, 6] and can transiently inhibit T cell proliferation 
[7]. NOT, a  NOD variant lacking redox-active catechol moiety is unable to yield any of  
these effects, suggesting these effects of  NOD are attributed to NOD’s redox active 
nature. These in vitro finding are substantiated in vivo in Brain-dead model of  the kidney 
and the heart transplant where NOD treatment of  the brain dead donors (rats) yielded 
better graft function and reduced acute rejection in the renal allograft recipients com-
pared to the untreated rats as well as diminished expression of  the pro-inflammatory 
cell adhesion molecules like (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) 
in the kidney and the heart [11]. These anti-inflammatory effects yielded by NOD in the 
brain-dead transplantation model can be explained due to anti-oxidative properties of  
the catechol structure present in NOD and due to semblance between in vitro and in vivo 
experiments. However, NOD treatment failed to display the anti-inflammatory effects 
in vivo in  ischemia induced AKI model in Fisher and TRPV1-/-Sprague Dawley rats, and 
in the renal allograft recipients [21]. These findings raise the question why under certain 
conditions NOD can deliver anti-oxidative property in vivo and why under certain condi-
tions NOD treatment yields no effect. Before investigating all these properties in vivo it is 
of  prime importance to understand what anti-oxidant properties are displayed by NOD 
in vitro and what cellular pathways are affected by NOD’s redox active nature and what 
structural entity of  NOD is responsible for its anti-oxidative property.
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2e-oxidation and Unfolded Protein Response
NOD is a  redox active molecule with hydrophobic character which passively diffuses 
into cell and different cellular compartments and interferes with the redox equilibrium 
of  the respective cellular compartment. This is supported by the fact that NOD induced 
Unfolded Protein Response (UPR) in  a  dose-dependent fashion while NOT, which is 
structurally similar to NOD except that it contains a low redox active tyramine moiety did 
not induce UPR [34]. The catechol moiety present in the NADs might participate in 2e-ox-
idation reactions, in which the catechol structure is oxidized to quinones by donation of  
two protons 2H + and two electrons (2e-) to the oxidizing agent. These quinones in turn are 
easily reduced back to catechols, a process referred as 2e-redox cycling Figure 2.
Figure	2.	A schematic showing catechol moiety in NAD undergoing 2e-redox cycling.
In the mitochondria and the endoplasmic reticulum (ER) 2e-redox cycling is of  
pivotal importance for functioning of  the respiratory chain and for the oxidative pro-
tein folding i.e. formation of  disulphide bonds between cysteine residues in proteins to 
provide the protein right confirmation. NOD interferes with the 2e-redox cycling thereby 
shifts an oxidizing ER environment to a more reducing. This disrupts efficiency of  the 
protein folding. It has been shown in-test tube assay that NOD interferes with the activ-
ity of  protein disulphide isomerase (PDI) which catalyses protein folding. Accumulation 
of  the misfolded proteins within ER lead to “ER stress” [35] which subsequently induce 
a signal transduction pathway called the UPR to restore cell homeostasis. First adaptive 
responses are invoked like the upregulation of  molecular chaperones and protein-pro-
cessing enzymes to increase the folding and handling efficiency, translational attenuation 
to reduce the ER workload and prevent further accumulation of  the unfolded proteins, 
and an increase in  the ER-associated protein degradation (ERAD) and autophagy. If  
despite activation of  these components clearance of  unwanted proteins fails to restore 
protein-folding homeostasis, UPR progresses into the “terminal UPR” that ultimately 
promotes apoptosis. NOD induced UPR dose dependently and activated all the proximal 
UPR sensor as PERK, IRE1 and ATF6. NOD seems to induce an adaptive UPR response as 
it did not induced apoptosis but induced growth arrest. Whether NOD induced ER stress 
results in autophagy or induces adaptive UPR in vivo needs to be evaluated.
A wide range of  cellular disturbances such as nutrient deprivation, hypoxia, loss 
of  calcium homeostasis and change in  redox imbalances which happen during Isch-
emia Reperfusion Injury (IRI) can also induce UPR. IRI has been shown to induce ER 
stress in  renal tubule epithelial cells. Indeed after cardiac arrest-induced IRI in  mice, 
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an increase in  phosphorylation of  PERK, a  proximal UPR sensor, in  tubular epithelial 
cells is reported [36]. Furthermore, ER chaperone BiP/Grp78 which is fundamental for 
the activation of  the three main sensors of  UPR, was activated in mice following 35 min 
of  bilateral renal ischemia and reperfusion [37]. Likewise chemical inducer of  UPR, BIX is 
shown to selectively induce ATF6 pathway (one of  the three main proximal UPR sensors) 
and ameliorate renal IRI in vivo [38, 39].
Although ER stress and consequently UPR to a limited extent is described yielding 
protective effect in IRI, yet the mechanism underlying ER stress in AKI remains poorly 
understood. Several have demonstrated role of  autophagy in ER stress-related protective 
effects in  renal IRI. For instance, Chandrika et  al. showed that tunicamycin (ER stress 
inducer) induced UPR and autophagy in renal tubular cells in vitro and in kidneys in mice. 
They also reported inhibition of  autophagy increased tubular cell death in vitro and wors-
ened ischemia induced AKI in mice, indicating a protective role of  autophagy [40]. Study 
conducted by Ling and colleagues further demonstrated that the exogenous H2S alleviated 
renal IRI by up-regulating ER stress-induced autophagy in rats [41].
Although a number of  studies state a protective role of  UPR/ER stress in renal IRI 
yet there is also evidence that UPR/ER stress in renal IRI might be detrimental. Intermedin 
(IMD), a  protein which belongs to calcitonin/calcitonin gene-related peptide family and 
is potent systemic and pulmonary vasodilator. Intermedin supresses BiP, an important 
ER stress sensor, CHOP (which is induced by  ER stress and it mediates apoptosis) , and 
caspase-12. Overexpression of  Intermedin in rats IRI model significantly reduced apop-
tosis in  renal epithelial cells and improved renal function after IRI in  rats, suggesting 
a pathological role of  ER stress in renal IRI [42]. Exact cause of  the discrepancy between 
this study and the study mentioned in previous paragraph remains unclear. However, it is 
important to acknowledge that the mechanism underlying ER stress in AKI remains poorly 
understood. Based on  the limited information perhaps it can be surmised that an initial 
adaptive UPR post IRI tends to restore homeostasis and repair by  stopping translation 
of  new proteins and getting rid of  the non-functional protein, rescuing cells by digesting 
the damaged parts/compartments of  the cells by means autophagy. When these adaptive 
responses are insufficient UPR progress into terminal phase which leads to pathophysio-
logical developments.
Oxidation-reduction reactions exist in  all cells and are essential to maintain cell 
homeostasis and signalling, including energy metabolism, gene expression, cell cycle 
regulation, immune response, cell growth, and cell apoptosis [43]. In addition to UPR, cell 
cycle progression is also regulated by the cellular redox environment as it changes toward 
a more oxidizing environment as G1 cells move through the cell cycle [44, 45]). As cellular 
uptake of  NOD shifts the redox milieu to a  more reducing milieu, also explains the G1 
arrest of  activated T cells [10] and endothelial cells in the presence of  NOD. Growth arrest 
might suggest that the cell choose to go into senescence instead of  apoptosis, however this 
still needs to be evaluated. It also remains to be determined if NOD treated cells exhibit 
growth arrest which is temporary and can be reversed by removal of  NOD or it promotes 
the cells to enter senescence.
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The influence of  NADs on the respiratory chain, another cellular process which are 
redox sensitive, is still elusive and warrants further studies as an energy shift from mito-
chondrial oxidative phosphorylation to glycolysis dramatically affects cell metabolism 
and its consequences [46]. Apart from inhibition of  cell cycle progression NADs may act 
immunosuppressive on  lymphocytes as has been shown for NADA [47] and NOD [10]. 
Inhibition of  redox-dependent transcription factors like NF-κB, NFAT, and AP-1, is most 
likely underlying the immunosuppressive effect of  NADs.
Keap1-Nrf2-ARE pathway
This pathway acts as an early warning and attack system to ROS induces adaptive response 
during oxidative stress. Under normal physiological conditions Keap1 is associated with 
Nrf2 which leads to ubiquitination and subsequent degradation of  Nrf2 [48]. Under oxi-
dative stress increased level of  intracellular ROS promotes the dissociation of  Nrf2 and 
Keap1. Dissociated Nrf2 trans locates to nucleus and translates detoxification enzymes 
such as HO-1 and MnSOD [48]. NOD is also able to induce Nrf-2 in vitro and consequently 
increases expression of  HO-1 in HUVECs. NOD’s ability to activate HO-1 is solely depen-
dent on an intact catechol structure as NOT, NOD structural variant with tyramine entity 
is not able to induce HO-1. NADA is also able to induce HO-1 in vitro. Several studies have 
demonstrated that HO-1 expression yields cytoprotective effects [49] in AKI. Whether or 
not NOD is able to induce Nrf-2 and HO-1 in vivo and exhibit cytoprotective still needs 
to be determined. It has been reported that the presence of  these compounds scavenge 
ROS and enhance or stimulate adaptive anti-oxidant pathways during or immediately 
after ischemia facilitates reduction/neutralization of  the ROS and thereby reducing the 
injury to the tissue. Despite the fact that NOD is also able to scavenge ROS by virtue of  
its catechol structure in  vitro. Absence of  beneficial effects with NOD administration 
in TRPV1-/-Sprague Dawley AKI hints NOD mediated Keap1-Nrf2-ARE might not play any 
protective role in vivo.
Compounds which can neutralize ROS and activate the Keap1-Nrf2-ARE pathway 
have been already proven beneficial to treat IRI of  kidneys e.g. Curcumin [50, 51] and Res-
veratrol [52]. Curcumin is produced by turmeric, a member of  the ginger family, and it 
induces the expression of  cytoprotective proteins regulated by NRF2 such as superoxide 
dismutase, catalase, glutathione reductase, glutathione peroxidase, HO-1 [50]. Similarly, 
Resveratrol, a polyphenolic compound found in grapes, berries, red wines, and peanut 
skins is reported to ameliorate ischemia-induced AKI by upregulating Nrf2 expression, 
downregulating the TLR4-induced NF-κB signalling pathway [53]. All these compounds 




The journey of  the development and characterization of  NOD has brought us to new 
avenues where three interesting aspects have emerged, and should be considered for the 
future research work – firstly, the potential of  using endogenous NADs as drug candidates 
should be explored, secondly, the potential of  NOD as a drug should be further evaluated, 
and thirdly, the knowledge acquired during through the development of  NOD, can be 
deployed to develop an improved version of  a bi-functional synthetic NAD, where the 
role of  the fatty acid tail is not restricted to facilitate membrane crossing. I will describe 
each of  these in the following paragraphs.
There is nothing better than to use endogenous compounds as drugs to promote 
healing, or limit damage. NADs display renoprotective effects in IRI. They are agonist at 
TRPV1 and Cannabinoid receptors and exhibit anti-inflammatory effects dependent and 
independent of  these receptors. These properties make these endogenous interesting 
drug candidates to be used for situation where ischemia is anticipated e.g. surgical pro-
cedures where IRI injury is anticipated. However, there are several questions which need 
to be addressed in order to increase the merit of  these compounds as drugs candidates 
such as information regarding toxicity of  NADA and OLDA. Further studies are required 
to investigate the metabolism of  NADA by other enzymes in additional cellular locations 
including COX and LOX, which will help determine which enzymatic mechanism for 
degradation of  NADA predominates in vivo. NADA has a long hydrocarbon chain which is 
necessary for TRPV1 activation and makes NADA it hydrophobic. This poses a challenge 
on the development of  drug formulation. Another small point to consider is that NADA 
is not stable at the room temperature thus definitive drug formulation with NADA will 
further add to costs during drug development, production and storage.
In terms of  emerging drug candidate NOD is only a little bit better characterized 
than NADA, as reno-protective effects displayed by NOD can be narrowed down to the 
ability of  NOD to activate TRPV1. Furthermore, this thesis gives first insights in the bio-
distribution of  NOD. Despite these information NOD is still far away from being imple-
mented in the clinical settings. Toxicological studies and detailed pharmacodynamics 
and pharmacokinetics still needs to be performed for NOD. As in  the case of  NADA, 
metabolites as well as precursors yield biological properties, it is of  importance to eval-
uate the biological properties of  NOD’s metabolites. The effects of  NOD so far have been 
only studied in  the endothelial cells [21] and T cells [10, 21], it is of  utmost importance 
that in vitro studies with different cells from kidney should be also be done. In particular 
endothelial cells from glomeruli as macro-vascular and micro-vascular endothelial cells 
exhibit different responses. Since NOD is mostly applied systematically, it is necessary to 
evaluate if NOD can cross blood-brain barrier and if it can its interaction with neuronal 
cells should be established. In this context it is also important to evaluate the cytotoxic 
properties of  NOD with respect to the other cells which are sensitive to oxidative stress. 
Although the anti-inflammatory properties of  NOD are attributed to the ability of  NOD 
to scavenge ROS and on its redox active nature [9]. Effect of  NOD on potential ROS sources 
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such as xanthine oxidase, NADPH oxidase (Nox), mitochondria, and uncoupled nitric 
oxide which are major contributors to reperfusion-induced oxidative stress and cause 
reperfusion-induced organ dysfunction and tissue damage [55] still needs to be deter-
mined. Although, NOD is a promising drug candidate yet there are several known several 
unknowns which need to be determined before considering it for clinical application.
Finally, dopamine conjugation with octanoic acid to develop a more hemodynamic 
neutral dopamine bring us to an interesting point where development of  dopamine con-
jugate of  fatty acids which possess anti-inflammatory properties is interesting. This can 
lead to development of  bi-functional drugs which might be able to address IRI not just 
by TRPV1 activation or by virtue of  redox-active catechol structure but also by anti-in-
flammatory characteristics of  the fatty acid used. Especially, dopamine conjugate with 
PUFAs like DHA and EPA and derivatives of  these fatty acids which are processed into 
anti-inflammatory compounds called Resolvins [56] might hold a promise for IRI inju-
ries. Resolvins have been reported as natural anti-inflammatory response of  the body 
limiting inflammation via monocyte/macrophage uptake of  debris, apoptotic PMNs, 
and killing/clearing microbes [57]. Although these resolvins are not redox active but they 
exhibit anti-inflammatory properties which might yield synergistic effect to catechol 
entity. Several of  the Resolvins have been described to exhibit beneficial effect in  IRI 
such as RvD1 alleviates Ischemia Reperfusion injury in the lung [58]; in liver [59] and rvd2 
is beneficial in  cerebral ischemia. Since DHA and EPA are majorly found in  brain it is 
important to evaluate the toxic effect of  these compounds on neuronal cells as well. Liu et. 
al suggest that dopamine adducts derived from brain polyunsaturated fatty acids might 
be involved in pathogenesis in Parkinson disease [1]. Before development of  such com-




 1. Liu, X., et al., Formation of  dopamine adducts derived from brain polyunsaturated fatty 
acids: mechanism for Parkinson disease. J Biol Chem, 2008. 283(50): p. 34887–95.
 2. Dexter, D.T., et al., Increased levels of  lipid hydroperoxides in the parkinsonian substantia 
nigra: an HPLC and ESR study. Mov Disord, 1994. 9(1): p. 92–7.
 3. Liu, X., N. Yamada, and T. Osawa, Amide-type adduct of  dopamine-plausible cause of  Par-
kinson diseases. Subcell Biochem, 2014. 77: p. 49–60.
 4. Huang, S.M., et al., An endogenous capsaicin-like substance with high potency at recombi-
nant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A, 2002. 99(12): p. 8400–5.
 5. Chu, C.J., et al., N-oleoyldopamine, a  novel endogenous capsaicin-like lipid that produces 
hyperalgesia. J Biol Chem, 2003. 278(16): p. 13633–9.
 6. Hauer, D., et al., Plasma concentrations of  endocannabinoids and related primary fatty acid 
amides in patients with post-traumatic stress disorder. PLoS One, 2013. 8(5): p. e62741.
 7. Vettel, C., et al., Dopamine and lipophilic derivates protect cardiomyocytes against cold pres-
ervation injury. J Pharmacol Exp Ther, 2014. 348(1): p. 77–85.
 8. Losel, R.M., et al., N-octanoyl dopamine, a non-hemodyanic dopamine derivative, for cell 
protection during hypothermic organ preservation. PLoS One, 2010. 5(3): p. e9713.
 9. Hottenrott, M.C., et al., N-octanoyl dopamine inhibits the expression of  a  subset of  kap-
paB regulated genes: potential role of  p65 Ser276 phosphorylation. PLoS One, 2013. 8(9): p. 
e73122.
 10. Wedel, J. , et al., N-Octanoyl dopamine transiently inhibits T cell proliferation via G1 cell-cy-
cle arrest and inhibition of  redox-dependent transcription factors. J Leukoc Biol, 2014. 96(3): 
p. 453–62.
 11. Spindler, R.S., et al., N-Octanoyl Dopamine for Donor Treatment in a Brain-death Model of  
Kidney and Heart Transplantation. Transplantation, 2015. 99(5): p. 935–41.
 12. Li, S., et al., Donor preconditioning after the onset of  brain death with dopamine derivate 
n-octanoyl dopamine improves early posttransplant graft function in the rat. Am J Trans-
plant, 2017.
 13. Tsagogiorgas, C., et al., N-octanoyl-dopamine is an agonist at the capsaicin receptor TRPV1 
and mitigates ischemia-induced [corrected] acute kidney injury in rat. PLoS One, 2012. 7(8): 
p. e43525.
 14. Pegorini, S., et al., Capsaicin exhibits neuroprotective effects in a model of  transient global 
cerebral ischemia in Mongolian gerbils. Br J Pharmacol, 2005. 144(5): p. 727–35.
 15. Wang, L. and D.H. Wang, TRPV1 gene knockout impairs postischemic recovery in  isolated 
perfused heart in mice. Circulation, 2005. 112(23): p. 3617–23.
 16. Harada, N., et al., Ischemia/reperfusion-induced increase in the hepatic level of  prostacyclin 
is mainly mediated by activation of  capsaicin-sensitive sensory neurons in rats. J Lab Clin 
Med, 2002. 139(4): p. 218–26.
 17. Wang, M., et al., TRPV1 agonist capsaicin attenuates lung ischemia-reperfusion injury in rab-
bits. J Surg Res, 2012. 173(1): p. 153–60.
163 7
General Discussion
 18. Zhong, B. and D.H. Wang, TRPV1 gene knockout impairs preconditioning protection against 
myocardial injury in isolated perfused hearts in mice. Am J Physiol Heart Circ Physiol, 2007. 
293(3): p. H1791–8.
 19. Ueda, K., et al., Preventive effect of  TRPV1 agonists capsaicin and resiniferatoxin on ischemia/
reperfusion-induced renal injury in rats. J Cardiovasc Pharmacol, 2008. 51(5): p. 513–20.
 20. Chen, L., et al., Role of  TRPV1 channels in ischemia/reperfusion-induced acute kidney injury. 
PLoS One, 2014. 9(10): p. e109842.
 21. Klotz, S., et al., N-octanoyl dopamine treatment exerts renoprotective properties in  acute 
kidney injury but not in  renal allograft recipients. Nephrol Dial Transplant, 2016. 31(4): p. 
564–73.
 22. Zhong, B. and D.H. Wang, N-oleoyldopamine, a novel endogenous capsaicin-like lipid, pro-
tects the heart against ischemia-reperfusion injury via activation of  TRPV1. Am J Physiol 
Heart Circ Physiol, 2008. 295(2): p. H728–35.
 23. Zhuang, Q., et al., Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and 
Protecting Neuron from Cerebral Ischemia. Cent Nerv Syst Agents Med Chem, 2017. 17(2): p. 
141–150.
 24. Rimmerman, N., et al., Microsomal omega-hydroxylated metabolites of  N-arachidonoyl 
dopamine are active at recombinant human TRPV1 receptors. Prostaglandins Other Lipid 
Mediat, 2009. 88(1–2): p. 10–7.
 25. Caterina, M.J., et al., The capsaicin receptor: a heat-activated ion channel in the pain path-
way. Nature, 1997. 389(6653): p. 816–24.
 26. van der Stelt, M., et al., Neuroprotection by Delta9-tetrahydrocannabinol, the main active 
compound in  marijuana, against ouabain-induced in  vivo excitotoxicity. J Neurosci, 2001. 
21(17): p. 6475–9.
 27. Huang, W., et al., Transient receptor potential vanilloid gene deletion exacerbates inflamma-
tion and atypical cardiac remodeling after myocardial infarction. Hypertension, 2009. 53(2): 
p. 243–50.
 28. Adams, M.J., K.D. Ahuja, and D.P. Geraghty, Effect of  capsaicin and dihydrocapsaicin 
on in vitro blood coagulation and platelet aggregation. Thromb Res, 2009. 124(6): p. 721–3.
 29. Pan, Z., et al., TRPV1 activation is required for hypertonicity-stimulated inflammatory 
cytokine release in human corneal epithelial cells. Invest Ophthalmol Vis Sci, 2011. 52(1): p. 
485–93.
 30. Okada, Y., et al., TRPV1 involvement in  inflammatory tissue fibrosis in mice. Am J Pathol, 
2011. 178(6): p. 2654–64.
 31. Yang, Y., et al., Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 
1-induced inflammatory responses to corneal injury. Cell Signal, 2013. 25(2): p. 501–11.
 32. Nagarkatti, P., et al., Cannabinoids as novel anti-inflammatory drugs. Future Med Chem, 
2009. 1(7): p. 1333–49.
 33. Patwardhan, A.M., et al., The cannabinoid WIN 55,212–2 inhibits transient receptor poten-
tial vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl 
Acad Sci U S A, 2006. 103(30): p. 11393–8.
Chapter 7
164
 34. Stamellou, E., et al., N-octanoyl dopamine treatment of  endothelial cells induces the 
unfolded protein response and results in  hypometabolism and tolerance to hypothermia. 
PLoS One, 2014. 9(6): p. e99298.
 35. Walter, P. and D. Ron, The unfolded protein response: from stress pathway to homeostatic 
regulation. Science, 2011. 334(6059): p. 1081–6.
 36. Montie, H.L., et al., Renal ischemia and reperfusion activates the eIF 2 alpha kinase PERK. 
Biochim Biophys Acta, 2005. 1741(3): p. 314–24.
 37. Noh, M.R., et al., C/EBP homologous protein (CHOP) gene deficiency attenuates renal isch-
emia/reperfusion injury in mice. Biochim Biophys Acta, 2015. 1852(9): p. 1895–901.
 38. Gao, X., et al., The nephroprotective effect of  tauroursodeoxycholic acid on ischaemia/reper-
fusion-induced acute kidney injury by inhibiting endoplasmic reticulum stress. Basic Clin 
Pharmacol Toxicol, 2012. 111(1): p. 14–23.
 39. Prachasilchai, W., et al., The protective effect of  a newly developed molecular chaperone-in-
ducer against mouse ischemic acute kidney injury. J Pharmacol Sci, 2009. 109(2): p. 311–4.
 40. Chandrika, B.B., et al., Endoplasmic Reticulum Stress-Induced Autophagy Provides Cytopro-
tection from Chemical Hypoxia and Oxidant Injury and Ameliorates Renal Ischemia-Reper-
fusion Injury. PLoS One, 2015. 10(10): p. e0140025.
 41. Ling, Q., et al., Roles of  the Exogenous H2S-Mediated SR-A Signaling Pathway in Renal Isch-
emia/ Reperfusion Injury in Regulating Endoplasmic Reticulum Stress-Induced Autophagy 
in a Rat Model. Cell Physiol Biochem, 2017. 41(6): p. 2461–2474.
 42. Wang, Y., et al., Intermedin protects against renal ischemia-reperfusion injury by inhibiting 
endoplasmic reticulum stress. BMC Nephrol, 2015. 16: p. 169.
 43. Sarsour, E.H., et al., Redox control of  the cell cycle in  health and disease. Antioxid Redox 
Signal, 2009. 11(12): p. 2985–3011.
 44. Goswami, P.C., et al., Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regu-
lated by the 3'-untranslated region. Possible role of  redox-sensitive protein binding in mRNA 
accumulation. J Biol Chem, 2000. 275(49): p. 38384–92.
 45. Conour, J.E., W.V. Graham, and H.R. Gaskins, A combined in vitro/bioinformatic investiga-
tion of  redox regulatory mechanisms governing cell cycle progression. Physiol Genomics, 
2004. 18(2): p. 196–205.
 46. Burns, J.S. and G. Manda, Metabolic Pathways of  the Warburg Effect in Health and Disease: 
Perspectives of  Choice, Chain or Chance. Int J Mol Sci, 2017. 18(12).
 47. Sancho, R., et al., Immunosuppressive activity of  endovanilloids: N-arachidonoyl-dopamine 
inhibits activation of  the NF-kappa B, NFAT, and activator protein 1 signaling pathways. J 
Immunol, 2004. 172(4): p. 2341–51.
 48. Villeneuve, N.F., A. Lau, and D.D. Zhang, Regulation of  the Nrf2-Keap1 antioxidant response 
by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid 
Redox Signal, 2010. 13(11): p. 1699–712.
 49. Bolisetty, S., A. Zarjou, and A. Agarwal, Heme Oxygenase 1 as a Therapeutic Target in Acute 
Kidney Injury. Am J Kidney Dis, 2017. 69(4): p. 531–545.
 50. Trujillo, J. , et al., Renoprotective effect of  the antioxidant curcumin: Recent findings. Redox 
Biol, 2013. 1: p. 448–56.
165 7
General Discussion
 51. Bayrak, O., et al., Curcumin protects against ischemia/reperfusion injury in  rat kidneys. 
World J Urol, 2008. 26(3): p. 285–91.
 52. Buys-Goncalves, G.F., et al., Antioxidants as Renoprotective Agents for Ischemia during 
Partial Nephrectomy. Biomed Res Int, 2019. 2019: p. 8575398.
 53. Li, J. , et al., Resveratrol Alleviates Inflammatory Responses and Oxidative Stress in  Rat 
Kidney Ischemia-Reperfusion Injury and H2O2-Induced NRK-52E Cells via the Nrf2/TLR4/
NF-kappaB Pathway. Cell Physiol Biochem, 2018. 45(4): p. 1677–1689.
 54. Novosadova, E.V., et al., Neuroprotective Properties of  Endocannabinoids N-Arachidonoyl 
Dopamine and N-Docosahexaenoyl Dopamine Examined in  Neuronal Precursors Derived 
from Human Pluripotent Stem Cells. Biochemistry (Mosc), 2017. 82(11): p. 1367–1372.
 55. Granger, D.N. and P.R. Kvietys, Reperfusion injury and reactive oxygen species: The evolu-
tion of  a concept. Redox Biol, 2015. 6: p. 524–551.
 56. Duvall, M.G. and B.D. Levy, DHA-and EPA-derived resolvins, protectins, and maresins 
in airway inflammation. Eur J Pharmacol, 2016. 785: p. 144–155.
 57. Serhan, C.N. and B.D. Levy, Resolvins in  inflammation: emergence of  the pro-resolving 
superfamily of  mediators. J Clin Invest, 2018. 128(7): p. 2657–2669.
 58. Zhao, Q., et al., Resolvin D1 Alleviates the Lung Ischemia Reperfusion Injury via Comple-
ment, Immunoglobulin, TLR4, and Inflammatory Factors in Rats. Inflammation, 2016. 39(4): 
p. 1319–33.
 59. Kang, J.W., et al., Resolvin D1 activates the sphingosine-1-phosphate signaling pathway 






De behandeling van orgaandonoren met dopamine gaat gepaard met een significante 
verbetering van de initiële transplantaat functie bij ontvangers van een nier of  hart 
transplantaat. NOD is een synthetische N-acyl dopamine ontwikkeld voor gebruik bij 
orgaandonoren met als doel een hydrofoob dopamine derivaat te creëren dat geen invloed 
heeft op de systemische bloeddruk. Door zijn ontstekingsremmende, nier beschermende 
en cel protectieve eigenschappen is NOD een interessante kandidaat voor klinisch 
gebruik in settings van ischemie geinduceerde acute nierbeschadiging. Het belangrijkste 
doel van dit proefschrift was het onderzoeken van relevante chemische en biologische 
eigenschappen die NOD zijn nier beschermende effecten verlenen. We bestudeerden het 
vermogen van NOD om TRPV1 te activeren en het prominente redox-actieve karakter, dat 
het redoxmilieu binnen de intracellulaire compartimenten kan veranderen.
De experimentele studies beschreven in  dit proefschrift werden uitgevoerd, ten 
eerste om aan te tonen dat NOD bescherming biedt in een model van ischemie-geïndu-
ceerde acute nier schade, ookwel aute kidney injury (AKI) genoemd, via TRPV1 activering. 
Ten tweede om de moleculaire entiteiten binnen NOD af  te bakenen die nodig zijn voor 
TRPV1 activering en voor zijn ontstekingsremmende eigenschappen. Ten derde om de 
invivo weefseldistributie en eliminatiekinetiek van NOD te bestuderen en ten vierde om 
aan te tonen dat de redoxactiviteit van NOD het celgedrag significant beïnvloedt, d.w.z. 
dat NOD ER stress en UPR induceert. Het potentiële de potentiële mogelijkheden voor 
het gebruik van NAD’s in de transplatatiegeneeskunde wordt besproken in hoofdstuk	2.
In hoofdstuk	3 wordt het nier beschermende effect van NOD in  een setting van 
warme ischemie-geinduceerde AKI onderzocht. We hebben aangetoond dat de behande-
ling met NOD de nierfunctie bij warme ischemie-geïnduceerde AKI verbetert, zelfs wan-
neer de behandeling na het optreden van de nier ischemie wordt gestart. Een verbeterde 
nierfunctie ging niet gepaard met grote veranderingen in  de nierperfusie. Wij hebben 
aangetoond dat de nier beschermende eigenschappen van NOD via TRPV1 plaatsvindt. 
NOD behandeling van ontvanger ratten na niertransplantatie leidt niet tot een verbete-
ring van de nierfunctie in vergelijking met onbehandelde ontvanger ratten. Het gebrek 
aan een therapeutisch effect van NOD bij ontvanger ratten kon niet worden verklaard 
door het verlies van TRPV1 – functionaliteit.
In hoofdstuk	4 hebben we de chemische entiteiten binnen NOD onderzocht die 
TRPV1 activeren en verantwoordlijk zijn voor de ontstekingsremmende effecten. Door 
het veranderen van de aromatische-, amide-linker-en vetzuurgroepen van NOD hebben 
we nieuwe verbindingen gesynthetiseerd. Met behulp van calcium microfluorimetrie 
hebben we een EC50 waarde van 12,7µM voor TRPV1 activering door NOD gemeten. 
Acetylering van de orthodihydoxygroepen (geacetyleerd (A-) NOD) of  verkorting van de 
amide-linker (ΔNOD) verminderde de effectiviteit voor TRPV1 activering. Een verdere 
afname van het effect van ΔNOD werd gevonden de positie van de carbonyl-en amide-
groepen te verwisselen. De afwezigheid van één hydroxylgroep aan de aromatische ring 
(N-octanoyl tyramine (NOT)) of  het gebruik van een vertakte vetzuur als esterfunctie 
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(N-pivaloyl dopamine (NPiD)) resulteerde in een significante afname van de TRPV1-ac-
tivatie. Docking studies en site-directed mutagenese hebben soortgelijke ankerresiduen 
voor interacties van capsaïcine of  NOD met TRPV1 aan het licht gebracht. Echter,een 
mutatie van arginine naar alanine op positie 491 (R491) had alleen invloed op TRPV1 acti-
vering door NOD maar niet door capsaïcine. Met uitzondering van ΔNOD is de aanwezig-
heid van een intacte catecholstructuur een voorwaarde voor TNF-α induceerde remming 
van VCAM-1 en voor de inductie van heem oxygenase-1 (HO-1) expressie. NPiD en A-NOD 
vertonen beide ontstekingsremmende eigenschappen vergelijkbaar met NOD.
In hoofdstuk	5 hebben we de radiotracer [18F] F-NOD ontwikkeld om de in  vivo 
eliminatiekinetiek van NOD te bestuderen. Eerst hebben we aangetoond dat de biologi-
sche eigenschappen van F-NOD en NOD niet van elkaar verschillen, d.w.z. beide remmen 
de TNF-α-geïnduceerde VCAM-1 expressie, beide induceren de expressie van HO-1, 
beide beschermen de endotheelcellen tegen koud-geinduceerde schade en beide active-
ren TRPV1. [18F]F-NOD kan efficiënt radioactief  gelabeld en is stabiel inratten plasma 
en fosfaatbuffer. In vivo wordt [18F]F-NOD snel via het nier-en hepatobiliaire systeem 
geelimineerd.
Omdat redoxcondities tussen intracellulaire compartimenten verschillen, en NOD 
zeer éénvoudig in een greduceerde als ook in een geoxideerde vorm over kan gaan, bekeken 
we in hoofdstuk	6 of  synthetische N-acetyl dopamines (NAD's), ER stress bewerkstelligt 
met als consequentie dat de zogenaamde unfolded protein response (UPR) geinduceerd 
wordt. Deze eigenschap van NAD’s lijkt afhankelijk te zijn van de redox-activiteit van 
deze verbindingen. In niet toxische concentratries remt NOD de celproliferatie van 
HUVEC's sterk, zeer waarschijnlijk door een vertraging in  cell cyclus progressie zodat 
de cellen in de S-G2/M-fase va de cell cyclus blijven. In overeenstemming hiermee werd 
gevonden dat de expressie van verschillende genen, betrokken bij de S-G2/M-progres-
sie, door NOD aanzienlijk verlaagd worden. Interessant is dat behandeling met NOD op 
lange termijn resulteerde in hypo-metabolisme en thermotolerantie, zoals gesuggereerd 
wordt door een verminderde intracellulaire ATP-concentratie, activering van AMPK en 
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([Ca  +   +  ]i) Cytoplasmic calcium
[18F] Fluorine-18 radioisotope




ADP Adenosine diphosphate 
AKI Acute kidney injury
Allo Allogeneic
AMP Adenosine monophosphate
AMPK 5' AMP-activated protein kinase
A-NOD Acteylated NOD
AP-1 Activator protein 1 
ARE Antioxidant response element 
ASL Arterial spin labelling 
ATF6 Activating transcription factor 6 
ATP Adenosine triphosphate 
BBr3 Boron tribromide
BD Braindead 
Bq Becquerel, unit of  radioactivity
BSA Bovine serum albumin
C/EBP C/EBP homologous protein 





CB1 Cannabinoid receptor type 1 
CB2 Cannabinoid receptor type 2 
cDNA Complementary DNA 
CGRP Calcitonin gene-related peptide
CH2Cl2 Dichloromethane
Ci Curie, non-SI unit of  radioactivity 
CMV Cytomegalovirus









DGF Delayed graft function 
DHA Docosahexaenoic acid 
DMF Dimethylformamide
DMSO Dimethyl sulfoxide
DRG Dorsal root ganglion 
DTT Dithiothreitol
e- Eletron




ER Endoplasmic reticulum 
ERSE Acting ER-stress response element
Et2O Petroleum ether
F Phenylalanine
FAIR Flow-sensitive alternating inversion recovery 
FBS Fetal bovin Serum
FCS Fetal calf  Serum
FDA Food and Drug Administration
F-NOD 2-fluoro-N-octanoyl dopamine 
g Gram





HEK293 Human Embroynic Kidney cells 293
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
HO-1 Heme oxygenase-1 






HUVECs Human umbilical vein endothelial cells 
Hz Hertz
I Isoleucine
I/R-injury Ischemia reperfusion injury
ICAM1 Intercellular adhesion molecule 1)
IL-6 Interleukin 6 
IPC Ischemic preconditioning 
IRE1 Inositol requiring kinase 
JNK1 C-jun N-terminal protein kinase 1 (JNK1)
k Kilo












MALDI-TOF Matrix-assisted laser desorption/ionization-time of  flight






MOI Multiplicity of  infection
MRI Magnetic resonance imaging
mRNA Messenger RNA
n Nano
N  Asparagine 
Na  +  Sodium ion





NADA N-arachidonoyl dopamine 
NADH Nicotinamide adenine dinucleotide
NADPH Reduced form of  NADP
NADs N-acyl dopamines
NaHCO3 Sodium bicarbonate
NFAT Nuclear Factor of  Activated T-cells 
NF-κB Nuclear factor κb 
nm Nanometer
NMR Nuclear magnetic resonance
NO Nitrogen oxide 
NOD N-octanoyl dopamine 
NOT N-octanoyl tyramine 
NPiD N-pivaloyl dopamine 
Nrf-2 Nuclear factor erythroid 2-related factor 2
OLDA N-oleoyl dopamine
PBS Phosphate-buffered saline
PDI Protein disulfide isomerase
PERK (PKR)-like ER kinase 
PET Positron-emission tomography 
PG Prostaglandins
PMNs Polymorphonuclear leukocyte
PPAR Peroxisome proliferator-activated receptors
 ppm Parts per million
PVDF Polyvinylidene fluoride




ROI Regions of  interest 






sd Sprague Dawley rat




SP Substance P 
SUVbw Standardized uptake value based on body weight
Syn Syngeneic
T Threonine 





TLC Thin-layer chromatography 
TNF Tumor necrosis factor 
TRPV1 Transient receptor potential channel of  the vanilloid receptor subfamily, subtype 1
Tx Transplantation
UPR Unfolded protein response
UV Ultraviolet
VCAM1 Vascular cell adhesion protein 1 
VDW Van der Waals force
WT Wild type
Xbp1 X-box-binding protein 1 
Y Tyrosine
ΔNOD Delta NOD
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